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Abstract
ABSTRACT.
Thyroid hormones are essential for the normal development and the 
maturation of all vertebrates. They exert their effects via thyroid receptors; ligand -  
activated transcription factors that regulate gene expression by binding to specific 
DNA sequences (TREs - thyroid response elements) in the promoter-region of target 
genes and through interactions with a number of regulatory proteins, termed 
coactivators and corepressors. The balance of this finely tuned system can be 
disrupted by exposure to environmental contaminants. The development of high -  
throughput, in vitro screens for such contaminants, will allow more informed risk 
assessments to be made concerning the potential human health impact of the 
chemicals which are already in use, as well as facilitating the screening of newly - 
developed compounds.
The murine thyroid receptor (a and jS) cDNAs were PCR-amplified and 
cloned into a pET expression vector. Recombinant His-tagged fusion proteins were 
expressed in E.coli and purified by affinity chromatography.
A duel approach was used in order to monitor the effects of putative 
disrupters on transcription. Firstly, a cell culture reporter system was developed. 
CV1 cells were stably transfected with thyroid-responsive luciferase reporter 
construct and a number of clonal populations were isolated. Although an up- 
regulation of luciferase protein levels was observed in repsonse to treatment with 
thyroid hormone (T3), it was not as large as expected and the amount of thyroid 
receptor in cells was subsequently found to be a limiting factor.
Secondly, in vitro transcription assays comprising a nuclear extract and 
the thyroid-responsive luciferase reporter construct were employed. Transcription 
efficiency was assessed using radioactive primer extension assays, QPCR and the 
Hybridistion Protection Assay.
The interaction of recombinant TR with TRE-containing double­
stranded DNA duplexes was monitored using the electrophoretic mobility shift assay 
(EMSA). A protein titration allowed the calculation of the K& of TR for DNA. This 
quantitation of the affinity of TR for DNA was subsequently measured in the presence 
of known T3 analogues, thus providing the basis of a TR-DNA binding assay.
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Chapter One General Introduction
CHAPTER ONE 
GENERAL INTRODUCTION.
1.1. Environmental Endocrine Disruption.
All living organisms depend upon a large and intricate array of chemical 
signalling systems to guide biological development and regulate cell and organ 
activity (McLachlan, 2001). Over the past two decades, scientific interest and public 
concern regarding the ability of many environmental contaminants to interfere with 
these sensitive systems has grown dramatically. These molecules are believed to have 
the potential to alter the normal functioning of the various endocrine systems in 
wildlife and humans. Initially, concern was centered upon environmental chemicals- 
both synthetic and natural-that have the potential to mimic the action of the female 
hormone estrogen. Such pollutants were termed “environmental estrogens” or 
“xenoestrogens” and they have been linked to a variety of effects in a number of 
species. Examples include: imposex (masculinisation) of female gastropods of 
various species exposed to the anti-fouling agent, tributyltin (TBT; Mathiessen and 
Gibbs, 1998); infertility and reproductive tract tumours in mice exposed to 
diethylstilbesterol (Newbold et al., 2000); and reproduction-related changes in many 
fish species upon exposure to sewage and industrial effluent, including intersex - the 
production in male fish of the female egg yoke lipoprotein, vitellogenin and testis 
abnormalities, (Copeland, et al., 1986).
Following the initial concerns regarding environmental estrogens, and 
their effects on the reproductive system (particularly in females), the issue 
subsequently developed to encompass the concern that environmental chemicals could 
affect other elements of the endocrine system and impact on developmental as well as 
reproductive processes (Phillips and Harrison, 1999). Myers et al., (2003) defined 
environmental endocrine disruptors (EEDs) as:
“chemicals that can disrupt thyroid hormones, androgens, estrogens and other 
endocrine processes... by interfering with the hormonal signals that control normal 
development o f  the brain and other organ systems
1
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1.2. Thyroid Hormones.
1.2.1. Physiological Importance of Thyroid Hormones.
Thyroid hormones (THs; 3,5,3'-L-triiodothyronine, T3 and L-thyroxine, 
T4, structures shown in Figure 1.1) play critical roles in differentiation, growth, and 
metabolism. The effects of THs are mediated predominantly at the level of gene 
expression via thyroid hormone receptors (TRs).
TRs are ligand-activated transcription factors whose main function is to 
regulate target gene expression directly through binding to specific DNA sequences, 
called thyroid response elements (see Section 1.4.1). The TRs are encoded by two 
separate genes, designated TRa and TRp, located in different chromosomes (17 and 3, 
respectively, in humans). Alternative splicing of transcripts from each gene generates 
multiple isoforms, including T R al, TRa2 and TRa3 from the TRa gene, and TRpi 
and TRp2 from the TRp gene (Zhang and Lazar, 2000). Overall, the proteins encoded 
by TRa and TRp have similar biochemical and functional properties, although they do 
have distinct tissue distributions. In the adult rat, the a l and pi receptor mRNAs are 
found in all T3-sensitive tissues, although with differences in their relative 
abundancies. During brain development, TRa expression predominates at early stages 
and remains steady, whereas TRp expression is intially very low but exhibits a 
dramatic transient increase during the critical period of the central nervous system 
maturation (Jeannin et al., 1998).
TH levels are self-regulated by a negative feedback mechanism, and are 
required for the normal function of nearly all tissues, and is involved in the regulation 
of numerous processes, including: cardiovascular function -  heart rate, blood pressure 
and breathing; postnatal development - bone lengthening, gut maturation, inner ear, 
retina and muscle development; liver metabolism, the digestive system and body 
temperature (Flamant and Samarut, 2003 and Yen 2001). Basic foetal development 
begins within the first few weeks of gestation, and the foetus is entirely depedent on 
maternal thyroid hormones until the beginning of the second trimester. Although the 
foetal thyroid begins to grow towards the end of the first trimester, the production of 
thyroid hormones does not begin until the second trimester, and the hypothalamic- 
pituitary-thyroid axis is not mature until the third trimester. Thus, maternal thyroid
2
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hormone must be continuously available until birth, as crucial developmental 
processes take place before the foetal thyroid system is up and running. These 
include; spinal cord and hindbrain development, neuron formation, synapse 
development and formation of myelin (Brown, 2003).
The importance of TH-mediated gene expression, via the TRs has been 
demonstrated by the production of knockout mice. Impaired TH function, due to TR 
knockouts, leads to increased cell death and a delay in cerebellar development 
(O’Shea and Williams, 2002; Koibuchi and Chin, 2000). Transgenic mice lacking a 
functional TRa gene exhibit progressive hypothyroidism from birth. Animals display 
multiple disorders, which eventually lead to death, shortly after the weaning period. 
These include; a body temperature 0.5°C lower than normal, an average heart rate 
20% lower than control animals, and delayed maturation of bone and small intestine 
(Gauthier et al., 1999; Wikstrom et al., 1998). A lack of the TRp iso form leads to 
impaired auditory development whilst mice lacking both a functional TRa and TRp 
display hyperthyroidism, consistent with the negative regulation of TSH by liganded 
TRs (described in Section 1.2.3; Zhang and Lazar, 2000; Gauthier et al., 1999). TH 
action, mediated by a specific TR isoform, TRp2, has been shown to be necessary for 
the normal development of green cone photoreceptors, in rats (Ng et al., 2001).
3
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Figure 1.1. The naturally-occurring thyroid hormones. T3 (3,5,3'-L-triiodothyronine) 
and reverse T3 (rT3; 3,5',3'-L-triiodothyronine) are generated by outer- 
ring and inner-ring deiodination of T4 (L-thyroxine), respectively.
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1.2.2. Thyroid Hormone Synthesis.
The functional unit of the thyroid gland is the thyroid follicle. The first 
step in TH synthesis involves the active uptake of iodide (I ), from the blood, by the 
thyroid follicle cells. This requirement for iodide in TH synthesis necessitates a 
sufficient intake of dietary iodine (I2). Dietary iodine (I2) is reduced to the oxidative 
level of iodide (I*) before virtually complete absorption in the small intestine. The 
iodide is then transported across the follicular epithelium and concentrated in the 
follicular lumen. Iodide molecules are then oxidised by the enzyme thyroid 
peroxidase (with hydrogen peroxidase accepting the electrons) and bound in a matter 
of seconds to the 3 position of tyrosine molecules which are attached to the large 
glycoprotein, thyroglobulin, to form Monoiodotyrosine (MIT; Connors, 1997; and 
Ganong, 1995). MIT is then iodinated in the 5 position to form diiodotyrosine (DIT). 
Two iodotyrosine molecules are then coupled to yield the iodothyronine hormones, T4 
and T3 (Figure 1.1.), a process that is also thought to be catalysed by thyroid 
peroxidase (Connors, 1997).
All of these processes are contained within thyroglobulin, whose three 
dimensional structure promotes interaction between the MIT and DIT molecules. T4 
and T3 are then stored, bound to thyroglobulin, in the follicular lumen. THs are 
released into the blood by proteolytic cleavage of thyroglobulin, when required 
(Brent, 1994).
1.2.3. Regulation of Thyroid Hormone Secretion.
The mechanisms regulating TH secretion are summarised in Figure 1.2. 
Release of thyrotrophin-releasing factor (TRF) from the hypothalamus induces the 
anterior pituitary to produce thyroid stimulating hormone (TSH or thyrotrophin). TSH 
stimulates both the synthesis and secretion of THs. TSH acts via G-linked receptors 
in the cell surface membrane of thyroid follicle cells. Binding of TSH leads to the 
activation of adenylate cyclase, a subsequent rise in cAMP levels, leading to the 
synthesis and release of THs (Connors, 1997; Ganong, 1995).
The majority of hormone released from the thyroid gland is in the form 
of T4, as total serum T4 is 40-fold higher than serum T3. Only 0.03% of the total 
serum T4 is free (unbound), with the remainder bound to carrier proteins such as 
thyroxine binding globulin (TBG), albumin, and thyroxine-binding prealbumin 
(transthyretin). Approximately 0.3% of the total serum T3 is free, with the remainder
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bound to the thyroid-binding proteins. Protein-bound THs and free hormone are in 
dynamic equilibrium and it is the free TH that enters target cells and generates a 
biological response (Yen, 2001). At the target tissues, approximately 85% of T4 may 
be converted to T3 by outer-ring deiodination at the 5 position, by thyroxine 5' -  
deiodinase (Brent, 1994). TH levels are balanced by negative feedback mechanisms. 
High levels of THs inhibit secretion of TSH from the pituitary, and TRP from the 
hypothalamus, thus limiting the amount of TH produced (Connors, 1997).
1.2.4. Thyroid Hormone Metabolism.
Deiodination is the most important metabolic pathway of thyroid 
hormones, in quantitative terms and because of its dual role in the activation and 
inactivation of T4.
Outer ring deiodination (ORD) of T4 by type I or type II 5'-deiodinases 
generates the biologically active T3, whilst inner ring deiodination (IRD) of T4 by 
tyrosyl-ring deiodinase generates the inactive metabolite reverse T3 (rT3; 3,5,,3,-l - 
triiodothyronine). T3 and rT3 undergo further deiodination, predominantly to the 
common metabolite 3,3'-diiodothyronine (3,3'-T2), which is generated by IRD of T3 
and by ORD of rT3. Thus, ORD is an activating pathway by which the prohormone 
T4 is converted to active T3, whereas IRD is an inactivating pathway by which T4 and 
T3 are converted to the metabolites rT3 and 3,3'-T2, respectively (Yen, 2001). See 
Figure 1.1 for the structures of T4, T3 and rT3.
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Figure 1.2. The self-regulatory control of thyroid hormone (TH) synthesis.
Thyrotrophin releasing factor (TRP) induces the anterior pituitary to 
produce thyroid stimulating hormone (TSH, or thyrotrophin), which in 
turn stimulates the synthesis and secretion of THs from the thyroid gland. 
High levels of of THs inhibit secretion of TRH and TSH.
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1.3. Thyroid Disease.
Thyroid disease is manifested as a decrease in the endocrine activity of 
the thyroid gland (hypothyroidism), as an excessive activity of the gland 
(hyperthyroidism), or as structural and morphologic changes that do not necessarily 
result in a change in thyroid hormone status (euthyroidism).
1.3.1. Hypothyroidism.
Hypothyroidism refers to the exposure of body tissues to a subnormal 
amount of thyroid hormones, due to under secretion of THs from the thyroid gland. 
Hypothyroidism may arise from a number of causes, including, insufficient dietary 
intake of iodine, a failure by the thyroid gland to efficiently utilise accumulated 
iodide, and the ingestion of substances (foodstuffs, drugs, pollutants) that inhibit 
thyroid function. The symptoms and signs of hypothyroidism in adults are myriad, 
and can include one or more of the following: fatigue, weight gain, dry skin, yellow 
skin, cold intolerance, constipation, mental impairment, infertility, coarseness of hair 
and goiter (Connors, 1997). Hypothyroidism in adults can also lead to myxedema, 
which is characterised by infiltration of liquid into the subcutaneous tissue, leading to 
swelling (Connors, 1997; Pitt-Rivers and Tata, 1960). Although the term myxedema 
refers specifically to the associated skin changes, the syndrome of adult 
hypothyroidism is also sometimes called myxedema.
In infants, the most serious consequences of TH deficiency involve 
mental and physical development. Without treatment, TH deficiency causes severe 
developmental impairment, and neurological disturbances. The result is cretinism (see 
Section 1.3.1 .b.).
a) Goiter.
A goiter is an enlargement of the thyroid gland. It has previously been 
defined as a thyroid gland that is twice larger than normal, or about 40g in weight 
(Burrow, 1989). The classic explanation for goiter formation is that, due to iodide 
deficiency, the thyroid gland must grow as a homeostatic compensatory mechanism. 
Iodide deficiency results in inadequate TH production, giving rise to a compensatory 
release of TSH (see Figure 1.2.), leading eventually to goiter formation. This allows 
retention of TH synthesis and secretion. Specific problems may arise from the 
development of a goiter; the goiter may become large enough to constrict the neck and
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interfere with eating and breathing. In addition, the cosmetic effect can also be 
undesirable (Connors, 1997).
Historically, the connection has often been made between the 
environment and its ability to interfere with the thyroid system. McCarrison (1917) 
recognised contamination of the water supply as being goitrogenic in low-iodine 
areas. He noted that goiter prevalence increased downstream from the water supply in 
a group of villages in the Himalayan foothills. The incidence of goiter increased from 
12% at the source to 45% at the terminus of the river, which served as both a source of 
drinking water, and as an open sewer for the villages along the banks of the river. 
Subsequently, the residents of this area were found to be markedly iodine deficient. 
McCarrison was able to produce goiter in himself and his colleagues by the ingestion 
of suspended matter from the river water. More recent studies showed that E.coli in 
drinking water could produce anti-thyroid compounds (Gaitan et al., 1980).
Cassava (also known as tapioca and manioc) is a major world-source of 
carbohydrate, especially in developing countries. The root contains compounds that 
release free cyanide on hydrolysis. Following ingestion of improperly prepared 
cassava, the cyanide is converted to thiocyanate, which blocks thyroid function. A 
significant difference in the prevalence of goiter has been shown to occur among 
individuals living in different parts of an isolated island on Kivu Lake, in Zaire 
(Burrow, 1989). The differences in goiter prevalence were due to the different 
methods of preparing cassava.
b) Cretinism.
In areas of severe iodine deficiency, goiter may become endemic. 
Endemic goiter is common in many areas in which the soil is deficient in iodine. The 
resultant low dietary iodine intake can result in the development of a euthyroid goiter, 
or, if the deficiency is severe enough, of a hypothyroid goiter (Connors, 1997). A 
consequence of the hypothyroidism that may develop in endemic-goiter regions is the 
occurrence of cretinism.
Cretinism has been defined as a “permanent neurologic and skeletal 
retardation resulting from an inadequate supply of thyroid hormone during gestation” 
(Burrow, 1989). The intrauterine period is crucial in the development of cretinism -  
most of the neural effects and mental retardation, which accompany the disease, are 
determined prenatally. Cretins may display a variety of neurologic defects, including
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mental retardation, deafness, mutism, and spasmic diplegia. The hypothyroidism that 
may also be present, leads to retarded linear growth and maturation of body parts. 
Cretinism, can, however be prevented. Iodine prophylaxis has been shown to be 
effective in preventing the disease (Burrow, 1989).
1.3.2. Hyperthyroidism.
Hyperthyroidism may be defined as a group of disorders resulting from 
supraphysiologic tissue and circulating concentrations of thyroid hormones. 
Hyperthyroidism may result from a number of causes including, thyroid carcinoma, 
exposure to excess dietary iodine, over administration of thyroid hormone, and the 
most common cause, Graves’ disease (see next Section).
The symptoms and signs of hyperthyroidism include the following: 
nervousness, weight loss, heat intolerance, sweating, tremor, alterations in appetite, 
fatigue, muscle weakness and sleep disturbances (Connors, 1997; and Ganong, 1995).
a) Graves’ Disease.
In Graves’ disease the thyroid gland is diffusely enlarged and 
hyperplastic, and there is a protrusion of the eyeballs, called exopthalmos. These 
symptoms give rise to some of the many synonyms that exist for Graves’ disease, 
including exopthalmic goiter, toxic diffuse goiter, primary hyperthyroidism, and 
autoimmune thyroidism.
It is now generally accepted that Graves’ disease is an autoimmune 
disorder. Antibodies (called TSAb, for thyroid stimulating antibody) are produced 
against components of the TSH receptor on the thyroid cell membrane, and the 
receptor is stimulated. This leads to an increase in adenylate cyclase, and 
consequently, cAMP (see Section 1.2.3.). The net result is a stimulation of the thyroid 
cell, resulting in increased TH secretion (see Figure 1.2; Ganong, 1995; and Volpe, 
1989). Increasing levels of THs lead to decreased levels of circulating TSH, but tend 
to cause increased formation of TSAbs, leading to yet further TH secretion (Ganong, 
1995). TSAbs are capable of stimulating the thyroid cell for a much longer interval 
than TSH (Volpe, 1989). Graves’ disease can be treated, by lowering levels of 
circulating THs. This tends to lower, but not completely prevent, formation of the 
antibodies.
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1.4. Thyroid Hormone Receptors.
1.4.1. Mode of Action.
The effects of THs are mediated predominantly at the level of gene 
expression via thyroid hormone receptors (TRs). TRs are ligand activated 
transcription factors whose main function is to regulate target gene expression 
directly, through binding to specific DNA sequences, known as thyroid response 
elements (TREs), in the regulatory regions of target genes (Zhang and Lazar, 2000; 
Wu and Koenig, 2000). The ability to bind specific sequences of DNA in target genes 
is critical to TR function. The minimal core hexad consensus sequence recognised by 
nuclear receptors (NRs) often contains the sequence AGGTCA known as the half site 
(Zhang and Lazar, 2000; Mangelsdorf and Evans, 1995). This half site can be 
configured in a variety of structured motifs (Figure 1.3.A). The most potent of TREs 
is the direct repeat, although TRs also bind to everted repeats (ER) and inverted 
repeats (IR), also known as palindrome TRE. Although TRs are capable of binding to 
TREs as monomers or homodimers, they preferentially bind to TREs as heterodimers 
with the 9-cis retinoic acid receptor (RXR), another member of the NR Superfamily. 
RXR/TR heterodimer formation is required for high affinity binding to the TREs 
(Mangelsdorf and Evans, 1995). TR will only form a heterodimer with ligand-free 
RXR, and dimerisation actually precludes binding of ligand to RXR -  in this instance, 
RXR is referred to as the “silent partner” (Aranda and Pascual, 2001). TRs can 
enhance or inhibit gene expression depending on the nature of the TRE. Most of the 
natural, characterised TREs are “positive” TREs, in which gene transcription is 
repressed by unliganded TRs and activated by T3-occupied TRs (e.g. growth 
hormone, malic enzyme, myosin heavy chain-a). In contrast, on negatively regulated 
genes (e.g. TSHa and p subunits, myosin heavy chain-p), gene expression is activated 
in the absence of ligand and repressed in the presence of ligand (Wu and Koenig, 
2000).
Heterodimer formation is thought to enhance DNA-binding affinity, as 
well as provide target gene specificity, determined by the spacing between the two 
half sites (Mangelsdorf et al., 1995). Accordingly, TR/RXR binds DR4, that is two 
half sites in one orientation separated by 4bp (Zhang and Lazar, 2000). In addition to 
spacing, subtle differences in the sequence of the hexad half site and the 5' extension
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of the TREs can have dramatic effects on the activity of a receptor (Mangelsdorf et al., 
1995).
TRs are members of the nuclear receptor (NR) superfamily. Other 
members of this family include receptors for the retinoids: retinoid X receptors 
(RXRs) and retinoic acid receptors (RARs), vitamin D receptors (VDRs) and steroid 
receptors (SRs). To date, there are over 150 different members of the family, 
spanning a large diversity of species, from worm to human (Mangelsdorf and Evans, 
1995). Also contained within the family, are a growing number of receptors for which 
the cognate ligands have yet to be identified, the so-called orphan receptors. The 
family is often divided into the steroid receptor family and the TR/VDR/retinoid 
receptor, (or non-steroid) family. Members of the NR superfamily exhibit a modular 
structure with distinct functional domains. They are characterised by the highly 
conserved DNA- (DBD) and ligand-binding domains (LBD) (Wu and Koenig, 2000; 
Mangelsdorf et al., 1995). The general modular organisation of a typical member of 
the NR superfamily is shown in Figure 1.3B.
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Figure 1.3. Panel A: Nuclear Receptor response elements. The core sequence AGGTCA can be arranged in a 
number of ways, separated by any number of nucleotides, “n”.
Panel B: A schematic representing the modular structure of a typical nuclear receptor. The ninth 
heptad is coloured yellow.
Abbreviations: AF1 activation domain 1; AF-2, activation domain 2; DBD DNA-binding domain; LBD ligand-binding 
domain; DR direct repeat; IR inverted repeat, (adapted from Wu and Koenig, 2000).
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1.4.2. The C Domain.
The C domain encompasses the DBD of all NRs. The DBD is the most 
conserved region of the NR superfamily. It spans a region of 66 amino acids, and is 
composed of two globular modules, followed by a carboxy-terminal extension (CTE) 
(Mangelsdorf and Evans, 1995). Each module consists of a zinc ion, tetrahedrally 
coordinated with four cysteine residues. These two zinc fingers mediate specific 
sequence recognition and confer spacing specificity. The first (N-terminal) zinc finger 
is the more conserved of the two. An amphipathic a-helix (P box) in the C-terminus 
of the first zinc finger mediates the half-site sequence recognition by directly 
contacting the major groove nucleotides of the TRE (see Figure 1.4). In addition to 
the major groove contacts, TRs also make additional minor groove contact, through 
the CTE, which effectively extends the contact surface of the TR DBD to beyond the 
consensus 6bp half site. The second zinc finger provides the structural basis for the 
spacing recognition, as well as providing a weak dimerisation interface. These 
interactions are mediated through a regulatory sequence of amino acids, called the D 
box (Figure 1.4; Zhang and Lazar, 2000; Mangelsdorf and Evans, 1995; Mangelsdorf 
et al., 1995). As has been previously mentioned, RXR/TR heterodimer formation is 
required for high affinity binding to TREs. There is a strict binding polarity of 
RXR/TR heterodimers on DR4, such that RXR occupies the 5' half site, and TR 
occupies the 3' half site.
1.4.3. The E Domain.
The C-terminal half of the receptor (E domain) encompasses the ligand 
binding domain (LBD), which possesses the essential property of hormone 
recognition and ensures both specificity and selectivity of the physiologic response. 
The LBD is moderately conserved and consists of approximately 225 amino acids 
(Mangelsdorf and Evans, 1995). The LBD is functionally complex, performing 
various activities, including ligand binding, receptor dimerisation and hormone- 
inducible transcriptional activation or repression.
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Figure 1.4. Schematic diagram detailing the modular arrangement of the DBD from Human T R al. Each 
finger contains a central zinc ion, tetrahedrally coordinated to four cysteine residues. The first 
zinc finger mediates TRE recognition by direct contact with the nucleotides of the major 
groove, via the P-box (green residues). The second zinc finger is involved in receptor 
dimerisation, and spacing specificity, effects mediated via the D-box (blue residues).
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In contrast to the dimerisation interface in the DBD, dimerisation motifs 
in the LBD permit the heterodimeric complex to interact with response elements. The 
LBD is responsible for DNA-independent dimerisation that in vitro allows formation 
of certain dimers in solution before DNA targeting (Kakizawa et al., 1997). This 
dimerisation is believed to stabilise the complex and promote the recognition of DNA. 
Several heptad repeats in the LBD are well conserved among members of the NR 
superfamily. This region of heptad repeats of lie, Leu or Val residues forms a 
hydrophobic surface that acts as a receptor dimerisation interface, which is structurally 
similar to the leucine zipper dimerisation domain found in Jun-Fos (Landschulz et al., 
1988). These hydrophobic amino acids are positioned on the same side of a a-helical 
formation, which interdigitates with a similar heptad from the second receptor, thus 
forming a heterodimer (Kakizawa et al., 1997).
A conserved region known as the ninth heptad, located in the 11th cx- 
helix, near the C-terminus (Figure 1.3B) is involved in the formation of TR-RXR 
heterodimers and TR homodimers (Wu and Koenig, 2000). The AF2 (activation 
function; Figure 1.3B) domain, which is responsible for mediating ligand-dependent 
transcriptional activation, consists of the amino acid motif XXLEXX (where X 
represents a hydrophobic residue, Wagner et al., 1995). The crystal structures of 
several NR LBDs, including that of TRa, have revealed a common structure of 12 01- 
helices and several p-tums folded into 3 layers to create a central hydrophobic binding 
pocket for the ligand (Wu and Koenig, 2000; Wagner et al., 1995). The binding of 
ligand induces significant conformational changes. The ligand itself is completely 
buried within the interior of the structure and contributes to the hydrophobic core of 
the protein. It makes multiple contacts with several helices and p-strands to stabilise 
the conformation. The most important change is the repositioning of helix 12, which 
contains the AF2 motif. Helix 12 folds back toward the LBD, realigns with helix 3 
and 4, and contacts the ligand, thereby closing the ligand cavity and generating a 
surface for coactivator recruitment (mousetrap model, Wu and Koenig, 2000; Zhang 
and Lazar, 2000; Mangelsdorf and Evans, 1995; Wagner et al., 1995). The 
repositioning of helix 12 plays an important role in NR function: studies identified a 
hydrophobic cleft, composed of helices 3-5 and 12 that is crucial for coactivator 
binding (Wagner et al., 1995).
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1.4.4. The A/B Domain.
The N-terminal region (A/B domain) is the least conserved among the 
NR superfamily. It is a hypervariable region of between 25 (VDR) and 603 
(mineralocorticoid receptor) amino acid residues in length. The A/B domain is highly 
divergent between the TRs. It varies not only between TRa and TRp, but also 
between the two TRp isoforms, TRpl and TRp2. The A/B domain of TR contains a 
ligand-independent transactivation factor (AF1), which appears to modulate A/B 
domain function through interaction with basal transcription factors, especially TFIIB 
(Hadzic et al., 1995). It is likely that this N-terminal domain is a modulator of TR 
function as whose presence is required to allow full transcriptional activation as 
opposed to being an essential factor, as illustrated by the fact that the A/B domain is 
not required for ligand-dependent transcriptional activation by rat TRpi (Zhang and 
Lazar, 2000).
In addition to modulating ligand-independent activation function, the 
A/B domain also modulates ligand-dependent interaction with corepressors. 
Hollenberg et al., (1996) showed that NCoR functions as a ligand-dependent 
transcriptional repressor in the presence of TRpl and TRal. However, this function 
was isoform-specific in that the ligand-independent and -dependent activity of the 
TRP2 isoform was unaffected by the presence of NCoR. They showed that TRp2 was 
able to interact physically with NCoR, but that a functional interaction was prevented. 
Oberste-Berghaus et al., (2000) went on to show that TRp2 exhibited greater T3- 
independent activation on TREs compared to TRa and TRpl due to its ability to 
interact with certain coactivators (CBP, SRC-1, and pCIP) in the absence of T3 
through a domain which mapped to the amino-terminal half of its A/B domain. Since 
TRP2 is found almost exclusively in the pituitary and hypothalamus it is likely, that it 
plays a unique role in negative regulation by thyroid hormone of centrally located 
genes, for example thyrotropin releasing factor (TRF).
1.4.5. The D Domain.
The region between the DBD and LBD consists of a short hinge region, 
comprised of hydrophilic residues. This hinge region allows retention of spatial 
flexibility. This flexibility gives the DBDs rotational capabilities, which allow them 
to swivel according to the orientations of the half sites to which they bind. Each
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DNA-binding head must be able to rotate at least 180° relative to the LBD, in order to 
accommodate rotational differences associated with receptor-TRE binding 
(Mangelsdorf and Evans, 1995).
1.4.6. The F Domain.
The F domain is hypervariable in length and is the least understood of all 
the NR superfamily domains. It is absent in some receptors, including TRs, and has 
been removed from others, with no loss in function (Tsai and O’Malley, 1994).
1.5. Transcriptional Regulation.
1.5.1. The Basal Transcriptional Machinery.
Promoters transcribed by RNA polymerase II (RNAP II) are recognised 
by two types of transcription factor: the basal or general transcription factors (GTFs) 
that interact with the core promoter elements, and the sequence-specific transcription 
factors, including the nuclear receptors (NRs), which generally interact with 
sequences located further upstream. The core promoter may contain the TATA box 
close to an initiator sequence that spans the transcriptional start site where RNAP II 
binds (Aranda and Pascual, 2001). Transcription requires the assembly of the pre­
initiation complex (PIC), composed of template DNA, RNAP II and five GTFs.
TFIID (general transcription factor IID) is composed of TBP (TATA 
binding protein) and TBP-associated factors (TAFs). The TBP of TFIID binds to the 
TATA box, sitting astride it like a molecular “saddle”, inducing a sharp bend in the 
DNA and contacting the largest subunit of RNAP II (Woychik and Hampsey, 2002). 
TFIID binding is followed by the concerted recruitment of TFIIB, which binds the 
promoter through base-specific contacts in the major groove upstream and in the 
minor groove downstream of the TATA box. This asymmetrical binding is likely to 
account for the unidirectional assembly of the PIC and the direction of transcription. 
The subsequent binding of RNAP II (unphosphorylated) and TFIIF stabilizes the 
DNA-TBP-TFIIB ternary complex, and is a prerequisite for entry of TFIIE and TFIIH 
into the PIC (Woychik and Hampsey, 2002).
TFIIE affects late events in PIC assembly, including recruitment of 
TFIIH and subsequent regulation of TFIIH activities. TFIIE and TFIIH are required
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for ATP-dependent formation of the open promoter complex prior to formation of the 
first phosphodiester bond. TFIIH consists of nine subunits and has a molecular mass 
similar to that of RNAP II. It can be resolved into two subcomplexes: core-TFIIH, 
which includes two ATP-dependent DNA helicases of opposite polarity (XPB and 
XPD), and a cyclin-dependent protein kinase complex. Following TFIIH binding, 
promoter melting is facilitated by XPB and XPD and the C-terminal domain of the 
largest RNAP II subunit is phosphorylated by TFIIH, facilitating transcription 
initiation, promoter clearance and progression into the elongation phase of 
transcription. Following termination, a phosphatase recycles RNAP II, allowing the 
GTFs and RNAP II to initiate another cycle of transcription (Woychik and Hampsey, 
2002).
1.5.2. Chromatin Structure and the Histone Code.
Mammals package 2-3 billion base pairs of chromatinised DNA into the 
nucleus of a cell. Chromatin is a compact and ordered structure composed of a basic 
repetitive structural element known as the nuclesome. Nucleosomes consist of 146bp 
of DNA wrapped almost twice around a protein core containing two copies each of 
four histone proteins: H2A, H2B, H3 and H4 (Orphanides and Reinberg, 2002). An 
array of nucleosomes folds into a 30nm chromatin fibre, which must be compacted at 
least 200 to 300-fold in order achieve the final compacted size - a total of 2metres of 
human DNA ultimately fits within the nucleus of a cell (Khorasanizadeh, 2004). This 
condensation of chromatin provides a major impediment to transcription by restricting 
the access of transcription factors to DNA.
In addition to the structured histone fold octameric core, each histone 
forms extensions consisting of disordered N-terminal tails that protrude from the 
nucleosome. The histone tails are only partially visible in all these structures and 
show no secondary structures. By extending beyond the disk-shaped nucleosome 
surface, the tails form ideal surfaces for covalent modifications (Khorasanizadeh, 
2004). The N-terminal tails of all four histones contain multiple targets for covalent 
modifications and various combinations of these modifications have been observed 
(Orphanides and Reinberg, 2002).
Histones are subject to a range of posttranslational modifications 
including: the acetylation of lysines, the methylation of lysines and arginines, the 
phosphorylation of serines and threonines, the ubiquitination of tyrosines, the
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sumolation of lysines and ADP-ribosylation of glutamic acids (Dutnall, 2003). This 
led to the proposal that the modification of the histone N-termini make up a “histone 
code” and that specific histone modification patterns control the association of 
proteins with chromatin, through their effect on the strength and specificity of direct 
physical interaction with histones (Orphanides and Reinberg, 2002). The association 
of histone binding proteins with chromatin leads directly or indirectly to changes in 
the functional state of the underlying DNA (e.g. transcriptionally active, or inactive), 
through changes either in the higher order structure of chromatin or in the ability to 
subsequently recruit transcriptional machinery, or a combination of both. Histone 
acetylation by histone acetylases (HAT) and the reverse effect carried out by histone 
deacetylases (HDACs) has been correlated with activation or repression of 
transcription, respectively. The deacetylation of histone tails leads to a more compact 
chromatin structure that is much less accessible to the transcriptional machinery and is 
therefore transcriptionally silent.
In addition to the covalent modification of histones, the physical 
structure of chromatin can be perturbed by the ATP-dependent chromatin remodelling 
complexes. For example, the SWI/SNF complexes facilitate access of DNA-binding 
proteins to DNA by using the energy of ATP-hydrolysis to alter nucleosome structure 
and/or facilitate nucleosome mobility (Li et al., 2003).
1.5.3. Role of TR.
As a transcription factor, a key function of the TR is to regulate target 
gene expression in response to multiple signalling pathways. As has been previously 
stated, TR homodimers and TR/RXR heterodimers constitutively bind TREs in the 
absence and presence of ligand. TRs are one of a limited number of transcription 
factors that retain the capacity to bind to their recognition elements even when they 
are wrapped into nucleosomes (another example being the glucocorticoid receptor; 
Collingwood et al., 1999). Unliganded TR represses basal transcription. Ligand 
binding causes derepression and enhances transcriptional activation. A group of 
regulatory proteins, called coactivators and corepressors mediate activation and 
repression, respectively, by acting as bridging factors between the heterodimer and the 
basal transcription machinery (Kim et al., 1999; Beato et al., 1995). These 
coregulators cannot bind DNA, but interact directly with DNA-bound TRs, as a result 
of which they are recruited to the proximity of the target gene promoter region (Zhang
20
Chapter One General Introduction
and Lazar, 2000). The coregulatory proteins (coactivators and corepressors) elicit
their effects in a number of ways, including:
i) ATP-dependent remodelling of chromatin,
ii) Covalent modification of chromatin,
iii) Contacting the general transcription factors.
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1.5.4. Gene Activation - the Role of Coactivators.
a) Chromatin Remodelling.
One of the primary functions of activated receptors can be viewed 
essentially as facilitating access of the basal transcription machinery to the promoter 
to initiate transcription. Chromatin plays an important role in regulating the basal 
activity of many promoters and molecules designed to overcome the thermodynamic 
restraints it imposes are thought to be recruited at an early stage in the model of 
receptor action. One of the best-characterised chromatin remodelling complexes is the 
ATPase-containing SWI/SNF multiprotein complex (McKenna and O’Malley, 2002). 
The role of chromatin remodelling in TR-mediated transcription has been well 
established, with strong evidence provided that transactivation by liganded TR/RXR 
heterodimers is dependent on chromatin remodelling complexes (Wong et al., 1998). 
However, further studies have shown that in addition to chromatin remodelling, 
histone acetyltransferase (HAT) activity is also requried in order to fully activate the 
TSHa promoter (Li et al., 2003).
b) Acetyltransferases.
A number of the coactivator proteins that interact with TR have been 
shown to possess intrinsic histone acetyltransferase activity (Oberste-Berghaus, 2000; 
Spencer et al., 1997). Acetylation of histone lysines disrupts the electrostatic 
interactions between DNA and the core histone proteins, thus facilitating the access of 
the basal transcriptional machinery to the promoter (Zhang and Lazar, 2000).
The steroid receptor coactivator (SRC) family of proteins interact 
directly with liganded TRs and also serve as adaptor molecules to recruit other 
coactivators, such as p300/CBP (CREB-binding protein; Leo and Chen, 2000). 
Although some studies have found the SRCs to possess a weak intrinsic 
acetyltransferase (HAT) activity, p300/CBP and pCAF (p300/CBP-associated factor) 
possess potent acetyltransferase activity and appear to be the predominant 
acetyltransferases for histones (McKenna and O’Malley, 2002). p300/CBP is 
recruited indirectly to liganded TR via the SRCs, whilst pCAF is part of a 
multipolypeptide coactivator complex that can interact directly with liganded TR and 
p300/CBP (Li et al., 2003).
Li et al., (2003) showed that the SRC proteins and p300/CBP function 
together to form an activation pathway: TRp/RXRa heterodimers induce promoter-
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proximal disruption of nucleosomal arrays upon binding to chromatin, and acetylation 
of nucleosomal histones enhances T3-dependent activation. They showed that the 
primary role of SRC coactivators is to recruit p300, consistent with the observation 
that p300 does not exhibit strong direct binding to TR and that deletion of the SRC 
interaction domain in p300 greatly diminishes the coactivator activity of p300 with 
TRp (Li et a l , 2003).
The SRC family of coactivators mediate ligand-dependent direct
interactions with nuclear receptors via a centrally located receptor-interacting domain 
(RID) which contains the conserved motif LXXLL called the NR box (where “L” is 
leucine and “X” is any amino acid). The RID of SRCs contains three NR boxes, 
which interact with the AF2 domain of liganded TRs (Heery et al., 1997; Section 
1.4.3) by formation of an amphipathic a-helix, with the leucine residues comprising a 
hydrophobic surface on one side of the helix. The helix interacts with the AF2 
domain of the liganded receptor via a hydrophobic groove made up of residues from 
receptor helices 3,4,5 and 12 that is the result of the conformational change induced 
by hormone binding (Leo and Chen, 2000). Nuclear receptors can differentially 
interact with different combinations of NR boxes to form distinct coactivator 
complexes, and the sequences adjacent to the motif determine the preference for 
receptor binding (Wu and Koenig, 2000). Mutation of a single NR box however, does 
not completely abolish coactivator binding, suggesting that multiple NR boxes 
contribute to the overall high-affinity binding of the receptor (Leo and Chen, 2000).
c) The TRAP/Mediator Complex.
The most universal cofactor that serves to transduce regulatory
information between gene-specific transcription factors (TRs) and the basal 
transcriptional machinery is a large, modular complex, known as Mediator. Mediator 
itself is unable to bind specific DNA sequences, but interacts physically with RNA 
Polymerase II (RNAP II), although RNAP II itself is not a component of mediator 
(Woychik and Hampsey, 2002; Cosma, 2002).
The human TRAP/Mediator is a 1.5-2.0MDa transcriptional regulatory 
complex that is composed of more than 25 polypeptides. It was originally isolated as 
a TR-associated protein (TRAP) complex that mediates TR-activated transcription
from DNA templates in conjunction with the general transcription machinery. A
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small subset of the TRAP complex subunits are homologous to the multifunctional 
cofactor complex in yeast, termed Mediator (Ito and Roeder, 2001).
The TRAP complex is targeted to the LBD of liganded TR through a 
single protein, TRAP220 (Yuan et al., 1998). This protein contains two LXXLL 
motifs within its RID (LXM1 and LXM2), and interactions with TR are again 
mediated via hydrophobic interactions with the AF2 domain (Coulthard et al., 2003; 
Yuan et al., 1998). As described in the previous section for the SRC family of 
proteins, the LXXLL motifs of TRAP220 also exhibit preferential binding to certain 
nuclear receptors, with LXM1 and LXM2 binding preferentially to RXR and TR, 
respectively (Coulthard et al., 2003). In addition to the binding preferences of the 
LXXLL motifs, the sequences immediately flanking the motifs as well as the spacing 
between motifs further determines binding specificity (Coulthard et al., 2003).
Whilst TRAP220 is also able to interact directly with the basal 
transcription factor TATA box-binding protein (TBP), and has been shown to enhance 
TRa function in a cell free environment (Yuan et al., 1998), the entire 
TRAP/Mediator complex is required for efficient transactivation of TR-mediated 
transcription (Coulthard et al., 2003).
d) An Ordered Recruitment.
A study carried out by Sharma and Fondell (2002) demonstrated that 
following the binding of ligand in vivo, TRP first recruits SRC proteins and p300, 
resulting in the acetylation of histones with subsequent generation of a less compact 
chromatin structure. This, in turn, results in the recruitment of the TRAP complex to 
the promoter, which in turn, directly interfaces with RNAP II and potentiates 
transcription initiation. This step-wise recruitment of SRC, p300 and finally the 
TRAP complex to the TR-bound promoter is consistent with the fact that the binding 
of SRCs and TRAP220 to TR is mutually exclusive (See Figure 1.5: Ito and Roeder, 
2001).
It has been shown that coregulatory proteins (corepressors and 
coactivators) utilise a similar binding surface in TRs, composed of helices 3 and 5.
Competition assays with SMRT (see next Section) and SRC1 demonstrate that SMRT
is able to inhibit the interaction between SRC1 and the receptor. Furthermore, the 
same study suggests a competition between SMRT and SRC1 for receptor binding,
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even in the presence of ligand (Sohn et al., 2003). This is consistent with a recent 
study, which implies a dominant role of corepressor release to allow coactivator 
binding (primarily with RAR) (Kao et al., 2003). Taken together it is possible to 
envisage the transcriptional switch between activation and repression not as a static 
on-off switch, but rather as a dynamic equilibrium which is shifted to one or the other 
conformation dependent on ligand, type of response element and cofactor ratios 
(Eckey et al., 2003).
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F ig u re  1.5. A multistep model for thyroid receptor (TR) function Transcription from a positive TRE*contairung target gene in a chromatin template (DNA plus 
associated histones and nucleosomal structures) is repressed in the absence of T3 (ligand) and activated in the presence of ligand. Binding of ligand leads to a 
conformational change m TR  and subsequent release of corepressor proteins ATP-dependent chromatin remodeling complexes are recruited, along with the SRC 
proteins, which subsequently recruit p300/CBP to ligand-bound TR The acetyltransferase activity of p3Q0/CBP and pCAF results in the loosening of DNA- 
histone interactions, thus facilitating the formation of the PIC (pre-initiation complex) PIC formation is mediated by the TRAP/Mediator complex, which replaces 
the SRC/p300/CBP coactivator proteins and interacts with ligand-bound TR via TRAP220. Abbreviations: NCoR, nuclear receptor corepressor, CBP, GREE­
NS bindingprotein; GTF, general transcription factors); HAT, histone acetyltransferase, HDAC, histone deacetylase, pCAF, p300/CBP-associated factor, RID,
receptor-interacting domain, RNAP II, RNA polymerase II; RXR, 9-cis retinoic acid receptor, SMRT, silencing mediator for retinoid and thyroid receptor, SRC, 
steroid receptor coactivator, TBP, TATA-binding protein; TR, thyroid receptor, TRAP, thyroid receptor-associated protein(s), TRE, thyroid response element 
(adapted from Ito and Roeder, 2001).
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1.5.5. Gene Silencing.
a) The Role of Corepressors,
i) Positively-Regulated Genes.
The promoter regions of genes that are positively regulated by TRs 
contain positive TREs. Corepressors associate with unliganded TR to repress 
transcription (See Figure 1.5). Ligand binding induces a conformational change in the 
AF2 domain of TRs, resulting in displacement of the corepressor complex; the LBD 
(ligand binding domain) consists of 12 a-helices which are arranged to create a pocket 
for ligand binding. Helix 12 plays a crucial role in the switching of the repressor from 
a silencer to an activator. In the unliganded conformation, helix 12 protrudes away 
from the core structure of the LBD and allows corepressor binding. Hormone binding 
induces helix 12 to contact the LBD core, resulting in corepressor release and 
coactivator association (Eckey et al., 2003). Deletion of helix 12 leads to constitutive 
silencing even in the presence of ligand, indicating that helix 12 is involved in the 
coordination of repression and activation (Apriletti et al., 1998).
Two of the first corepressors identified for TR were NCoR (Nuclear 
receptor corepressor) and SMRT (silencing mediator for RAR and TR). They are 
functionally and structurally related, share significant sequence homology, and are 
recruited to target promoters by unliganded TRs, in a ligand-reversible manner (Chen 
and Evans, 1995; Horlein et al., 1995). NCoR and SMRT show ligand-independent 
interaction with TR and RAR in vitro, and exhibit modular structures, with carboxyl- 
termini as the NR-interacting regions and amino termini as the autonomous repression 
domains (Nagy et al., 1997; Chen and Evans, 1995).
Although both corepressors interact with TR, NCoR is preferentially 
recruited to TR. The nuclear receptor-interacting domains (RIDs) of these 
corepressors are located in the C-terminus and are defined by the presence of the 
CoRNR boxes (corepressor nuclear receptor boxes), containing a OXXO® motif 
(where ® is any hydrophobic amino acid and X is any amino acid). Sequences 
flanking the CoRNR motif determine NR specificity. Studies have shown that a short 
interaction domain containing the CoRNR motif is essential for corepressor 
interaction with unliganded TR (Hu et al., 1999). Although SMRT and NCoR share 
two RIDs, NCoR has an additional RID located N-terminal of the two conserved 
NIDs, that seems to be responsible for preferential binding to TR. NCoR appears to
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stabilize the TR homodimer by preventing its dissociation from TREs, whilst it is 
postulated that the C-terminal NID interacts with the RXR of a TR/RXR heterodimer 
(Eckey et al., 2003).
Both NCoR and SMRT have been shown to interact with the protein 
Sin3, which itself associates with histone deacetylases (HDACs) to form a corepressor 
complex (Nagy et al., 1997). Antibody blocking of each component of the SMRT- 
Sin3-HDAC complex causes relief of repression by TR and RAR, suggesting that 
each component of the complex is important for repression (Wu and Koenig, 2000; 
Nagy et al., 1997). The finding of HDACs in the SMRT-NCoR-Sin3 repressor, 
coupled with the fact that histone deacetylase contributes to a compact chromatin 
structure, suggests that gene silencing is effected by excluding the recruitment of, or 
by restricting the accessibility of, basal transcription factors to targeted promoters.
NCoR and SMRT have also been shown to interact with TBP (TATA- 
binding protein) and TAFs (TBP-associated factors), in line with the observation that 
overexpression of NCoR prevents the functional interaction of TFIIB with TAFII32, 
which is a critical step in the assembly of the transcription initiation-complex (Wong 
and Privalsky, 1998).
ii) Negatively-Regulated Genes.
The promoter regions of genes that are negatively regulated by TRs 
contain negative TREs (nTREs). In contrast to the TR-mediated transcriptional 
regulation of positive genes, the mechanisms underlying the TR-mediated control of 
negatively regulated genes remain relatively poorly understood.
For all nTREs, transcription is constitutively activated in the presence of 
ligand-free TR, whilst the addition of ligand reverses this stimulation. Tagami et al., 
(1997) showed that the overexpression of NCoR and SMRT enhanced basal 
transcription from negative TREs, in a ligand-reversible fashion. A more recent study 
by Berghagen et al., (2002) demonstrated that TRa-SMRT complexes bound to a 
positive TRE had a different conformation to those bound to a nTRE, suggesting that 
allosteric changes resulting from binding of TR to different types of TREs can dictate 
whether a cofactor acts as a coactivator or corepressor. A study by Sanchez-Pacheco 
and Aranda (2003) subsequently showed that binding of TR to a nTRE was associated 
with histone acetylation, and that this acetylation was reversed in the presence of 
ligand.
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b) The Role of TRp.
TR can also mediate gene silencing by directly targeting the basal 
transcriptional machinery. TRp has been shown to interact with the basal 
transcriptional factor TFIIB, whilst the addition of hormone (T3) leads to a significant 
decrease of this interaction (Baniahmad et al., 1993). Tong et al (1995) showed that 
ligand-free TRp or a TRp-RXR heterodimer was able to inhibit the formation of a pre­
initiation complex (PIC) by interacting with the TFIEB-TBP protein complex
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1.6. Environmental Endocrine Disruptors.
Potential sources of exposure to EEDs are myriad, and include 
contaminated food and water, combustion sources and contaminated consumer 
products. EEDs are often pervasive and tend to bio-accumulate in the environment. 
Some are very persistent, are transported over large areas and are found even in the 
last remaining pristine habitats. Others are rapidly degraded in the environment or 
animal body, or may be present for short periods of time, but at critical periods of 
development of the organism (McLachlan, 2001). The effects of EED’s on 
developing organisms are of greatest concern, since developmental stages are typically 
more vulnerable to signal disruption than adult stages. This is thought to occur for 
several reasons, including the absence of fully developed protective enzyme systems 
and higher metabolic rates. Altered gene expression can induce dramatic changes in 
developmental outcomes, and the disruptive effects of developmental exposure are 
permanent and irreversible (“organisational” effects). In adults, however, adverse 
effects can often be reversed by removing the EED, thus returning gene expression 
levels and organ functioning to normal (“activational” effects; Myers et al., 2003).
There are now over 600 registered pesticides and 80,000 industrial 
chemicals in commercial use today (Keith, 1997). Whilst the potential action on the 
thyroid system of many of these chemicals has yet to be characterised, there are 
numerous chemicals which are recognised as having potential thyroid-disrupting 
properties. A group of twelve chemical compounds have been identified by the 
United Nations Environment Programme (UNEP) as powerful threats to human and 
wildlife health on a global basis (the “dirty dozen”). These chemicals belong to a 
class known as persistent organic pollutants (POPs). POPs are organic compounds 
that resist photolytic, biological, and chemical degradation. Most are semivolatile, 
which allows them to move long distances across the globe in the atmosphere before 
deposition occurs by a process called the "grasshopper effect." This process, which is 
often seasonal, involves a repeated pattern of release of a chemical into the 
atmosphere, such as through evaporation, and its subsequent deposit elsewhere, such 
as through rainfall. Due to the persistent nature of POPs, the chemicals are spread 
widely throughout the world through numerous iterations of this cycle (Fisher, 1999).
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Some of the synthetic chemical which have been linked to adverse 
thyroid-mediated effects in animals are included on UNEP’s list of 12 POPs which 
require urgent attention. These include the pesticides DDE, DDT, dieldrin, and their 
metabolites, polychlorinated biphenyls (PCBs) and dioxins. In addition, bisphenol A 
(used in epoxy resins), phthalates (widely found in plasticizers, used in many 
industrial and manufacturing contexts including the production of PVC), 
polybrominated diphenyl ethers (PBDEs -  used as flame retardants in plastics, paints, 
furniture and upholstery) and the heavy metals cadmium, lead and mercury have also 
been implicated (Myers et al., 2003; Brucker-Davies, 1998).
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1.6.1. Agonists and Antagonsists of the Thyroid System.
There are a number of ways in which, in principle, a chemical might 
exert an influence on the thyroid system. These include:
> Inhibiting iodine uptake by the thyroid gland and/or inhibiting 
hormone synthesis in the gland.
> Binding of exogenous chemicals to the serum proteins 
normally intended to transport T4 to target cells.
> Altering the breakdown and elimination of THs in the liver.
> Antagonising the effect of T3 by residing on the thyroid 
receptor and thereby denying access to T3.
> Mimicking the ways in which the natural hormone may 
operate in its binding to the hormone-receptor molecule.
>  Modulating the interactions of co-regulator proteins with 
TRs.
Shown below are the molecular structures of some of the chemicals 
which have been identified as being putative EEDs (see text for specific references.)
32
Chapter One General Introduction
HO CHo-CH T 4
COOH
HO
COOH
Cl Cl
ho^]M(3^ oh
Cl Cl
4,4-diOH-
3 ,3 ' ,5 ,5 'T C B
Br
Br Br
P B D E
  Br Br
CH,
HO— (( )>—C —( (  ) )—OH B P A
ch 3
Figure 1.6. Structures of thyroid hormones and chemicals which have been identified 
as possessing putative thyroid-modulating activity.
Abbreviations: TCB tetrachlorinated biphenyl; PDBE polybrominated 
diphenyl ether; BPA bisphenol A (4,4' isopropylidenediphenol).
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a) Polychlorinated Biphenyls.
Polychlorinated biphenyls (PCBs) are a strongly suspected EED that are 
listed by the EPA, the Centres for Disease Control and Prevention, and the WWF as a 
potential endocrine modifying chemical (Keith, 1997). These compounds were used 
as coolant fluid in transformers and fire retardants in capacitors and were produced in 
vast quantities from the 1930s to the late 1970s. Although their production was 
banned in 1979, they are still leaching from industrial and waste sites and leaking 
from old capacitors or transformers still in use today. As mentioned previously, PCBs 
are included on UNEP’s list of 12 POPs which require urgent attention. Consistent 
with many POPs, PCBs exhibit low solubility in water and high solubility in lipids. 
Combined with the chemicals’ persistence, these properties allow PCBs to 
bioconcentrate and bioaccumulate in the fatty tissues of organisms. They are present 
as a mixture of lipophilic congeners that can cross the placenta. Some of the 
congeners are very persistent, with a half-life of elimination from adipose tissue of 
several decades (Brucker-Davies, 1998). There are 209 congeners in total, with a 
variable number (1-10) of chlorine atoms attached to the benzene rings. 
Bioconcentration is the uptake of a chemical directly from water into an aquatic 
organism and is measured as a ratio of the amount of a chemical concentrated in an 
organism compared to the amount of the chemical in the surrounding environment. 
Bioaccumulation refers to the process of uptake from both water and dietary sources. 
These processes lead to biomagnification, in which tissue concentrations of a 
contaminant increase as it passes through two or more trophic levels in the food chain 
(Fisher, 1999).
PCBs in the environment may associate with organic components of 
soils, sediments, and biological tissues, or with dissolved organic carbon in aquatic 
systems. Environmental PCBs have been show to induce thyroid-related changes in 
rats, mice, mink, seals, birds and primates. The main effects in mammals are the 
occurrene of goiter, lowered T4 levels, elevated thyroid stimulating hormone (TSH) 
levels and normal or decreased T3 levels (Goldey and Crofton, 1998; Brucker-Davies, 
1998). The main source of human PCB exposure is through food, especially fish. In 
Norway, the consumption of crabs from a contaminated fjord was found to be 
associated with the presence of PCBs in serum. Humans consuming large amounts of 
contaminated seafood show elevated concentrations of PCBs in their tissues, due to
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the low biodegradation and excretion of these compounds (Johansen et al., 1997). 
PCBs have been detected in human milk, and studies suggest that mothers 
accidentally exposed to PCBs may give birth to children who display neurological 
disturbances (Johansen et al., 1997; Huisman et al., 1995). PCBs decrease circulating 
levels of T4 in animals (Hallgren and Damerud, 2002; Zoeller et al., 2000; Brucker- 
Davies, 1998; Goldey and Crofton, 1998) and it has been speculated that PCBs exert 
neurotoxic effects on the developing brain by causing a state of relative 
hypothyroidism (Crofton et al., 2000). This concept it supported by the observations 
of Goldey and Crofton, (1998) who used T4 replacement therapy in rats to show that 
the toxic effects of PCB exposure (hearing loss) could be partially ameliorated by T4 
replacement. A study by Stewart et al., (2003) used magnetic resonance imaging to 
show that the association between PCB body burden and behavioural measures of 
response-inhibition is stronger in young children that have a smaller corpus callosum, 
an area of the brain affected by thyroid hormone.
Although the effects of PCBs on brain development may be attributable 
to their ability to reduce circulating levels of thyroid hormone, the developmental 
effects of PCB exposure are not fully consistent with hypothyroidism. Zoeller et al., 
(2000) demonstrated that a mixture of PCBs, (Aroclor 1254, A1254) caused a dose- 
dependent increase in expression of the thyroid responsive gene RC3/Neurogranin, 
despite observing a severe reduction in circulating concentrations of T4. This is 
consistent with the observations that PCBs (or their metabolites) are able to bind TR 
and act as agonists in vivo. Cheek et al., (1999) examined the ability of PCBs to bind 
to human thyroid hormone receptors and thyroid hormone transport proteins. Out of 
all the compounds, only hydroxylated PCBs bound to the human thyroid receptor, but 
had a greater binding affinity to the thyroid transport protein, transthyretin. This was 
followed up by a later study which showed that hydroxylated PCBs exhibited thyroid 
hormonal activity through interaction with TR; Kitamura et al., (2005) reported that 
nine separate hydroxylated PCB congeners could bind to the rat TR with an IC50 as 
low as 50pM. These results suggest that hydroxylated PCBs have the potential to 
disrupt thyroid hormonal activity in vivo by interaction with TR; hydroxylated PCBs 
were shown to have agonistic activity for thyroid hormone on GH3 cells, a rat 
pituitary cell line where proliferation and growth hormone secretion is dependent on 
thyroid hormones. The structure of 4,4'-diOH-3,3',5,5'-TCB (tetrachlorinated 
biphenyl), which was shown to bind most potently to TR by Cheek et al., and was also
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shown to bind TR by Kitamura et al., (2005) as well as exhibiting agonistic activity 
for thyroid hormone on GH3 cells, is shown in Figure 1.6.
However, not all studies indicate that PCBs act as agonists on TRs. 
Bogazzi et al., (2003) showed that A1254 (Aroclor 1254) was able to bind specifically 
to the rat TRp at approximately 10 pM and that this concentration inhibited CAT 
activity on the ME-TRE in cultured cells by approximately 50%. Although A1254 
reduced the binding of T3 to TR by 30%, it did not affect the interaction of TR with 
the ME-TRE in a gel shift (EMSA) assay. It was postulated that A 1254 produced a 
conformational change in TR, leading to its increased proteolysis by trypsin. A later 
study by Miyazaki et al., (2004) showed that PCBs could inhibit TH-mediated 
transcription by binding to thyroid receptors and causing partial dissocciation of 
TR/RXR heterodimers from the TRE.
It is clear that PCBs are neurotoxic in humans and animals, and that they 
can interact directly with the TR. However, the consequences of PCB exposure on TR 
action appear to be quite complex. This complexity includes acting as an agonist or 
antagonist and may include TR isoform selectivity in as much as most studies have 
been performed using TRp, leaving TRa relatively unstudied in this context. In 
addition, considering that there are 209 different chlorine substitution patterns on the 
biphenyl backbone and that these can be metabolized (hydroxyl- and methylsulfonyl- 
metabolites), it is possible that different chemical species exert different effects. 
Finally, PCBs may exert different actions on TRs depending on associated 
heterodimer partners, promoter structure, or different co-factors (Zoeller, 2005).
b) Pesticides.
Ethylenebis(dithiocarbamate) (EBDC) fungicides are among the most 
common used in the USA. They are absorbed dermally and are metabolised to 
ethylene thiourea. The EPA classifies ETU as a carcinogen, as it has been shown to 
cause thyroid cancer in animal models, and it has also been shown to be genotoxic in 
bacterial and animal systems. In humans, the use of dithiocarbamate fungicides has 
been identified as causing an increase in circulating TSH amongst agricultural 
workers (Steenland et al., 1997), consistent with previous studies in rats, whereby 
exposure to ETU caused a decrease in T4 and an increase in TSH levels. The 
observed disruption in thyroid homeostasis was correlated with morphological
36
Chapter One General Introduction
changes in the thyroid gland and was postulated to be linked with the prevalence of 
thyroid tumours in the rats (Houeto et al., 1995).
Crain et al., (1998) examined the plasma levels of thyroxine and 
triiodothyronine in juvenile alligators of three lakes in Florida, as well as the 
relationship of the thyroid hormones to alligator size. The concentrations of thyroid 
hormones were found to be elevated in alligators from a lake contaminated by a 
pesticide spill in 1980, which consisted of as much as 15% DDE and DDT. In the 
reference lake thyroid hormone levels had a strong negative correlation to alligator 
size. Although it is recognized that pristine conditions no longer exist, and that in 
practice, the characteristics of an acceptable reference site may be influenced by 
socioeconomic demands the reference lake in this study was situated in a National 
Wildlife Refuge and considered to be a relatively pristine, natural environment with 
minimal influences from agricultural and municipal activities. Thyroxine levels in the 
males of the contaminated lakes were negatively correlated to size, but there was no 
clear relationship in the females. Triiodothyronine levels of the females in the 
contaminated lake had a negative relationship to size, but there was no correlation in 
the males of either contaminated lake to triiodothyronine. These results clearly 
indicate the alteration of the thyroid hormone system in alligators living in 
contaminated lakes. There are two significant questions that emerge from this study; 
first, if thyroid hormone levels are abnormal during a juvenile state is this an 
indication of embryonic exposure and is, therefore, a permanent alteration; and 
second, will the observed alterations have a significant impact of the reproductive 
potential of this cohort of alligators? (Crain et al., 1998).
c) Brominated Flame Retardants.
Polybrominated diphenyl ethers (PBDEs) are a group of aromatic 
compounds in which one to ten hydrogens in the diphenyl oxide structure are replaced 
by bromine (See Figure 1.6 for structure). PBDEs with three to ten bromine atoms are 
used in commercial flame retardants. These are commonly used in a wide variety of 
products and processes, including plastics, paints, electronic parts and fabrics. The 
emission of flame retardants to the indoor environment from products in service has 
been a focal point in the debate about the use of brominated flame retardants. The
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most obvious sources of emissions to the air would be from products where the flame 
retardants are used as additives, for example in printed circuit boards in consumer 
electronics or thermoplastic components that heat up during operation, e.g. computer 
monitors and TV screens. The emission of brominated flame retardants from office 
machines has been demonstrated by the detection of these compounds in the indoor 
atmosphere of office rooms and computer halls and PBDEs have been detected in 
human breast milk (Damerud et al., 1998). Fowles et al., (1994) exposed mice 
(orally) to a commercial PBDE mix, DE-71, and looked for endocrine effects. Mice 
that were treated with a range of concentrations of DE-71 in a single dose exhibited 
significantly lower T4 serum concentrations at all doses, bar one. Total and free T4 
concentrations were dose-dependently decreased in mice following subchronic 
exposure over a 14 day period. Ilonka et al., (2000) conducted competitive binding 
experiments to measure the potency of brominated flame retardants to intefere with 
thyroid hormone function. Their results showed that brominated flame retardants, 
especially the brominated phenols and tetrabromobisphenol A, were very potent 
competitors for T4 binding to human transthyretin (a TR-binding transporter protein) 
in vitro. A study by Hallgren and Damerud (2002) observed similar effects upon 
exposure of rats to the PBDE, DE-47, whereby T4 serum concentrations were 
lowered. They also postulated that this was due to the binding of in-vivo formed DE- 
47 metabolites to transthyretin.
d) Bisphenol A.
Bisphenol-A (BPA, 4,4' isopropylidenediphenol, see Figure 1.6 for 
structure) is produced at a rate of over 800million kg/annum in the U.S. alone (Keith, 
1997). It is used primarily in the manufacture of plastics including polycarbonates, 
epoxy resins that coat food cans, and in dental sealants. It has been reported at 
concentrations of between l-10ng/ml in serum of pregnant women, in the amniotic 
fluid of their fetus, and in cord serum taken at birth. In addition, BPA concentrations 
of up to lOOng/g have been reported in placenta (Schonfelder et al., 2002).
Moriyama et al., used transient gene expression studies to show that 
Bisphenol A acts as a T3 antagonist. T3 induced transcriptional activity on a positive 
TRE was suppressed by BPA in a dose-dependent manner and these effects were
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observed in the presence of physiological concentrations of T3. In contrast, BPA 
activated gene transcription on the TSHa negative TRE, which is suppressed by T3. 
Using a mammalian two-hybrid system, they demonstrated that BPA was able to 
recruit the corepressor N-CoR to TRp and so postulated that BPA’s antagonistic 
effects were due to it’s replacement of T3 on the TR and subsequent recruitment of N- 
CoR.
A study by Zoeller et al., (2005) showed that developmental exposure of 
rats to BPA gave rise to elevated T4 levels in the pups of BPA-exposed animals, 
whilst TSH levels remained unaltered. This is consistent with the inhibition of TRP- 
mediated negative feedback. However, expression of the thyroid-responsive RC3 
gene in BPA-treated animals was increased in the dentate gyrus. Since TRa is 
expressed in the dentate gyrus, Zoeller postulated that BPA may act as a selective TRp 
antagonist in vivo.
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1.7. International Chemical Assessment Activities.
In the U.S. in 1996, Congress passed a Food Quality Protection Act and 
amendments to the Safe Drinking Water Act, directing the Environmental Protection 
Agency (EPA) to determine whether, and to what extent, industrial chemicals disrupt 
reproductive and thyroid hormones. In reponse to its congressional mandate, the EPA 
formed the Endocrine Disruptor and Testing Advisory Committee (EDSTAC). In its 
1998 final report, EDSTAC recommended that the EPA address the effects of 
pesticides, commercial chemicals and other environmental chemicals on the endocrine 
system -  which comprises the pituitary and adrenal glands, the ovaries and testes, the 
pancreas, the hypothalamus, the parathyroid and the thyroid gland (Brown, 2003).
Efforts to test chemicals for endocrine modulating effects are being 
coordinated at the international level by the Organisation for Economic Cooperation 
and Development (OECD). In 1996, the OECD established a Task Force on 
Endocrine Disruptor Testing and Assessment (E-DTA), with representation from both 
governmental and non-governmental entities. From the E-DTA emerged two 
“validation management groups” (VMG), each with a mandate to oversee the 
development and validation of various in vivo test methods, for mammalian and 
ecotoxicological effects, respectively. However, in June 2002, a special session of the 
E-DTA recommended the addition of a number of non-animal approaches (including 
the in vitro thyroid screening assays) to the OECD’s proposed “toolbox” of assay 
systems. This significant move culminated in a unanimous recommendation to 
establish a third VMG specific to non-animal screening and testing methods. The E- 
DTA’s recommendations were subsequently ratified at the OECD Joint Meeting in 
November 2002.
1.7.1. EDSTAC -  Tiered Testing.
The EDSTAC proposal from its final report (1998) included: (1) a 
process to prioritise chemicals for evaluation, along with tiered; (2) screening (Tier 1); 
and (3) testing (Tier 2) batteries. Since there are currently in excess of 80,000 
chemicals in commercial use today (Keith, 1997), only a subset of high priority 
chemicals would initially enter the screening program. Prioritization would include an 
estimation of the chemical’s ability to interact with steroid hormone receptors using 
either quantitative structure activity modelling (QSAR) for chemicals that bind steroid
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receptors, or high-throughput pre-screening (HTPS) using hormone-dependent gene 
expression assays, among several other factors (Gray Jr et al., 2002).
The screening battery recommended by EDSTAC was designed to detect 
alterations of hypothalamic-pituitary-gonadal (HPG) function, estrogen, androgen and 
thyroid hormone synthesis and AR-, ER- and TR- (androgen, estrogen and thyroid 
receptor, respectively) mediated effects in mammals and other taxa. Chemicals 
positive in Tier 1, based upon a “weight-of-evidence” analysis, would be considered 
as potential EEDs and subjected to testing (Tier 2). Tier 1 screening assays (T1S) 
should be sensitive enough to detect EEDs, whilst issues of dose-response, relevance 
of the route of exposure, sensitive life stages and adversity are resolved in Tier 2 
Testing (T2T; Gray Jr, L.E. 1998). In this tiered approach, use of animals is 
minimised, as only chemicals displaying positive responses in T1S would be 
evaluated further in T2T. In addition, testing statistical “false positives” can be almost 
entirely eliminated by assuring that T1S assay results are replicated before moving to 
T2T.
T1S in vitro assessments of EEDs would compliment the results of the 
T1S in vivo assays. Short-term in vivo mammalian assays were proposed for the Tier 
1 Screening Battery because of major limitations of in vitro assays. In vitro assays 
cannot account for metabolic activation of xenobiotics, resulting in “false negative” 
responses (positive in vivo, but negative in vitro). These assays can also yield false 
positive responses when chemicals are examined at in vitro concentrations which are 
orders of magnitude above those seen in vivo (Gray Jr et al., 2002).
1.7.2. Extant Tier 1 Screening Assays.
1.7.2.1. Estrogen Disruption,
a) In Vitro Assays.
A number of assays have been developed to screen substances for 
estrogenicity. These assays include competitive ligand-binding assays, recombinant 
receptor-reporter assays, and yeast-based screens. Murk et al., (2002) describe a 
sequential testing strategy for the identification of xenoestrogens found in wastewater. 
The binding of a compound to the estrogen receptor (ER) is measured in the ER 
competitive ligand binding assay (radioactive). Binding to the ER of both agonists
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and antagonists gives a positive response, and all compounds can reach the ER 
without having to pass a cell membrane. The next assay to be used is the Yeast 
Estrogen Screen (YES) assay. This assay uses a yeast cell transformed with a human 
ER and a plasmid containing the estrogen-responsive element (ERE) upstream of the 
LacZ reporter gene, encoding P-galactosidase. Activation of the receptors results in 
increased red colouring of the assay medium. This assay is a measure of agonistic 
action. In the ER-CALUX (chemically activated luciferase gene expression) assay, 
reporter gene expression is also a measure of the ER-mediated cascade of events 
resulting in gene expression. In this assay, the T47D human breast adenocarcinoma 
cells were stably-transfected with an estrogen-responsive luciferase reporter construct. 
Both hydrophilic and lipophilic compounds can pass the cell membrane and 
antiestrogenic potency can be detected as well. In all assays, ERa is the important 
isoform (Murk et al., 2002).
b) In vivo Assays.
Estrogen agonists and antagonists are detected using the “pubertal female 
rat assay”, described by Goldman et al., (2000). In this assay, weanling female rats 
are dosed daily by gavage for 2 1  days and the age at vaginal opening (puberty) is 
monitored and the females are necropsied at approximately 42 days of age. 
Measurements taken include uterine and ovarian weight and histology, as well as 
serum thyroid hormones. This assay detects alterations in estrogens, HPG function, 
inhibition of steroidogenesis and thyroid hormone status.
1.7.2.2. Androgen Disruption,
a) In Vitro Assays.
Wong et al., (1995) used recombinant human androgen receptor (AR) in 
a whole-cell binding assay (radioactive) to compare the binding affinities of known 
androgen disruptors. They also utilised a transient transfection approach in order to 
assess the effects of disruptors on AR-mediated transcription. Cell lines which have 
been stably-transfected with androgen responsive luciferase reporter constructs have 
since been developed (Wilson et al., 2002).
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b) In Vivo Assays.
Androgen agonists and antagonists can be detected using the 
Hershberger assay (Gray, 1998). In this assay, (anti)androgenic activity is assessed 
simply by weighing androgen dependent tissues in the castrated male rat. The weights 
of the ventral prostrate, Cowper’s glands, seminal vesicle, glans, penis and levator 
ani/bulbocavemous muscles are measured in castrated male rats (with or without 
exogenous testosterone) after 1 0  days of oral treatment with the test compound.
A second T1S in vivo assay which can be used as an alternative to the 
Hershberger assay is the “pubertal male rat assay”. Intact weanling males are exposed
to the test substance for about 30days, the age at puberty is determined and
reproductive tissues are evaluated and serum taken for hormonal analyses.
1.7.2.3. Estrogen and Androgen Disruption.
A second non-mammalian vertebrate T1S assay is a short-term 
reproduction test with the fathead minnow (Pimephales promelas) that can be used to 
detect chemicals that would adversely affect processes controlled by the estrogens and 
androgens. This test, also known as the “fish gonadal recrudescence assay”, is 
initiated with sexually mature animals. Reproductive performance of the fish is 
monitored for two to three weeks prior to chemical exposure in order to provide 
baseline data for pre- versus post-exposure statistical analyses. The duration of 
chemical exposure is about 2 1  days, during which survival, behaviour, appearance 
(e.g. secondary sex characteristics), fecundity and fertility are monitored. At 
conclusion of the test, the adults are sampled to determine gonadal condition (relative 
gonad weight, histopathology) and plasma concentrations of sex steroids (17 0 - 
estradiol, testosterone, 11-ketotestosterone) and vitellogenin (Gray Jr et al., 2002).
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1.7.2.4. Thyroid Disruption.
a) In Vitro Assays.
There exist, as yet, no recognised in vitro assays for the T1S screening of 
chemicals for potential thyroid-disrupting properties.
b) In Vivo Assays.
There exist a number of T1S in vivo assays for the detection of thyroid- 
disrupting chemicals. The pubertal male and pubertal female rat assays have been 
described above. In addition to these two assays, EDSTAC recommended a further 
two assays with non-mammalian vertebrates for T1S screening of EEDs, one of which 
is specific to thyroid disruption; a metamorphosis assay with the amphibian Xenopus 
Laevis was designed to detect EEDs that could affect the vertebrate thyroid system. 
X.Laevis is a particularly sensitive environmental species, and it was suggested that 
the assay be initiated with stage 60 X. laevis, and rate of tail resorption be monitored 
over the course of a 14 day chemical exposure; an agonist would enhance resorption, 
while an antagonist would inhibit the process (Gray Jr et al., 2002).
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1.8. Aims of this Project.
The ultimate aim of this project is the development of simple in vitro 
tests, which will act in accordance with the EDTA’s recommendations and augment 
the OECD’s proposed “toolbox” of assays, providing evidence of thyroid disruption 
by chemicals which are, or which might be released into the environment. High- 
throughput screening assays will be developed, which may utilise non-radioactive 
detection technologies, such as the chemiluminescent acridinium ester (AE).
1.8.1. Transcriptional Activation.
Thyroid hormones act predominantly at a pre-translational level, 
selectively affecting gene expression through thyroid receptors (TRs), whose mode of 
action is modulated by regulatory proteins. Although TR-DNA binding is a pre­
requisite for the modulation of gene expression, it does not reflect the complexity of 
other cellular factors that influence T3-moderated gene transcription.
In order to address the problems of both the complexity of the 
modulation of gene expression and the effects of biological processing, two parallel 
approaches will be used. Cell-free (in vitro) systems, using a nuclear extract and 
purified recombinant TR will be developed. A cell culture approach will also be 
developed, in order to address two important factors, cell entry and metabolism.
Constructs containing known TREs upstream from a reporter sequence 
(luciferase) will be introduced into both cell-free and cell culture systems, together 
with standard control constructs (where required). Reporter gene expression levels 
(luciferase mRNA and luciferase protein for cell-free and cell culture systems, 
respectively) will initially be quantified using standard techniques. Following 
optimisation of assays, including extraction and purification procedures, quantification 
of the reporter gene mRNA synthesis and transcription of the internal control will be 
detected using the HPA technology.
The development of in vitro transcription assays will require pure, 
recombinant TR; murine TRs (TRa and TRp) will be inserted into an expression 
vector and transformed into E.coli. Authentic recombinant receptors will be liberated 
from the purification fusion protein by proteolytic cleavage. Recombinant TR will 
subsequently be utilised in the in vitro transcription assays and will also allow the 
development of TR-DNA binding assays.
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1.8.2. Binding Studies.
A pre-requisite of TR-mediated control of gene expression is the binding 
of TR to DNA. In order to assess the impact of any chemical moderator on this 
protein-DNA interaction it is essential to have a sensitive and quantitative assay 
technique. Therefore, assay technology will be developed to probe the interaction of 
TR with DNA.
The binding of recombinant TR to DNA will be monitored using the 
electrophoretic mobility shift assay (EMSA). Modulation of binding in the presence 
of T3 and known T3 analogues is a complexity that will be studied after rapid binding 
assay systems have been developed. Utilisation of the acridinium ester (AE) 
technology will allow the development of non-radioactive screens for compounds that 
disrupt the interactions of recombinant TR with AE-labelled oligos.
The development of these screens will allow more informed risk 
assessments to be made concerning the potential human health impact from the release 
of novel chemicals into the environment, or the risk to communities/workforces 
exposed to chemicals that are already in use.
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CHAPTER TWO 
MATERIALS AND METHODS.
2.1 Materials.
Routine Laboratory materials were purchased from Fisher Scientific Ltd 
(Loughborough, Leicestershire, UK) and Sigma Chemicals Ltd (Poole, Dorset, UK). 
The suppliers of more specific chemicals, reagents and equipment are listed in Table
2 . 1.
Reagent Supplier
Hybond™ -C extra nitrocellulose membrane 
Hybond™ -N neutral nylon membrane 
Megaprime™ DNA Labelling System
Amersham Biosciences UK Ltd 
(Buckinghamshire, UK)
Splittix™
Foetal bovine serum 
Foetal bovine serum (stripped)
Autogen Bioclear 
(Caine, Wiltshire, UK)
BCIP/NBT premixed colour development reagent BioRad Laboratories Ltd 
(Watford, Hertfordshire, UK)
Dynabeads® mRNA DIRECT™ Kit Dynal Biotech ASA 
(Oslo, Norway)
Culture flasks/dishes and disposable plastics Greiner 
(Stonehouse, UK)
Chicken TRa Insight Biotechnology Ltd 
(Wembley, Middlesex, UK)
BenchMark™ prestained protein ladder 
pcDNA3.1(-) vector 
TOPO® XL PCR Cloning Kit
Invitrogen 
(Paisley, UK)
0.22pm Nucleopore™ filters Millipore UK Ltd 
(Watford, Hertfordshire, UK)
Autodetect 1 
Autodetect 2 
Hybridisation buffer 
Probe storage buffer 
Selection reagent
MLT Research Ltd 
(Cardiff, Wales, UK)
Oligonucleotide primers MWG Biotech UK 
(Milton Keynes, UK)
47
Chapter Two Materials and Methods
Protogel Acrylamide Solution National Diagnostics, Hessle, Yorkshire, UK
Restriction endonucleases New England Biolabs 
(Beverly, MA, USA)
pET15b vector Novagen
ProteoJuice™ Protein Transfection Reagent (Oxfordshire, UK)
ABI Prism™ Dye Terminator Cycle Sequence Perkin Elmer Applied Biosystems
Reaction Ready Kit (Warrington, UK)
Sephadex-G50 Nick columns Pharmacia Ltd 
(Tadworth, Surrey, UK)
DNA ligase Promega Ltd
DNA molecular weight markers(X and <)>) (Southampton, UK)
dNTPs
G418 (neomycin) -  sulphate
HeLaScribe Nuclear Extract In Vitro
Transcription System,
Luciferase Assay Reagent
MMLV reverse transcriptase
pGEM® -T vector
Reporter Lysis Buffer (RLB)
Taq DNA polymerase
TransFast™ Transfection Reagent
Wizard SV Plus™ Mini and Maxi prep DNA
Purification Systems,
Wizard Genomic DNA Purification Kit
QIAquick™ Gel Extraction Kit QIAGEN
Ni-NTA AP Conjugate (Crawley, UK)
NiNTA agarose
Expand™ High Fidelity PCR System Roche Diagnostics Ltd 
(Sussex, UK)
75 x 12mm Polystyrene Assay Tubes Sarstedt 
(Leicester, UK)
lOx TAE Sigma Chemicals Ltd
Ficoll (Type 400) (Poole, Dorset, UK)
poly(dl-dC)
Salmon testes DNA
Triiodothyronine (T3)
TRI reagent™
pRG224 Luciferase reporter vector A gift from Dr. R.C. Caswell, 
Cardiff University, Cardiff, Wales
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Table 2.1. Materials and Reagent supply.
All standard buffers and reagents required for molecular biological 
procedures were prepared according to the protocols of Sambrook et al., (1989). 
Sterilisation was achieved by autoclaving at 121 °C and 15p.s.i. for 2 0 min. A list of 
buffers and solutions along with their compositions is shown in Table 2.2.
Solution Components
Preparation of Plasmid DNA
Section 2.2.1.3
a) Small-scale
b) Large-scale
Cell Resuspension Solution
50 mM Tris (pH 7.5), 
lOmMEDTA, 
100 pg/ml RNase A
Cell Lysis Solution 0.2 M NaOH, 1% SDS
Neutralisation Solution
4.09 M Guanidine Hydrochloride, 0.759 M 
Potassium Acetate,
2.12 M Glacial Acetic Acid, (adjusted to pH 4.2)
Column Wash
60 mM Potassium Acetate, 10 mM Tris-HCl (pH 
7.5), 60 % Ethanol
Reverse Transcriptase
(Section 2.2.1.11.)
5x MMLV-RT buffer
50 mM Tris-HCl (pH 8.3), 
75 mM KC1,
3 mM MgCl2, 10 mM DTT
Isolation of Genomic DNA
(Section 2.2.1.16.)
Nuclei Lysis Solution
Protein Precipitation Solution
Southern Blotting
(Section 2.2.1.17.)
Denaturing solution 0.5M NaOH, 1.5MNaCl
Transfer solution 0.25M NaOH, 1.5MNaCl
Hybridisation buffer
50% (v/v) formamide, 5x SSPE, 5x Denhardt’s 
solution (see below), 0.1% (w/v) SDS and 
200|ig/ml salmon testes DNA
20x SSC 3M NaCl, 0.3M sodium citrate, pH 7.0
20x SSPE 3M NaCl, 200mM NaH2P 04.H20 , 20mM EDTA,
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pH 7.7
5Ox Denhardt’s reagent
l%(w/v) BSA, 1% (w/v) ficoll type 400 and 1% 
(w/v) polyvinylpyrrolidone
Wash Solution I (low stringency) 2x SSC, 0.1% (w/v) SDS
Wash Solution II (medium stringency) 0.5x SSC, 0.1% (w/v) SDS
Wash Solution III (high stringency) O.lxSSC, 0.1% (w/v) SDS
In vitro transcription reactions
(Section 2.2.1.18.)
HeLa Nuclear Extract lx Transcription Buffer
20mM HEPES (pH 7.9 at 25°C), lOOmM KC1, 
0.2mM EDTA, 0.5mM DTT, 20% Glycerol
HeLa Extract Stop Solution
0.3M Tris-HCl (pH 7.4 at 25°C), 0.3M sodium 
acetate, 0.5% SDS, 2mM EDTA, 3pg/ml tRNA
Formamide Loading Dye
98% formamide, lOmM EDTA, 0.1% 
bromophenol blue
Quantitative PCR
(Section 6.3.1.2)
lOxQPCR buffer
200 mM Tris-HCl (pH 8.3), 
500 mM KC1, 40 mM MgCl2, 
10 pM ROX
Transient transfection using calcium- 
phosphate precipitation
(Section 2.2.2.3.a.)
2x HBS
250mM NaCl, 50mM HEPES, 1.5mM Na2P 04, 
pH 7.15.
O.lxTE ImM Tris, 0.1 mM EDTA
Acridinium Ester Assays 
(Section 3.)
Hybridisation buffer (2x)
250mM lithium hydroxide, 190mM succinic acid, 
pH 5.2, 3mM EDTA, 3mM EGTA, 17% (w/v) 
lithium lauryl sulphate
Selection reagent
190mM sodium tetraborate, 6.4% Triton X-102, 
pH 7.5
Autodetect I 0.032M hydrogen peroxide, 0.001M nitric acid
Autodetect 2 1.575M sodium hydroxide
Wash Buffer
lOmM Tris-HCl, pH 7.5, 0.15M LiCl, ImM 
EDTA, 0.1% 0.1% (w/v) lithium lauryl sulphate
Protein SDS-PAGE
(Section 2.2.3.3.)
4% (w/v) SDS, 125mM Tris-HCl (pH 6.8), 20% 
(v/v) Glycerol, 0.02% (w/v) Bromophenol Blue,
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2x SDS-PAGE sample loading buffer 2% (v/v) P-mercaptoethanol.
lOx SDS-PAGE running buffer
1.92M Glycine, 250mM Tris-HCl (pH 8.8), 0.1% 
(w/v) SDS
Coomassie blue solution
0.025% (w/v) Coomassie blue, 50% (v/v) 
methanol, 10% (v/v) acetic acid
Destain solution 10% (v/v) methanol, 10% (v/v) acetic acid
Western Blotting
(Section 2.2.3.4.)
Anode I solution 300mM Tris, 20% (v/v) methanol
Anode II solution 25mM Tris, 20% (v/v) methanol
Cathode solution
25mM Tris, 20% (v/v) methanol, 40mM caproic 
acid
Detection of recombinant proteins using the 
His conjugate
(Section 2.2.3.5.)
TBS buffer lOmM Tris-HCl pH 7.5, 150mM NaCl
TBS-Tween buffer
20mM Tris-HCl pH 7.5, 500mM NaCl, 0.05% 
Tween 20
Purification of recombinant proteins using 
Ni-NTA agarose
(Section 2.2.3.6.)
Lysis buffer
50mM NaH2P04, 300mM NaCl, lOmM 
imidazole, pH 8.0
Wash buffer
50mM NaH2P04, 300mM NaCl, 20mM 
imidazole, pH 8.0
Elution buffer
50mM NaH2P 04, 300mM NaCl, 250mM 
imidazole, pH 8.0
Storage buffer 50% glycerol in PBS, 5mM DTT
EMSA
(Section 2.23.1.)
Binding buffer (lOx) 340mM KC1, 50mM MgCl2, ImM DTT
Dilution buffer 40mM KC1, O.lmM EDTA
Miscellaneous
lx TE buffer lOmM tris, ImM EDTA
PBS
137mM NaCl, 2.7mM KC1, 8.1mM Na2HP04 and 
1.5mM KH2P 0 4
Table 2.2. Buffer, Solution and Reagent composition.
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2.1.1. Water.
Where the grade of water is not specified, sterile ddH20 was used. For 
all applications involving DNA manipulations, sterile HPLC-grade water was used.
2.1.2. Antibiotics.
Stock solutions of antibiotics were dissolved in the appropriate solvent 
(sterile ddt^C) for ampicillin and kanamycin and lOOmM HEPES pH 7.3 for G418) to 
the required concentration, passed through a 0.22pm Nucleopore™ filter and stored at 
-20°C in 250pl volumes (thus avoiding multiple ffeeze-thaw cycles). The stock 
concentrations of antibiotics prepared were 1 0 0  mg/ml ampicillin,
30 mg/ml kanamycin and 50mg/ml G418.
2.1.3. Sterilisation Conditions.
Where necessary, all equipment and reagents were sterilised prior to 
employing any technique involving nucleic acid manipulations. Sterilisation was 
achieved by autoclaving at 121°C and 15psi for 20 min. Any heat-sensitive 
components were sterilised by filtration through a 0.22pm Nucleopore™ filter.
2.1.4. Media.
LB nutrient broth and LB agar were prepared as described by the 
Manufacturer (Sigma), that is, by the addition of the appropriate number of capsules 
to water. Antibiotics, where required, were added at an appropriate concentration -  
usually a 1 : 1 0 0 0  dilution of the stock solution.
2.1.5. Oligonucleotide Primers.
In order to minimise mispriming, primers were designed using the 
OLIGO® 1991 Primer Analysis Software (Version 4.0, Wojcieck Rychiick, National 
Biosciences, Plymouth, MN, USA). Primers selected for optimal Tm at the given 
length were assessed for self-complementarity as well as complementarity to the 
second primer, in order to reduce the risk of the formation of primer-dimers.
Lyophilised oligonucleotides were resuspended in water (lOOpmol/pl) 
and stored at -20°C. For specific oligonucleotide sequences, see Appendix 1.
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2.1.6. DNA vectors and E.coli Host Strains.
DNA fragments generated by PCR and restriction endonuclease 
digestion were ligated into pGEM® -T. Recombinant protein expression was 
performed in pET15b. A list of the E.coli host cell strains used for manipulations of 
recombinant DNA is shown in Table 2.3.
Bacterial host strain Selectable marker Supplier
E.coli DH5a N/A Invitrogen
E.coli BL21 (DE3) N/A Novagen
E.coli BL21 (DE3) Rosetta 
pLysS
Chloramphenicol Novagen
Table 2.3. List of all E.coli host strains employed for manipulations of recombinant 
DNA. The respective selectable markers and suppliers are also shown.
2.1.7. DNA Markers.
The DNA markers used were X/Hindlll and §\14IHae\l\. The 
fragment sizes of these markers are given in Table 2.4.
DNA Marker Fragment Sizes (bp)
X/Hindlll 23130, 9416, 6557, 4361, 2322, 2027, 
564, 125
^114/Haelll 1353, 1078, 872, 603, 310, 281, 271, 234, 
194, 118, 72
Table 2.4. DNA marker fragment sizes.
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2.1.8. Standard Cell Culture Materials.
Routine media and solutions for mammalian cell culture were obtained 
from Autogen Bioclear, Caine, Wiltshire, UK. The suppliers of more specific 
materials are listed in Table 2.1. The compositions of buffers and solutions used in 
cell culture techniques are detailed in Table 2.2.
2.1.9. Cell Lines.
Human Cell Lines were obtained from the European Collection of Cell 
Cultures (ECACC), Porton Down, Dorset, UK. Details of cell lines used are shown in 
Table 2.5.
Cell Line Description ECACC Number
U373 MG Human glioblastoma 
astrocytoma
89081403
CV-1 African green monkey 
kidney fibroblast
87032605
Table 2.5. Cell line, with description and ECACC Number.
2.1.10. Protein Markers.
The protein markers used were BenchMark™ Prestained Protein 
Ladder. Although it was possible for specific fragment sizes to vary between different 
batches of marker, they were, on the whole, consistent. An example of the fragment 
sizes of a typical batch of markers is given in Table 2.6.
Protein Marker Molecular weights (kDa)
BenchMark™ Prestained Protein Ladder 176.5, 113.7, 80.9, 63.8, 49.5, 37.4, 26.0, 
19.6, 14.9, 8.4.
Table 2.6. Protein marker molecular weig its (kDa).
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2.2. M ethods.
2.2.1. Molecular Biology Methods.
2.2.1.1. Agarose Gel Electrophoresis.
DNA samples were routinely resolved by agarose gel electrophoresis 
(0.5% - 2.0% w/v agarose gels, containing 500pg/l ethidium bromide). Samples were 
run at 120V for approximately 30min in a Pharmacia GNA-100 submarine tank, 
containing lx TAE buffer. Nucleic acid bands were visualised under UV light. The 
size of each separated fragment was estimated relative to the migration of DNA 
markers of known size, as detailed in Section 2.1.7.
2.2.1.2. PCR Amplification.
PCR was performed using a reaction mixture containing target DNA,
5 units of Taq polymerase, forward and reverse primers each at lpM, dNTPs each at 
0.02mM, 25mM MgCE, and lx PCR reaction buffer (containing 50mM Tris-HCl 
buffer, pH 8.0, lOOmM NaCl, O.lmM EDTA, 5mM DTT). Preparative mixtures 
(20pl) were contained within 0.2ml thin-walled PCR tubes. The thermocycling 
reactions were carried out in a Primus 25/96 Thermocycler (MWG Biotech).
2.2.1.3. Preparation of Plasmid DNA.
a) Small-scale Preparation of Plasmid DNA.
Plasmid DNA was purified from overnight cultures using the Wizard 
Plus™ SV Miniprep DNA purification system as described in the manufacturer’s 
protocol (Promega).
b) Large-scale Preparation of Plasmid DNA.
Plasmid DNA was purified from overnight cultures using the Wizard 
Plus™ SV Maxiprep DNA purification system as described in the manufacturer’s 
protocol (Promega).
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2.2.1.4. Purification of DNA.
a) Phenol-chloroform Extraction and Ethanol Precipitation.
i) Phenol-chloroform Extraction.
DNA was purified by the addition of an equal volume of phenol (pH 
8.0), followed by thorough vortexing and centrifugation at 13,000 x g  for 3min. The 
aqueous layer was removed and placed in a fresh tube. An equal volume of phenol 
was again added and the sample was mixed, centrifuged and separated as before. An 
equal volume of chloroform was added and the sample mixed and centrifuged for a 
third time. The aqueous phase, containing purified DNA was removed to a clean tube.
ii) Ethanol Precipitation.
Purified DNA was precipitated overnight at -80°C by the addition of 2 
volumes (v/v) of 100% ethanol and 0.1 volume (v/v) of 3M sodium acetate (pH 4.0). 
The DNA was recovered by centrifugation at 13,000 x g  for 15min at 4°C. The 
supernatant was removed and the pellet air-dried at room temperature. The DNA was 
resuspended in an appropriate volume of water.
b) Extraction of DNA from Agarose Gel.
DNA was fractionated by agarose electrophoresis as described in Section
2.2.1.1. The desired band was excised and purified using the QLAquick™ Gel 
Extraction Kit, as described in the manufacturer’s protocol (Qiagen).
2.2.1.5. Assessment of DNA Concentration and Purity.
Estimated DNA concentrations were obtained by spectroscopic analysis 
at 260nm, using a diode array spectrophotometer (Hewlett Packard model 825A , 
Meridien, CN, USA). Absorbance readings at 230nm and 280nm also allowed an 
estimation of DNA purity to be made.
2.2.1.6. Restriction Digest.
DNA samples were digested with restriction enzymes according to the 
manufacturer’s recommendations. Typically, 5-10 U of enzyme was added per l-2pg 
of DNA and reaction incubated at 37°C for 2h.
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2.2.1.7. Dephosphorylation of Digested DNA.
Digested vector was dephosphorylated in order to prevent re-ligation. 
Where necessary, calf intestinal phosphatase (lU/pg DNA) was added to a restriction 
endonuclease reaction after lh. The reaction was then incubated for a further hour 
(37°C). In order to terminate the dephosphorylation reaction, samples were resolved 
by agarose gel electrophoresis, and the DNA purified as detailed in Sections2.2.1.1. 
and 2.2.1.4.b. respectively.
2.2.1.8. Ligation of DNA into Plasmid Vectors.
Ligation reactions typically consisted of a vector:insert ratio of 1:3 (on 
the basis of molarity) and were carried out in a final volume of lOpl. DNA ligase was 
added to lp l of lOx DNA ligase buffer (300mM Tris-HCl, pH 7.8, lOOmM MgCh, 
lOOmM DTT and lOmM ATP) and the reaction mixture was incubated at 16°C 
overnight.
2.2.1.9. Transformation of Competent E.coli Cells by Plasmid DNA.
Aliquots (50pl) of competent DH5a cells were thawed on ice, prior to 
the careful introduction of the ligated sample (3 pi). Cells were incubated on ice for 
30min, then heat shocked at 37°C for 20sec. Following a further 2min on ice, 0.95ml 
of 37°C LB-broth was added to the sample, prior to a lh incubation at 37°C. The cells 
were then pelleted by spinning at 2000 x g  for 8 min, resuspended in 150pl LB-broth 
and plated out on LB-agar plates containing the ampicillin selection marker. The 
plates were allowed to stand for 2min to dry, before inversion and incubation at 37°C 
for 16h.
2.2.1.10. Preparation of total RNA.
Total RNA was prepared using the TRI reagent™ method. A whole 
mouse heart was homogenised in 1ml of TRI reagent™ using an homogeniser, and the 
mixture allowed to stand at RT for 5min. Chloroform (200pl) was added and the 
sample vortexed (5sec), before a further incubation of 15min at RT. The phases were 
separated by centrifugation (10,000 x g  for 15min at 4°C) and the upper, aqueous 
phase removed to a clean microcentrifuge tube. Iso-propanol (500pl) was added, and 
the mixture was incubated at RT for lOmin. Precipitated RNA was recovered by
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centrifugation (10,000 x g  for 15min at 4°C). The RNA pellet was washed in 70% 
(v/v) ethanol, vortexed and centrifuged (10,000 x g  for 5min at 4°C). The RNA pellet 
was air-dried at RT and resuspended in 100pi H2O. RNA samples were quantified 
and evaluated for purity by spectrophotometry (GeneQuant, Amersham Pharmacia 
Biotech, UK). RNA integrity was analysed by agarose gel electrophoresis (Section
2.2.1 .1 .). Samples were stored at -70°C until required.
2.2.1.11. Reverse Transcriptase Reaction.
A reverse transcriptase reaction containing the following components 
was made up in a sterile 1.5ml microcentrifuge tube: 50pmol oligo-dT primer,
50pmol random hexamers, ImM dNTPs, 400 U MMLV reverse transcriptase, reverse 
transcriptase reaction buffer, lOmM DTT and 20U RNasin® made up to a final 
volume of 15pl with H2O.
The RNA to be reverse transcribed was made up to up to 15 pi with H2O 
in a separate tube and denatured by heating at 65°C for 5min. The template (15pi) 
was then added to the reverse transcriptase mix, bringing the final volume to 30pl. A 
negative control mix was also produced, where all reaction components were 
combined in a sterile microcentrifuge tube, apart from the reverse transcriptase 
enzyme. Reaction mixes were briefly centrifuged (5sec pulse, 13,000 x g) and
incubated at 37°C for 2h. The reactions were terminated by denaturing the enzyme
(80°C for lOmin), and the cDNA stored at -20°C until required.
2.2.1.12. PCR Screening of Bacterial Colonies.
PCR was used to amplify cDNA inserts from bacterial colonies 
harbouring plasmid DNA. LB medium (2ml) was inoculated with a single, random, 
recombinant bacterial colony. Following a 3h incubation (37°C with constant 
agitation) 1 ml of bacterial culture was removed and pelleted by centrifugation (13,000 
x g  for lmin at RT). The supernatant was removed and the pellet resuspended in 
lOOpl H2O. Cells were lysed (95°C for 5min) and cell debris pelleted (13,000 x g for 
lmin at RT). An aliquot (1 pi) of supernatant was used as template in the PCR mix. 
Amplification reactions were subsequently carried out as detailed in Section 2.2.1.2.
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2.2.1.13. Sequencing of Plasmid DNA -  ABI Prism™ Dye Terminator Cycle 
Sequencing.
Sequencing reactions were carried out according to the manufacturer’s 
recommendations (ABI, 1995), with minor alterations. Terminator Ready Reaction 
mix was mixed with approximately 290ng of purified plasmid DNA (Section 2.2.1.3.) 
1.6pmol of the appropriate primer, and made up to a final volume of 15 pi with water. 
Thermal cycling was carried out in a Primus 25/96 Thermocycler (MWG Biotech), 
using the following cycling parameters:
Chain denaturation 95 °C
Primer annealing 50°C
Chain extension 60°C
Soak 4°C
Isopropanol (90pl) 70% (v/v) was added, the samples were vortexed and 
the DNA was allowed to precipitate in the dark (20min at RT). Samples were 
centrifuged at RT for 30min at 13,000 x g. The isopropanol was removed, and the 
pellet rinsed with a further 150pl of 70% (v/v) isopropanol. Following vortexing, 
samples were again spun at RT for 5min at 13,000 x g  and the supernatant removed. 
Pellets were allowed to air-dry in the dark and the tubes wrapped in foil before storage 
at -20°C, prior to sequencing.
The resulting amplified DNA fragments, now fluorescently labelled, 
were separated (using an acrylamide/urea gel matrix), detected and the sequence 
determined using an ABI ™ 377 DNA sequencer.
2.2.1.14. Sequence Analysis,
a) Bioedit Sequence Alignment
The Bioedit software -  sequence alignment editor version 4.8.10, was 
used for various DNA sequence analysis functions, including open reading frame 
analysis, translation and multiple alignments using the CLUSTAL W method 
(Thompson et al., 1994).
lOsec 
5 sec 
4min
25 cycles
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b) DNAsis.
The computer software, DNAsis, was used for sequence analysis, 
including procedures as mentioned in Section 2.2.1.14.a. as well as the generation of 
consensus sequences.
2.2.1.15. Sequence Identification -  Database Searches.
DNA sequences were compared to all database entries, searching for 
protein similarities (in all six reading frames), (BlastX searches), and nucleotide 
similarities (BlastN searches), using the Blast search analysis programme (Altschul et 
al., 1997) which is part of the EBI online software suite (www.ncbi.nlm.nih.gov/).
2.2.1.16. Isolation of genomic DNA from Cultured Cells.
Genomic DNA was isolated from cultured cells using the Wizard
Genomic DNA Purification Kit according to the manufacturer’s instructions 
(Promega) with some minor modifications. CV1 cells from a confluent T175 were 
detached by scraping with a rubber policeman and pelleted by spinning at 16,000 x g  
for lmin. The supernatant was removed and the cells resuspended by pipetting in 
500pl cold (4°C) PBS before a further lmin spin at 16,000 x g. The supernatant was 
decanted and the cell pellet was subjected to four cycles of freeze-thaw as follows; the 
pellet was frozen in liquid nitrogen and then thawed by heating to 95°C in a water 
bath.
Nuclei lysis solution (600pl) was added and the cells resuspended by 
pipetting. DNase-free RNase was added (12pg) and the sample was mixed by 
inversion before a 30min incubation at 37°C. Following a further 5min incubation to 
allow the sample to cool to RT, Protein Precipitation Solution was added (200pl) and 
the sample was vortexed vigorously for 20sec before a 4min spin at 16,000 x g. The 
DNA-containing supernatant was then carefully removed and added to 600pl 
isopropanol in a clean microcentrifuge tube. Gentle mixing by inversion caused the 
gradual appearance of white thread-like strands of DNA. The sample was then spun 
for lmin at 16,000 x g  and the supernatant decanted. Pelleted DNA was washed by 
the addition of 600pl 70% (v/v) ethanol and gentle inversion of the tube. Following a 
lmin spin at 16,000 x g , the ethanol was decanted and the pellet allowed to air-dry at
60
Chapter Two Materials and Methods
RT for 20mins. TE buffer (100 pi) was added to the pellet, which was subsequently 
rehydrated at 65°C for lh. Rehydrated samples were stored at 4°C.
2.2.1.17. Southern Blotting
a) Preparation of [a32P]-dCTP Labelled Probes.
DNA fragments were radiolabelled by the random priming method using 
the Megaprime DNA Labelling System, according to the manufacturer’s instructions 
(Amersham). In this way, 25-50ng of DNA was combined with random hexamers and 
boiled for 5min, prior to chilling on ice. Following the annealing of primers, labelling 
buffer (containing unlabelled dATP, dGTP and dTTP) was added along with Klenow 
polymerase (2pl) and 3pi of [a-32P]-dCTP (Amersham). Following an incubation of 
15min at 37°C the reaction was terminated by the addition of TE buffer (50pl).
b) Purification of Radiolabelled Probes.
A Sephadex-G50 Nick column (Pharmacia) was equilibrated with 9ml of 
TE buffer. The terminated labelling reaction (lOOpl) was carefully layered onto the 
column, followed by a further 300pl of TE buffer and the subsequent eluate (400pl) 
was collected as fraction 1. This step was repeated in order to obtain a second 
fraction, which contained the radiolabelled probe.
c) Downward Alkaline Transfer.
Genomic DNA (50pg) extracted from CV1 cells as described in Section
2.2.1.16, was digested with BaniHl and Smal, as described in Section 2.2.1.6.. 
Following separation by electrophoresis on a 1% agarose gel, DNA fragments were 
denatured by soaking the gel in denaturing solution for 30min and then transferred to a 
neutrally-charged nylon membrane (Hybond™-N). The assembly used in this method 
is shown in Figure 2.7; a layer of tissue paper 3-4cm thick was overlaid with 5 sheets 
of Whatmann 3mm paper with the top piece having been soaked in transfer buffer. A 
piece of the nylon membrane cut to the same size as the gel was also soaked in 
transfer buffer and placed on top of the stack. The agarose gel containing the 
denatured DNA was then placed on top of the nylon membrane, with care taken to 
ensure that the gel and nylon were correctly lined up and that no air bubbles had been
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trapped between the two. Three sheets of Whatmann paper (pre-soaked in transfer 
buffer) were then placed on top of the nylon, followed by two further sheets of 
Whatmann paper, cut larger than the previous pieces and also soaked in transfer 
buffer, which acted as a bridge with the tank containing transfer buffer. A plastic lid 
was placed on top of the stack in order to prevent evaporation, prior to a 5h incubation 
at RT to allow transfer of DNA to the nylon membrane.
Following transfer of DNA, the membrane was washed in 3x SSC in 
order to remove residual agarose and then wrapped in Saran wrap. Transferred DNA 
was irreversibly fixed to the membrane by U.V. cross-linking, using 12 x 104pJ in a 
U.V. Strata Linker 2400 bench top transilluminator (Stratagene).
d) Prehybridisation and Hybridisation of Nylon Membranes.
The membrane was placed between two sheets of nylon gauze, which 
were rolled up and placed in a hybridisation bottle. Hybridisation buffer (10ml) was 
added and the bottle placed in a rotary hybridisation oven at 42°C for 6 h. Following 
pre-hybridisation, radiolabelled probe (previously denatured by boiling for 5min) was 
added at approximately lOpmol/ml and the membrane incubated O/N at 42°C. The 
hybridisation solution was decanted, and the membrane subjected to two 30min 
washes at 65 °C in wash solution I (30ml). An increased washing stringency was then 
achieved by washing for 30min at 65 °C in wash solution II. If the observed 
radioactivity was still above 50 cpm on a GMG Geiger Muller counter, washing 
stringency was increased still further by washing in wash solution III. Membranes 
were subsequently wrapped in Saran wrap and autoradiographed.
e) Autoradiography.
Hybridised and washed membranes were exposed to a Kodak 
phosphoimager screen in an autoradiography cassette (with two intensifying screens) 
at RT, initially O/N. Bands were visualised using a BioRad Phosphoimager and 
subsequent exposure times were determined depending on the intensity of the signals 
observed. The radioactivity associated with bands was quantified as described in 
Section 2.2.4.9.e.
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Transfer 
Buffer
Cover
Whatmann 3mm 
paper
T issue paper
Figure 2.7. A schematic diagram showing the apparatus used in the downward 
alkaline transfer method (Southern Blotting). See text for details.
2.2.1.18. In vitro Transcription,
a) In vitro Transcription Reactions.
The HeLaScribe Nuclear Extract in vitro Transcription System 
(Promega) was used to allow the in vitro transcription of supercoiled DNA templates. 
HeLa nuclear extract was used as a source of transcriptional machinery, and reactions 
were performed essentially as per the manufacturer’s protocol (Promega), except that 
no radionucleotide was incorporated into the transcript. Reactions consisted of: 4U 
HeLaScribe HeLa Nuclear Extract (3.6/d), HeLa Extract lx Transcription Buffer 
(7.4pl), 8mM MgCL, recombinant TR and H2 O to a final volume of 25/d. Reaction 
mixes contained T3 (lOOnM) where indicated. Following a 30min incubation at 30°C 
to allow formation of the PIC, transcription was initiated by the addition of the rNTP 
mix (1/d, at lOmM each), before a further incubation at 30°C for lh. Transcription 
was terminated by the addition of HeLa Stop buffer. RNA was phenolicholoroform 
extracted and ethanol precipitated as described in Section 2.2.1.4.a. Precipitated RNA 
was resuspended in 9.5/d nuclease-free H2 O.
Membrane
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b) Analysis of RNA by Primer Extension.
RNA samples were combined with dNTPs (lpl; lOmM) and the primer 
pGL2 - specific to the luciferase ATG-codon, 5'- labelled with [y-3 2P] (lOOfmol; see 
Appendix ID for primer sequence. See next Section for primer-labelling protocol). 
Following an incubation at 70°C for lOmin, reactions were allowed to cool to RT for 
lOmin, in order to allow primer annealing. A reverse transcriptase reaction containing 
the following components was made up: 400U MMLV reverse transcriptase, reverse 
transcriptase reaction buffer, lOmM DTT and 20U RNasin® made up to a final 
volume of 20pl with H2O. Reactions were incubated at 37°C for lh before the 
addition of 20pl formamide loading buffer. Samples were analysed by electrophoresis 
and gels were dried prior to autoradiography as described in Sections 2.2.4.9.d and
2.2.4.9.e, with modifications; samples were run on 10% polyacrylamide gels 
containing 7M urea, alongside end-labelled <|>174//7aeIII DNA markers.
c) End-labelling of pGL2 Primer and §\14IHae\\A Markers.
DNA (lOOfinol primer, 250ng §\14/Hae\\\ Marker) was combined with 
T4-polynucleotide kinase (PNK; 10U) and 3 pi of [y-3 2P]-dATP (Amersham) in lx 
PNK Buffer. Following an incubation at 37°C for lOmin the enzyme was deactivated 
by a lOmin incubation at 90°C. H2O (90pl) was added and radiolabelled primer was 
purified, as described in Section 2.2.1.17.b.
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2.2.2. Cell Culture Methods.
Materials and Methods
2.2.2.1. Maintenance of Cell Lines in Culture.
Routine cell culture work was carried out under the laminar flow of 
a Class II hood (MDH, Andover, Hampshire, UK). Cells were maintained at 37°C in 
a hydrated atmosphere of 5% CO2 and air in DMEM supplemented with 10% FBS, 
2mM glutamine and 5000 units per ml (each) of penicillin and streptomycin. Cells 
which had been stably transfected with a plasmid containing the G418 selection 
marker (aminoglycoside phosphotransferase) were maintained as above, except that 
G418 was added to the growing medium to a final concentration of 800pg/ml.
2.2.2.2. Sub-culturing of Cells.
Confluent cells were washed twice with PBS, then sufficient Splittix 
was added to cover the cell layer (6 ml for a 175cm2 flask). The cells were then 
incubated at 37°C for 10-15min, during which time the cells became detached. Pre­
warmed (37°C) medium was then added to the flask, to give an appropriate final 
volume. The cell suspension was then plated out into new tissue culture flasks, at a 
ratio of approximately 1:7. The medium was changed after 24h, and subsequently 
every 3-4 days.
2.2.2.3. Transient Transfection of Adherent Cells.
Plasmid DNA constructs, containing the firefly luciferase gene, under 
the control of the human cytomegalovirus (hCMV) major immediate-early promoter, 
were prepared according to Section 2.2.1.3.b. DNA was ethanol-precipitated as 
described in Section 2.2.1.4.a. to a final concentration of lmg/ml. Assessment of 
purity and determination of concentration was performed as described in Section
2.2.1.5.
Each subsequent step of the Transfection procedure was carried out 
under the laminar flow of a Class II hood. Cells were seeded consistently at 
approximately 1 x 1 0  cells/1 0 cm of surface area in a cell-culture vessel (usually a 6 - 
well plate; surface area ~10cm2, or a T75; 75cm2 tissue culture flask). Cells were 
grown at 37°C for 16h. This incubation period allowed the attainment of between 70
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-  80% confluency, which then permitted effective transfection of DNA into the 
adherent cells.
a) Calcium-phosphate Precipitation.
Stock solutions required for the transient transfection of cells using 
calcium phosphate precipitation (2x HBS, O.lx TE and 2.5M CaCk, Table 2.2.) were 
prepared in advance and stored at 4°C. Cells were seeded and allowed to grow to 70- 
80% confluence as described above.
Four hours prior to transfection, the growth medium was removed and 
replaced with an equivalent volume of pre-warmed medium. All volumes are 
appropriate to a 6 -well plate; multiply x8  for equivalent T75 volumes. Transfection 
solution A (DNA in O.lx TE, total volume 225pl) and transfection solution B ( 2x 
HBS, 250pl) were prepared in sterile universal tubes. 2.5M CaCb, (25pi), was added 
to tube A and immediately mixed by pipetting with a plastic, sterile, Pasteur pipette. 
The resulting solution was then added drop-wise to tube B, with continuous agitation 
of the tube. A DNA-calcium phosphate precipitate was then allowed to form during a 
30min RT incubation period. This precipitate was then added drop-wise to the cells, 
prior to a 16h incubation at 37°C. Following this incubation period, the cells were 
washed twice with PBS, fresh media introduced and culture vessels returned to 37°C 
for a further 24h incubation.
b) TransFast™ Reagent.
TransFast™ reagent was resuspended, as recommended in the 
manufacturer’s protocol. (Promega). Cells were seeded and allowed to grow to 70- 
80% confluence as described in Section 2.2.2.3. The required amount of DNA was 
added to 1/3 the final flask volume of media, in a sterile tube (1ml or 5ml, for 6 -well 
plate and T75 respectively), and vortexed for 10-15sec. TransFast™ (3pl/pg DNA) 
was added to the DNA/medium mix, and once again, the solution was vortexed 
thoroughly. Each DNA/medium/TransFast™ mixture was incubated at room 
temperature for 15min, to allow the formation of the plasmid DNA-TransFast™ 
complex. The growth medium was then removed from a culture vessel, and the 
transfection mixture (1ml or 5ml) was layered carefully over the monolayer of 
adherent cells and incubated at 37°C for lh. The DNA/medium/TransFast™ mixture
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was then removed from the culture vessel, and the cells were overlaid with fresh 
medium, prior to a further 24h incubation at 37°C.
2.2.2.4. Isolation of Cell Clones.
Cloning rings were made by cutting a 1cm length from the large end of a 
lml pipette tip. Cloning rings and Vaseline were sterilised by autoclaving. Following 
the removal of growing medium from the cells, individual cell clones were located by 
holding the plate up to the light, and the location of the clones marked on the 
underside of the plate using a permanent marker. Once the growing medium had been 
removed, all work was carried out rapidly so as to minimise the drying out of cells. 
Using a sterile forceps, the cloning rings were lightly dipped in Vaseline before being 
placed on the surface of the plate, so as to surround a single clone. Splittix (2-3 drops, 
from a sterile Pasteur pipette) was added, and following an incubation of 30s, Splittix 
and detached cells from a single clonal population were transferred to one well of a 
24-well plate which already contained pre-warmed (37°C) medium (lml, non- 
selective i.e. containing no G418). Following a 48h incubation at 37°C, clonal 
populations of cells were sub-cultured in growth medium containing G418 (800pg/ml) 
until sufficient quantities of cells were available for freezing of stocks.
2.2.2.5. Harvesting of Adherent Cells.
Following transfection, cells were incubated at 37°C for 24 hours. A 
protocol was developed which allowed preparation of a cell lysate and isolation of 
mRNA from the same sample of transfected, adherent cells.
a) Preparation of Cell Lysate.
Cells were harvested from the growth surface, into 1/3 the original 
volume of medium in which they had grown, using a rubber policeman. Detached 
cells were resuspended, by pipetting, and centrifuged at 2,000 x g  for 5min, at 4°C. 
The supernatant was removed and the pelleted cells resuspended by vortexing in lml 
PBS at 4°C prior to a further spin at 4,000 x g  for 5min. The supernatant was again 
discarded, and the cells resuspended by pipetting, in 250pl of lx RLB (Reporter Lysis 
Buffer). Following a lOmin incubation at RT, and a single round of freeze-thaw 
(30sec on ice), the cells were vortexed thoroughly for 15sec, and spun at 13,000 x g
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for 2min. The supernatant (crude cell lysate) was removed to a fresh tube, and snap- 
frozen (liquid nitrogen). Each resulting lysate was assayed for firefly luciferase 
activity and protein concentration. The remaining pellets were also snap-frozen, 
subsequent to mRNA extraction.
b) Extraction of mRNA.
mRNA was isolated from cell pellets using the Dynabeads mRNA 
DIRECT™ Kit, as directed by the manufacturer’s protocol (Dynal Biotech). mRNA 
was eluted from the beads in an appropriate volume of water by heating at 75°C for 
2min. The tube was placed on the Magnetic Particle Concentrator (MPC) and allowed 
to stand for 2min. The supernatant, containing the mRNA, was removed to a fresh 
tube and stored at -80°C.
2.2.2.6. Measurement of Firefly Luciferase Activity in Cell Lysates.
Cell lysates prepared, as described in Section 2.2.2.5.a. were allowed to 
thaw to room temperature. Extracts were vortexed for 10-15 sec and centrifuged for 
30sec at 13,000 x g. A volume (20pl, unless otherwise stated) of cell extract was 
added to 100pi of Luciferase Assay Reagent in a reaction tube, and placed in a 
luminometer. Following an initial 2 second delay to allow sample stabilisation, the 
emitted luminescence was monitored over a period of 20sec. The relative light units 
(RLUs) generated by each sample were recorded directly, thus permitting further 
manipulation. If the RLU counts generated were above the upper limit of sensitivity 
of the luminometer (9999 RLUs), a smaller volume of cell extract was assayed and 
this dilution factor was taken into account prior to further manipulations of results.
2.2.2.7. Measurement of Total Protein of Cell Lysates.
The total protein concentration of cell lysates was determined by the
method of Bradford (1976), using a known concentration range of BSA as a standard.
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2.2.3. Protein Methods.
Materials and Methods
2.2.3.1. Analytical Scale Expression of Recombinant Proteins.
LB medium (10ml) containing the appropriate antibiotic selection was 
inoculated with an E.coli colony harbouring the required pET plasmid. The culture 
was grown at 37°C with constant agitation (225 rpm), overnight. A volume of this 
culture (200pl) was used to inoculate 10ml of fresh LB medium (1:50 dilution). The 
newly inoculated culture was incubated at 37°C until an OD600 of between 0.4 and 0.6 
was reached. Expression of recombinant protein was induced by the addition of 
IPTG. Final IPTG concentrations are detailed in the relevant sections of text. Induced 
cultures were subsequently grown at 20°C, 30°C or 37°C, with agitation.
Samples (lml) were removed at appropriate time points following 
induction, and pelleted by centrifugation (13,000 x g  for lmin at RT). Cell pellets 
were stored at -20°C, until required.
2.2.3.2. Production of Soluble and Insoluble Protein Fractions.
The frozen cell pellets were thawed and resuspended in 50pl of PBS. 
The cell suspensions were subjected to 3 cycles of freeze-thaw (alternating between an 
ice/water bath a 37°C water bath) and the lysates centrifuged (13,000 x g  for lmin at 
RT). The pellet (insoluble fraction) was resuspended in 50pl of PBS and 25pl 2x 
SDS-PAGE sample loading buffer. To the supernatant (soluble fraction) 25 pi of 2x 
SDS-PAGE sample loading buffer was added. Fractions were analysed by SDS- 
PAGE. All samples were stored at -20°C.
2.2.3.3. SDS-PAGE.
Recombinant protein samples were resolved by SDS-PAGE. The 
running gel contained 12.5% (v/v) Protogel acrylamide solution (Protogel is a 30% 
(w/v) acrylamide/methylene bisacrylamide solution, in a 37.5:1 ratio), 375mM Tris- 
HC1 (pH 8.8), 0.1% (w/v) SDS, 0.225% (w/v) APS, 13.2mM TEMED and H20  in a 
final volume of 10ml. The stacking gel contained 3.5% (v/v) Protogel acrylamide 
solution, 190mM Tris-HCl (pH 6.8), 0.1% (w/v) SDS, 0.45% (w/v) APS, 13.2mM 
TEMED and H20  in a final volume of 5ml.
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Prior to loading, samples (with 2x loading buffer already added) were 
heated at 100°C for 5mins. Samples were spun briefly (13,000 x g  for 15sec at RT) 
and lOpl of each sample was loaded onto the stacking gel. Gels were run at a constant 
70mA current to allow sufficient separation of the protein samples in a Biorad- 
miniprotean II™ protein gel apparatus containing 1 x SDS-PAGE running buffer. 
BenchMark™ Prestained Protein Ladder (Invitrogen) was also loaded and run 
simultaneously on the gel, in order to allow estimation of molecular weight (kDa) of 
recombinant protein samples. Proteins were visualised by staining in Coomassie blue 
solution for 45min followed by immersion in de-stain solution for lh. Gels were 
viewed on a white light source and a photographic record taken.
2.2.3.4. Western Blot Analysis.
Following separation by SDS-PAGE, proteins were transferred to a 
nitrocellulose membrane (Hybond™-C extra nitrocellulose membrane) by 
electroblotting. Five pieces of Whatmann 3MM paper, cut to the same size as the 
protein gel, were soaked in the appropriate blotting buffers -  two pieces each in anode
I and in cathode solution, and one piece in anode II solution. In order to assemble the 
electroblotting stack, the anode I filter papers were placed on the bottom half of a 
Sartorius Semi-Dry Blotter (Sartorius Ltd, Epsom, Surrey, UK) followed by the anode
II filter paper. The nitrocellulose was then put down on the anode filter papers, 
followed by the gel. Finally, the two cathode filter papers were placed on top of the 
gel, completing the stack. The blotter lid was placed on the stack and the proteins 
were transferred onto the membrane at a constant 150mA current for 45min.
2.2.3.5. Detection of Recombinant Proteins using the Ni-NTA AP Conjugate.
Following the transfer of proteins, the nitrocellulose membrane was
washed three times for lOmin each, in TBS buffer. Blocking was achieved by 
incubating the membrane in 3% (w/v) BSA in TBS buffer. The membrane was then 
washed a further three times for lOmin each, in TBS-Tween buffer followed by an 
hour’s incubation with a 1:1000 (v/v) dilution of the Ni-NTA AP conjugate, in TBS- 
Tween buffer. The Ni-NTA AP conjugate binds directly to His-tagged proteins and 
can be used for their detection without the need for antibodies. Following the 
incubation period, the membrane was washed three times (lOmin each) in TBS-Tween
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buffer, prior to colour development in premixed colour development buffer containing 
BCEP and NBT solutions. The developed membrane was rinsed three times in 
distilled water to stop the colour reaction, and allowed to air-dry. A photographic 
record was taken before storage, wrapped in aluminium foil.
2.2.3.6. Purification of Recombinant Proteins using Ni-NTA Agarose.
To allow purification using Ni-NTA agarose, the target recombinant 
protein must contain a 6 His-Tag (six consecutive histidine residues). Large-scale 
expression of recombinant protein was performed in 11 of LB medium. Cultures were 
induced as described previously (Section 2.2.4.1.), and incubated under optimal 
conditions, as detailed in the relevant sections of text. Cells were harvested by 
centrifugation (10,000 x g  for lOmin at 4°C) and stored overnight at -20°C. Cells 
from 11 of culture were resuspended in 20ml lysis buffer and then subjected to four 
cycles of French pressing.
Following cell lysis by French pressing, cell debris was pelleted by 
centrifugation (10,000 x g  for 20min at 4°C). The cell lysate, containing the soluble 
His-tagged recombinant protein was removed. Ni-NTA 50% slurry (5ml) was added 
to the cell lysate (20ml) and the resulting solution was mixed for lh at 4°C, with 
constant agitation.
The slurry-lysate mix was poured onto a column with the bottom outlet 
capped. The bottom cap was removed and the flow-through collected. The column 
was washed with wash buffer, until the OD2 8 0  of the flow-through dropped to zero. 
Recombinant protein was eluted in four fractions of elution buffer, of lml each. All 
samples were analysed by SDS-PAGE and stored at -20°C until required further.
2.23.1. Protein Quantification,
a) Bradford Assay.
Proteins were quantified, where specified, using a Bradford assay 
reagent. BSA standards from 2mg/ml to 0.06125mg/ml, were made by the serial 
dilution of a stock solution (lOmg/ml) with protein buffer (i.e. the buffer in which the 
protein was dissolved). Protein samples or BSA standards (20 pi) were then added to 
Bradford reagent (180pl) in a well of a 96 well plate. Absorbance at 590nm was
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measured, and unknown protein concentrations estimated from the standard curve 
produced.
b) The Bicinchoninic Acid (BCA) Protein Assay.
The BCA assay was used as an alternative method for protein quantification as 
it is less sensitive to detergents than the Bradford assay.
BSA standards from lOOOpg/ml to 200pg/ml, were made by the serial dilution of a 
stock solution (1 mg/ml) with protein buffer (i.e. the buffer in which the protein was 
dissolved). Protein sample or standard (25pi) was added to BCA assay working 
solution (200pl, Sigma) in a well of a 96 well plate (25 pi). The plate was covered 
and incubated at 37°C for 30min. Absorbance at 562nm was measured, and unknown 
protein concentrations estimated from the standard curve produced.
2.2.3.8. Protein Buffer Exchange -  Dialysis.
Pre-treated cellulose dialysis tubing (Fisher, UK) was prepared by 
boiling in distilled water for 10 minutes, until the tubing was softened. The protein- 
containing solution was placed in the tubing, and sealed using dialysis clips. The 
sealed tubing was then placed in a beaker containing a 200-fold volume of dialysis 
buffer, prior to overnight dialysis - carried out at 4°C on a magnetic stirrer.
2.2.3.9. Electrophoretic Mobility Shift Assay (EMSA).
a) Generation of Double-Stranded Oligonucleotides.
EMSA analysis was carried out using a double-stranded DNA probe, 
which was made by annealing complementary oligonucleotide pairs; forward and 
reverse oligos (400pmol of each) were incubated together at 100°C for lOmin in a 
medium salt buffer (Promega Buffer E to a final volume of 200pl) prior to chilling on 
ice. Each oligo was designed in such a way so that upon annealing, 5'- overhangs 
were created, which contained G residues (For oligo sequences see Appendix IE.), 
[a- P]-dCTPs were then base-paired with the overhanging G residues as part of the 
“filling in” reaction, described in the next Section.
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b) Radiolabelling of Double-Stranded Oligonucleotides.
Double stranded oligonucleotide was end-labelled with [a- P]-dCTP 
using the Megaprime DNA Labelling System, according to the manufacturer’s 
instructions (Amersham). In this way, double stranded oligonucleotide (40pmol in a 
final volume of 3 5 pi) was combined with labelling buffer (containing unlabelled 
dATP, dGTP and dTTP), Klenow polymerase (2pl) and finally, 3pi [a-32P]-dCTP. 
Reaction mixtures were incubated at 37°C for 30min and the reaction terminated by 
the addition of 50pl TE. Labelled probe was separated from unincorporated 
nucleotide as described in Section 2.2.1.17.b. The radioactivity of the probe was 
assessed by spotting 2pl on a 1cm2 piece of blotting paper, placing the paper in a 
scintillation vial and measuring the activity on a Wallace 1209 Rackbeta Liquid 
Scintillation Counter. If the radioactivity of the probe was greater than or equal to 
approximately 50,000 c.p.m./pl, the probe was considered suitable for use in EMSA 
analysis.
c) Binding-Reaction Conditions.
Various combinations of the indicated amounts of specific reaction 
components (recombinant protein, T3, antibody, competing oligonucleotides) were 
combined with dilution buffer to a final volume of 30pl. Binding buffer (lOx, 4pl) 
and poly[dI-dC] (lpg/ml, 3pl) were added, followed by radiolabelled oligonucleotide 
(3pi), bringing the final volume of all binding reactions to 40pl. Samples were 
incubated at RT for 20min, then 5pl of 20% (w/v) Ficoll was added prior to 
electrophoresis (Section 2.2.4.7.d) in order to facilitate gel-loading.
d) Electrophoresis of DNA-Protein Complexes.
DNA-protein complexes were resolved by electrophoresis using 5% 
(v/v) polyacrylamide gels (29:1 acrylamide:bisacrylamide) containing 0.5x TBE. 
Electrophoresis was carried out for 3-4h at 150V at 4°C using a vertical gel apparatus 
(Scotlab) with 0.5x TBE running buffer. In order to monitor the progress of 
electrophoresis, one lane of the gel was loaded with lOpl of lOx DNA-loading dye. 
Following electrophoresis, the gel was transferred to a piece of Whatmann 3MM 
paper, covered in clingfilm and dried under vacuum at 80°C for lh. DNA-protein 
complexes were visualised by autoradiography, as per Section 2.2.1.17.e.
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e) Quantification of Radioactivity Associated with Bands.
Autoradiograms of the dried gels were analysed densitometrically. 
Following visualisation of bands by autoradiography, as described in Section 
2.2.1.17.e, the radioactivity associated with individual bands was estimated using the 
Quantity One® quantitation software. Following the subtraction of background noise, 
the area under the intensity profile curve for each band was measured.
2.2.3.10. Competition EMSA.
In order to determine the specificity of DNA-protein interactions, an 
excess quantity of unlabelled-specific and non-specific oligonucleotides were added to 
the binding reactions. The specific oligonucleotide was of the exact same sequence as 
the radiolabelled probe, whilst the non-specific contained an unrelated sequence. 
Electrophoresis of DNA-protein complexes was then carried out as described in 
Section 2.2.4.7.d.
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CHAPTER THREE
DEVELOPMENT OF A CHEMILUMINESCENT ASSAY TO 
MEASURE LUCIFERASE mRNA.
3.1. Introduction.
The effects of thyroid hormones are mediated predominantly at the level 
of gene expression via the binding of the thyroid hormone receptors (TRs) to specific 
DNA sequences in the promoter region of target genes, known as thyroid response 
elements (TREs). In order to analyse the functional significance of such sequences, 
DNA from recognised TREs can be fused to a reporter gene. A commonly used 
reporter gene is the luciferase gene from the common firefly {Photinus pyralis). The 
reporter construct can be transfected into eukaryotic cells and the activity of the 
reporter gene can be estimated by measuring the luciferase protein activity levels. 
Alternatively, the construct could be used in cell-free in vitro systems which utilise an 
eukaryotic nuclear extract to produce mRNA, but which do not produce luciferase 
protein. Such systems would require a method of quantifying luciferase transcript 
levels.
The aim of this project, as outlined in Section 1.8, is “the development of 
simple in vitro tests, which will provide evidence of thyroid disruption by chemicals”. 
In order to develop systems which monitor the effects of putative disruptors on the 
formation of a transcriptionally active complex, (Section 1.8.2), a prerequisite is the 
ability to quantify the end point of such diagnostic tests. Although it is possible to 
measure the levels of protein expressed from a reporter gene in cellular systems, it is 
also possible to measure the levels of luciferase mRNA transcribed, both from a cell 
culture or a cell-free in vitro system. The quantification of luciferase mRNA and 
luciferase protein levels from a cell culture system would allow a comparison to be 
made between the temporal profiles for luciferase mRNA and luciferase protein 
expression. This would allow a distinction to be made between chemicals which have 
an adverse effect on mRNA transcription or on the translation of protein. Many of the 
current techniques commonly used for quantification of mRNA have disadvantages
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associated with them; transcript run-off assays rely on the use of a radioactive isotope 
and quantitative PCR relies on amplification and is both labour- and time-intensive.
The Hybridisation Protection Assay (HPA) is a technique which employs 
chemiluminescent technology and can be used for the detection of virtually any target 
nucleic acid, provided the sequence is known (Nelson et al., 1995). It does not 
employ an amplification step, and so is rapid and easy to perform. The HPA is 
quantitative and relatively sensitive. It follows a homogeneous format, which lends 
itself to a high-throughput format which would be advantageous in the development of 
systems that allow for the screening of large numbers of compounds. It is proposed to 
use the HPA to quantify luciferase mRNA from cellular and in vitro systems. The 
objective, therefore, was to design and optimise an HPA to allow the quantification of 
luciferase mRNA.
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3.2. Approach.
3.2.1. The Acridinium Ester.
Chemiluminescence is the process by which certain chemical reactions 
produce energy in the form of photons rather than as heat. The reactions are generally 
oxidative and involve the formation of excited intermediate molecules, which revert to 
their ground state by photonic emission. The concept of using non-isotopic labels to 
provide alternatives to radioimmunoassay is not new. Legislative restrictions on 
radioisotope usage as well as the increasing problem of radioactive waste disposal 
have spurred the development of alternatives (Woodhead, 1995).
The acridinium ester (AE) depicted in Figure 3.1 was developed for use 
as a chemiluminescent label in bioassays by Weeks et al., (1983). Advantages of 
using acridinium esters in a detection system include high sensitivity; ease of use, 
handling and disposal; precise control of detection (chemiluminescence can be 
measured against a background of virtually zero); and long shelf lives. The AE reacts 
rapidly with hydrogen peroxide under alkaline conditions (typically 1-5 seconds, see 
Figure 3.2), to produce light at 430nm. These rapid reaction kinetics permit detection 
over a very short time frame, thereby minimising background noise and improving 
overall sensitivity. Detection in a standard luminometer exhibits a linear response 
over an AE range of more than four orders of magnitude, with a detection limit of less 
than 1 fino 1/reaction (Nelson et al., 1995). An oligonucleotide labelled with AE can be 
used in a variety of simple assay formats to directly target nucleic acids. One such of 
these assays is the Hybridisation Protection Assay (HPA), which is described in detail 
in the next section.
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Figure 3.1. The structure of the N-hydroxysuccinimide ester of the N-methyl 
acridinium ester.
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Figure 3.2. The acridinium ester reacts with hydroperoxy anions (HOO’) to produce 
light. Shown is a typical kinetic profile of this light output, measured at 
430nm (adapted from Nelson, et al., 1996).
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3.2.2. The Hybridisation Protection Assay (HPA).
An overview of the steps involved in the HPA is shown in Figure 3.3.
The HPA is a three-step assay which utilizes an acridinium ester-labelled
oligonucleotide (AE-probe) to quantify specific target nucleic acid sequences. It is 
based on the selective chemical degradation of the AE label such that 
chemiluminescence associated with unhybridised probe is rapidly lost, whereas 
chemiluminescence associated with hybridised probe is minimally affected. 
Underlying this selective degradation (or differential hydrolysis) process is a highly 
specific chemical hydrolysis reaction, controlled by the local environment of the 
acridinium ester.
In the first step of the HPA, the AE-probe is hybridised to the nucleic 
acid to be quantified. The second step involves the hydrolysis of unhybridised AE- 
probe and the assay is completed by the detection of chemiluminescence associated 
with hybridised AE-probe; the third step.
3.2.2.I. Hybridisation.
An AE-probe is hybridised with the nucleic acid to be quantified, during 
which time the AE-probe will form a double-stranded complex with any 
complementary target present. The AE-labelled probe is designed in such a way that 
the AE is positioned in an interior portion of the probe to protect it. Upon 
hybridisation of probe to the target nucleic acid, this interior placement stabilizes the 
AE to hydrolysis by hydroxide ions, by providing it with an intercalation site within 
the double-stranded duplex. Hybridisation of probe to the target sequence is 
facilitated by the presence of helper oligos. These are unlabelled oligonucleotides 
(30mers) which are complementary to the 5' and 3' sequences which immediately 
flank the region of mRNA to which the probe is designed. They facilitate access to 
the probe-binding site by opening out the adjacent RNA sequence, allowing probe 
binding which might otherwise be prevented by the presence of any secondary 
structure present (Hogan and Milliman, 1991).
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Figure 3.3. A schematic representation showing the principle steps of the 
HPA (Hybridisation Protection Assay). AE: Acridinium Ester.
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3.2.2.2. Differential Hydrolysis.
Following the hybridisation step an alkaline differential hydrolysis buffer 
is added to the reaction and any unbound AE reacts with the hydroxide ions present to 
hydrolyse the ester bond. This renders the AE permanently non-chemiluminescent 
(Figure 3.4.a).
During this differential hydrolysis step, chemiluminescence associated 
with hybridised probe is minimally affected due to the protection of the AE within the 
intercalation site; a process which occurs upon hybridisation of probe to target nucleic 
acid, and subsequent formation of the double stranded duplex. The overall effect is to 
amplify the difference in the hydrolysis rates of hybridised and unhybridised AE 
probes. This selective hydrolysis step is rapid (typically 6 - 1 2  mins at 60°C) and 
even the presence of a single-base mismatch between AE probe and the target nucleic 
acid sequence causes the hydrolysis of the AE (Nelson et al., 1996).
3.2.2.3. Detection of Chemiluminescence.
Following the hybridisation and differential hydrolysis steps, the reaction 
conditions are adjusted in order to promote the hydrolysis of the remaining, hybridised 
AE. Upon reaction with the hydroperoxy anion (HOO*; present in the alkaline 
peroxide detection buffer which is now added) the ester bond is cleaved and 
chemiluminescence is produced (Figure 3.4.b). Therefore, following hybridisation 
and differential hydrolysis, the detection of any remaining chemiluminescence is a 
direct measure of the amount of target nucleic acid present.
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F igure  3.4. Panel A) Non-hybridised (single-stranded) AE-probe reacts with hydroxide to hydrolyse the ester bond, which yields the 
non-chemiluminescent acridinium carboxylic acid.
Panel B) Hybridised (double-stranded) AE-probe is protected from hydrolysis by hydroxide ions during the differential 
hydrolysis step. Hydrolysis by the hydroperoxy anion (HOO ) leads to production of light.
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3.2.3. Design and Synthesis of Chemiluminescent Oligonucleotide Probes.
A region of the firefly (P.pyralis) luciferase gene was selected and a 
28bp oligomer complementary to the corresponding section of the mRNA transcript 
was synthesized. The oligo contained a non-nucleotide amine-terminated 
phospharamidite linker arm (described by Arnold et al., 1989), to which a 
chemiluminescent acridinium salt was attached. The following guidelines were 
adhered to during the design process:
♦ The probe should be between 18-28bp in length.
♦ The GC-content of the probe should be approximately 50%.
♦ It is favourable to have Gs or Cs at either end of the probe.
♦ Tm of the probe should be higher than 65°C.
It was necessary to select a probe with a Tm greater than 65 °C since the 
hybridisation and selective hydrolysis steps are carried out at 60°C. The presence of 
G- or C- residues at both ends of the probe serves to tightly “clamp” the probe to its 
target nucleic acid and discourage hybrid melting.
Once a prospective probe sequence had been identified using the above 
guidelines, it was analysed using the OLIGO® 1991 Primer Analysis Software to check 
for self-complementarity and the risk of primer-dimer formation, as detailed in 
Section 2.1.5. The sequence of a prospective probe was also subjected to a BlastN 
search (Section 2.2.1.15.) in order to ensure that it was specific to the luciferase gene 
and that it would not bind to another nucleic acid species. As shown in Table 3.5, the 
oligonucleotide which was labelled with an acridinium ester was a 28mer with 3 C- 
residues at the 5' end and 2 G- residues at the 3' end, a GC-content of 50% and an 
estimated Tm of 84°C. Also shown are the helper probe sequences (Probe and helper 
sequences are detailed in Appendix 1C and their binding sites within the luciferase 
coding region is shown in Appendix 3C). The helper probes were unlabelled oligos 
(30mers), complementary to the regions directly adjacent to the target sequence, used 
in order to minimise any potential inhibition of hybridisation due to the presence of 
secondary structure within the mRNA transcripts.
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Oligo Sequence (5'—>3')
Luciferase
AE-probe
CCC TTA GGT AAC CTA GT#A GAT CCA GAG G
5' - helper AAT TCA TTA TCA GTG CAA TTG TTT TGT CAC
3' - helper ACG CAG GCA GTT CTA TGC GGA AGG GCC ACA
Table 3.5. DNA sequences of the AE-probe and helper oligonucleotides which were 
used in the luciferase HP A (see text for probe design criteria). The 
position of the linker arm to which the AE was attached is indicated by #.
An AE-labelled oligonucleotide probe was prepared by GenProbe (San 
Diego, CA, USA), essentially as described by Nelson et al (1995). The AE reagent 
shown in Figure 3.1 can be covalently attached to primary amine-containing 
compounds via a specific reaction of the N-hydroxysuccinimide (NHS) ester of the 
AE with the primary amine of the compound. The oligonucleotide was therefore 
directly labelled with AE, by first incorporating a primary amine into the DNA, then 
reacting this amine with the NHS-AE. An oligonucleotide labelled in this way 
displays exactly the same chemiluminescence characteristics (reaction kinetics, 
specific activity and sensitivity of detection) as the free label. The detection 
properties of the label are not compromised by attachment to oligonucleotides 
(Nelson, et al., 1995).
84
Chapter Three Chemiluminescent Assay Development
3.2.4. Preparation and Storage of Probes, Helper and Target Oligos.
Stock AE (Acridinium Ester) probes were stored in 10pl aliquots at 
20°C. A working dilution (1:10, v/v; ~ lOOfmol/pl) of probe was prepared and stored 
for one week. Subsequent probe dilutions, specific to each procedure, were made 
from the working dilution. AE probes, helper probes and target oligos (short 
oligonucleotides complementary to and of the exact same size as the AE-probe; see 
Appendix 1C) were diluted in HPLC-grade water and stored at -20°C. Prior to use, 
stock solutions of target and helper were heated at 60°C for 2min and vortexed 
thoroughly. All mRNA was stored at -80°C. Prior to use, mRNA was heated at 60°C 
for 5min, and vortexed for 20-30sec in order to destroy any intrinsic secondary 
structure. All AE-probes were stored as a 1:10 (5fmol/pl) dilution at -20°C. The 1:10 
dilutions of AE-probe were heated at 60°C for 2min, vortexed and the tube pulsed in a 
bench top microfuge prior to use.
3.2.5. Detection of Chemiluminescence.
Reaction tubes (Sarstedt 75 x 12mm polystyrene assay tubes) which had 
been incubated in a water bath were blotted with a moist tissue in order to remove any 
droplets of water, and the chemiluminescence associated with each tube was measured 
in a single-tube portable luminometer (Stratec Electronic, Lumino, Birkenfeld, 
Germany), by automatic sequential injection of 200pl Autodetect 1 and 200pl 
Autodetect 2, followed by the measurement of the light emission over a period of 
5 sec.
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3.3. Results.
3.3.1. Calculation of Differential Hydrolysis Ratio.
The HPA technique is based on selective chemical degradation of the AE 
label such that chemiluminescence associated with unhybridised probe is rapidly lost, 
whereas chemiluminescence associated with hybridised probe is minimally affected.
In order to maximise the signal to noise ratio, it is necessary to select a differential 
hydrolysis time which allows the hydrolysis of as much unbound probe as possible, 
whilst minimally affecting the hydrolysis of bound probe.
Reaction components were combined in a 1.5ml microfuge tube, as
detailed in Table 3.6. “Hybrid” reactions consisted of AE-probe which would
hybridise with the complementary target oligo present, “Control” reactions contained 
AE-probe, but no target with which to hybridise and “Blank” reactions contained 
target but no AE-probe. All reactions were incubated at 60°C for lh, and lx 
hybridisation buffer (300pl) was added to each microfuge tube. Eleven sets of 
duplicate aliquots (lOpl) from each reaction (Hybrid, Control and Blank) were 
pipetted into 75mm Sarstedt reaction tubes. In order to determine the initial levels of 
chemiluminescence present in each reaction, a “time-zero” measurement was taken; 
that is the chemiluminescence was measured when the samples had been subjected to 
(virtually) zero time under the selective hydrolysis conditions. Selection reagent 
(lOOpl) was added to a duplicate set of tubes for each preparation (Hybrid, Control 
and Blank), the contents mixed briefly by swirling, and the chemiluminescence 
associated with each tube was measured, as detailed in Section 3.2.5.
Selection reagent (lOOpl) was then added to all the other tubes, which 
were vortexed and returned to 60°C. At the desired time points, duplicate tubes were 
removed from the waterbath and placed in an ice/water slurry for 30sec, prior to 
detection of chemiluminescence. Results are shown in Figure 3.7.
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HYBRID CONTROL BLANK
2x hybridisation 
buffer
15pl 15pl 15pl
AE probe 
(O.Olpmol/fd)
5pl 5pl -
Target 
(O.lpmoUid)
lOpl - lOpl
h 2o - lOpl 5 pi
Final Volume 30pl 30pl 30pl
Table 3.6. Assay components as used during the optimisation of differential
hydrolysis conditions. A probe concentration of 0.01pmol/pl and a 
target concentration of 0. lpmol/pl was used. The above reactions were 
combined in 1.5ml microfuge tubes and incubated at 60°C for lh, prior 
to the addition of lx hybridisation buffer (300pl). Duplicate aliquots 
(1 Ojj.1) from each reaction tube were then pipetted into 75mm Sarstedt 
reaction tubes and Selection reagent (lOOpl) was added. The Sarstedt 
tubes were vortexed and returned to 60°C. At the desired time points, 
duplicate tubes were removed from the waterbath and placed in an 
ice/water slurry for 30sec, prior to detection of chemiluminescence
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Figure 3.7 Acridinium ester hydrolysis of hybridised (▲) and unhybridised (■) 
Probe. Reaction components were combined in a 1.5ml microfuge tube, 
as detailed in Table 3.6; “Hybrid” reactions consisted of AE-probe and 
complementary target oligo in a ratio of 1:20 (0.05pmol:lpmol), 
“Control” reactions contained AE-probe but no target oligo. All 
reactions were incubated at 60°C for lh, and lx hybridisation buffer 
(300pl) was added to each microfuge tube. Selection reagent (lOOpl) 
was then added to duplicate aliquots (10pl) from each reaction, prior to 
incubation at 60°C. Samples were removed at the desired timepoints and 
the associated chemiluminescence detected. Chemiluminescence is 
expressed as a percentage of the activity of unhydrolysed label and is 
plotted relative to the time of exposure to hydrolysing conditions. The 
chemiluminescence of unhydrolysed probe was measured immediately 
upon the addition of selection reagent to samples, i.e. when the time of 
exposure to hydrolysing conditions was nil (T=0). Although the trend 
observed whilst calculating the differential hydrolysis ratio was 
reproducible, it was possible that the actual figures would vary due to the 
following factors; the number of freeze-thaw cycles to which the probe 
had been subjected, batch-to-batch variation between probes, batch-to- 
batch variation between reagents (buffers manufactured in-house).
88
Chapter Three Chemiluminescent Assay Development
Best line fit of data was obtained by regression analysis. The equations 
generated from regression analyses for the hybridised and unhybridised probe are 
shown below, along with the R2 values for each fit:
Hybrid y = -0.0131x +1.9438 R2 = 0.998
Control y = -0.4858x + 1.7899 R2 = 0.964
Using the data from the equations generated by regression analysis, the 
differential hydrolysis (DH) ratio was calculated as follows:
Hybrid half-life: log 50% hydrolysis 
Gradient (log/min) 
0.301 22.97(min)
0.0131
Control half-life: 0.301
0.4854
0.62(min)
DH ratio: = hybrid to.5
control to.5
22.97 = 37.04
062
Since the DH ratio is calculated by dividing the hybrid half-life by the 
half-life for control samples, then the larger this figure, the greater the signal to noise 
ratio. The impact of these hydrolysis half-lives (22.97min and 0.62min for 
hybridisied and unhybridised probe, respectively) becomes clear if the amount of 
chemiluminescence that remains for the hybridised and unhybridised forms of the 
probe with time is calculated. The theoretical percentage of remaining 
chemiluminescent label after a given hydrolysis time can be calculated using the 
equation:
(0.5)n x 100 = percentage remaining chemiluminescence 
where n is the ratio of elapsed time to the half-life of chemiluminescence loss (i.e. the 
number of half-lives transpired during a given incubation time, T/t1/2). Using the half-
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lives given above, the calculated values for percentage remaining chemiluminescence 
after the 15min differential hydrolysis step would be 64% for hybridised probe and 
0.0000052% for unhybridised probe. This represents greater than a 12million-fold 
discrimination between hybridised and unhybridised probe.
3.3.2. Residual Fraction.
In order to determine conditions which allow maximal hydrolysis of 
unhybridised probe during the differential hydrolysis step, it was necessary to generate 
a Residual Fraction profile for the AE-probe. This involved hydrolysing free 
(unhybridised) AE-probe in selection reagent, across a range of time points. Thus, it 
was possible to estimate the hydrolysis time which would give minimal levels of 
background chemiluminescence. A series of 14 time points were investigated; the 
following components were combined in triplicate sets of 75mm Sarstedt reaction 
tubes:
25pi 2x hybridisation buffer 
lOpl AE probe (5fmol/pl)
15pl H20
All tubes were incubated at 60°C for 30min. Selection reagent (300pl) 
was added to the duplicate tubes for the time-zero measurement, the contents mixed 
by swirling and the associated chemiluminescence measured as detailed in Section
3.2.5. Selection reagent (300pl) was added to all other tubes, which were vortexed 
briefly and returned to 60°C. Duplicate tubes were removed at the desired time 
points, placed in an ice/water slurry for 30sec and the associated chemiluminescence 
was measured. Results are shown in Figure 3.8.
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Figure 3.8. The residual fraction profile of the unhybridised luciferase AE-probe. A 
probe concentration of 50fmol/reaction was used. Triplicate reactions 
consisting of 2x hybridisation buffer (25pi), AE probe (lOpl) and H2 O 
(15pl) were incubated at 60°C for 30min. Selection reagent (300pl) was 
added, reactions vortexed and returned to 60°C. Tubes were 
removed at the desired time points, placed in an ice/water slurry for 
30sec and the associated chemiluminescence measured. Error bars 
represent standard deviations for each set of triplicate reactions. As with 
differential hydrolysis experiments, the trend observed was consistently 
reproducible, although it was possible that the actual figures would vary 
due to the factors mentioned previously; the number of freeze-thaw 
cycles to which the probe had been subjected, batch-to-batch variation 
between probes, batch-to-batch variation between reagents (buffers 
manufactured in-house).
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The residual fraction profile for unhybridised luciferase AE-probe 
(Figure 3.8) shows a rapid decrease in chemiluminescence following the addition of 
selection reagent. This is due to the hydrolysis of the AE by the hydroxide ions, 
present in the differential hydrolysis buffer. Although the number of RLUs appears to 
have reached a plateau at a time of approximately 12 minutes, and the decrease in the 
level of RLUs between the times of 12 and 15 minutes is negligible, a hydrolysis time 
of 15min was found to produce consistently lower RLUs for control samples (i.e. 
unhybridised AE-probe, data not shown). It can be seen, also, from the differential 
hydrolysis data (Figure 3.7) that an additional 3min hydrolysis time causes a relatively 
small decrease in RLUs for AE-probe hybridised samples. It was decided, therefore, 
using both the differential hydrolysis data (Figure 3.7), and the residual fraction 
profile (Figure 3.8) to use a selective hydrolysis time of 15 minutes in all assays 
utilising the luciferase AE probe.
3.3.3. Hybridisation Kinetics.
In order to determine the incubation time which allowed maximal 
hybridisation of AE-probe to target, the following components were combined in 13 
duplicate sets of 75mm Sarstedt reaction tubes:
25 pi 2x hybridisation buffer 
5 pi H20
lOpl AE probe (2.5fmol/pl) 
lOpl target (O.lfmol/pl)
For every timepoint, a duplicate set of control (probe, no target) and 
blank (no probe, target and reagents only) tubes were also set up. All reactions were 
incubated at 60°C, and a duplicate set removed to an ice/water slurry at every minute, 
between 3 and 15mins. Selection reagent (300pl) was then added and the tubes 
incubated for a further 15min at 60°C. Chemiluminescence associated with each 
sample was detected as before (Section 3.2.5).
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Figure 3.9. Hybridisation kinetics of the luciferase AE-probe. 2x hybridisation
buffer (25pl), H2O (5pl), AE probe (lOpl at 2.5fmol/pl) and target (lOpl 
at O.lfmol/pl) were combined in duplicate sets of 75mm Sarstedt reaction 
tubes. For every timepoint, a duplicate set of control (probe, no target) 
and blank (no probe, target and reagents only) reactions were also set up. 
All reactions were incubated at 60°C, and at each time point a duplicate 
set was removed to an ice/water slurry. Selection reagent (300pl) was 
added prior to a further incubation (15min) at 60°C. Chemiluminescence 
associated with each sample was then detected as before (Section 3.2.5).
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The data for the hybridisation kinetics of the luciferase AE-probe (Figure 
3.9) indicate that maximal hybridisation levels appear to be achieved after 
approximately 15 to 18 minutes. However, in order to ensure consistently optimal 
hybridisation of probe to target, and since it is the hybridisation incubation period 
used in a typical HPA format (Nelson et al., 1995), a hybridisation time of 30min was 
used in all subsequent assays utilising the luciferase AE probe.
3.3.4. Thermal Stability.
In order to determine the melting temperature of the AE-probe 
hybridised to target, the hybrid was subjected to an incubation at a range of 
temperatures prior to selective hydrolysis and detection of chemiluminescence. The 
following components were combined in a microfuge tube:
15 pi 2x hybridisation buffer 
5pl AE probe (O.Olpmol/pl) 
lOpl target (O.lpmol/pl)
A control mix was also set up, with H2O (lOpl) replacing the target. The 
contents were mixed and incubated at 60°C for 30min. lx hybridisation buffer 
(lOOOpl) was added to each tube. Ten sets of duplicate aliquots (50pl) for each mix 
were pipetted into 75mm luminometer tubes. A duplicate set of hybrid and control 
reactions were incubated at each temperature for 7min, before being placed on ice. 
Following the completion of all hybridisations, tubes were removed from the ice, and 
selection reagent (150pl) added. Tube contents were mixed by vortexing, incubated at 
60°C for 15min and the chemiluminescence associated with each tube was detected as 
before (Section 3.2.5).
Hybridised luciferase AE-probe bound to target, is stable at temperatures 
up to and including 58°-62°C (Figure 3.10). Using the AE-probe data, as described in 
Table 3.5 the Tm of the AE-probe was estimated, using the method described by 
Sambrook et al., (1989):
AE-Probe Tm = (%GC x 0.41) + 64.9 -  (600/oligo length)
= (50 x 0.41) + 64.9 -  (600/28) = 64°C
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This estimation of AE-probe Tm correlates with the profile shown in 
Figure 3.10, where temperatures of 64°C and above lead to melting of the AE-probe- 
target hybrid. The melting of the hybrid, caused by incubation at 64°C and above, 
leads to hydrolysis of the AE molecule during the differential hydrolysis step, and the 
subsequent loss of RLUs, as observed in Figure 3.10.
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Figure 3.10. The thermal stability profile for the luciferase AE-probe hybridised to its 
complementary target oligonucleotide. 2x hybridisation buffer (15 pi), 
AE probe (5pl at O.Olpmol/pl) and target (lOpl at O.lpmol/pl) were 
combined in a microfuge tube. Control reactions were also set up, with 
H2O (lOpl) replacing the target. Reactions were mixed and incubated at 
60°C for 30min. lx hybridisation buffer (lOOOpl) was then added to 
each reaction and ten sets of duplicate aliquots (50 pi) for each mix were 
pipetted into 75mm luminometer tubes. A duplicate set of hybrid and 
control reactions were incubated at each temperature for 7min, before 
being placed on ice. Following the completion of all hybridisations, 
tubes were removed from the ice, and selection reagent (150pl) added. 
Tube contents were mixed by vortexing, incubated at 60°C for 15min 
and the chemiluminescence associated with each tube was detected as 
before (Section 3.2.5).
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3.3.5. Helper Probe Assessment.
A helper probe assessment was carried out in order to determine whether 
or not the helper probes affected the efficiency of AE-probe binding. Since the 
purpose of the helper probes is to facilitate AE-probe binding in the presence of 
mRNA secondary structure (Section 3.2.2.1), it was necessary to use luciferase 
mRNA in this assessment. Luciferase mRNA was produced using the control plasmid 
from the RiboMax™ In Vitro Transcription Kit as per the manufacturer’s instructions 
(Promega), and was kindly donated by Dr Ceri Morris (MLT Research Ltd, Cardiff, 
UK).
Reaction components were combined in duplicate 75mm luminometer 
tubes as indicated in Table 3.11 Where only one helper was used, two reactions were 
set up -  one for the 5' and one for the 3' primer. Following an incubation at 60°C for 
30min, selection reagent (300pi) was added, tubes were mixed by vortexing and 
returned to the 60°C waterbath for 15min prior to the detection of chemiluminescence 
associated with each tube, as described previously (Section 3.2.5).
Blank
No helpers 
Control Hybrid
One helper 
Control Hybrid
Two helpers 
Control Hybrid
2x hyb. 50 50 50 50 50 50 50
Probe - 10 10 10 10 10 10
51 helper - - - 5 5 5 5
3' helper - - - - - 5 5
mRNA - - 10 - 10 - 10
h 2o 50 40 30 35 25 30 20
Total 100 100 100 100 100 100 100
Table 3.11. Assay components, as used for the assessment of helper probes. All 
figures shown are volumes, in microlitres. The probe concentration used 
was 2.5fmol/pl, the helper oligos were 5pmol/pl and the luciferase 
mRNA concentration was 0.24ng/pl.
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Figure 3.12. The facilitation of AE-probe binding to synthetic luciferase mRNA by 
the inclusion of helper oligos. AE-probe (25fmol) was incubated in 
the presence (“Hybrid”) or absence (“Control”) of luciferase mRNA for 
30min at 60°C, as detailed in Table 3.11. Selection reagent (300p.l) was 
added, tubes were mixed by vortexing and returned to the 60°C 
waterbath for 15min prior to the detection of chemiluminescence 
associated with each tube, as described previously. Reactions were 
carried out in duplicate -  mean values have been plotted and error bars 
represent standard deviation.
The hybridisation of the luciferase AE probe to luciferase mRNA is 
greatly facilitated by the presence of helper probes (Figure 3.12). Binding of AE 
probe is improved in the presence of either helper individually, but maximal binding 
of AE probe to mRNA is achieved in the presence of both 5* and 3' helper probes. It is 
likely that this is due to the helper probes binding the mRNA and opening out any
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secondary structure present; helper probes are 30bp oligos that are complementary to 
the regions of mRNA directly 5' and 3' to the site of binding of the AE probe thus 
making the binding site for the AE probe more accessible. Figure 3.12 represents data 
from a single experiment, however the experiment was run three times to ensure 
reproducibility.
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3.3.6. Sensitivity.
In order to determine the limit of sensitivity of the luciferase HP A, a 
fixed concentration of AE-probe was firstly titrated against serial dilutions of the 
target oligo, and secondly against serial dilutions of luciferase mRNA in the presence 
of non-luciferase mRNA - in order to more closely mimic the actual experimental 
conditions under which the HPA technique might be applied; namely, for the 
quantification of luciferase mRNA extracted from cultured, adherent cells.
a) Target Oligo Titration.
The following components were combined in triplicate sets of 75mm 
luminometer tubes:
50pl 2x hybridisation buffer 
30pl H20
lOpl AE probe (5fmol/pl) 
lOpl target (serial dilutions)
A set of 5 control reactions (probe, no target) and triplicate blank (target, 
no probe) tubes were also set up. Two-fold dilutions of target were used, starting at 
the highest concentration of 100fmol/pl Tubes were incubated at 60°C for 30min. 
Selection reagent (300pl) was added and the tubes vortexed, before being returned to 
60°C. Samples were subjected to selective hydrolysis for 15min - as determined by 
the differential hydrolysis ratio (Section 3.3.1). Following hydrolysis, tubes were 
removed from the waterbath, and the associated chemiluminescence was measured, as 
detailed in Section 3.2.5.
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Figure 3.13.A. The sensitivity profile for the luciferase AE-probe. AE-probe
(50fmol/reaction) was hybridised to serial dilutions of target oligo. A 
set of control (probe, no target) and blank (target, no probe) reactions 
were also set up. Tubes were incubated at 60°C for 30min. Selection 
reagent (300pl) was added, tubes vortexed and returned to 60°C for 
15min selective hydrolysis - as determined by the differential 
hydrolysis ratio (Section 3.3.1). Following hydrolysis, 
chemiluminescence associated with tubes was measured as detailed 
in Section 3.2.5. Best line fit of data was obtained by regression 
analysis. The R2 value for the fit was R2 = 0.989. Log of the 
average RLUs for control samples (5 replicates containing probe, 
no target) was 3.60 and the standard deviation for these 5 values was 
0.15.
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b) Luciferase mRNA Titration.
The luciferase mRNA used in this experiment was produced using the 
control plasmid from the RiboMax™ In Vitro Transcription Kit as per the 
manufacturer’s instructions (Promega), and again, was kindly donated by Dr Ceri 
Morris (MLT Ltd). The non-luciferase mRNA was simply mRNA extracted from 
non-transfected, cultured cells, as described in Section 2.2.2.5.b. The following 
components were combined in triplicate sets of 75mm luminometer tubes:
50pl 2x hybridisation buffer 
lOpl H20
lOpl non-luciferase mRNA (from T75)
lOpl AE probe (5fmol/pl)
lOpl luciferase mRNA (serial dilutions)
5pl 5'- helper (5pmol/pl)
5 pi 3'- helper (5pmol/pl)
A set of 5 control (all components, except luciferase mRNA) and 
triplicate of blank (all components, except probe) tubes were also set up. Two-fold 
dilutions of luciferase mRNA were used, starting at the highest concentration of 
lOfmol/pl.
Tubes were incubated at 60°C for 30min. Selection reagent (300pl) was 
added and the tubes vortexed, before being returned to 60°C. Samples were subjected 
to selective hydrolysis for 15min - as determined by the differential hydrolysis ratio 
(Section 3.3.1). Following hydrolysis, tubes were removed from the waterbath, and 
the associated chemiluminescence was measured, as detailed in Section 3.2.5. The 
results are shown in Figure 3.13.B.
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Figure 3.13.B. The sensitivity profile for the luciferase AE-probe. AE-probe
(50fmol) was hybridised with serial dilutions of luciferase mRNA for 
30min at 60°C. A set of control (probe, no target) and blank (target, 
no probe) reactions were also set up. Selection reagent (300pl) was 
added, tubes vortexed and returned to 60°C for 15min selective 
hydrolysis - as determined by the differential hydrolysis ratio 
(Section 3.3.1). Following hydrolysis, chemiluminescence 
associated with tubes was measured as detailed in Section 3.2.5. Best 
line fit of data was obtained by regression analysis. The R2 value for 
the fit was R = 0.997. Log of the average RLUs for control samples 
(5replicates containing probe, no luciferase mRNA) was 3.63 and the 
standard deviation for these 5 values was 0.16.
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c) Determination of the Sensitivity Limit.
In order to determine the limit of sensitivity of the luciferase AE-probe 
from the plots shown above, the standard deviation of the log RLUs for the five 
control values (“controls” contained AE probe but no target) was calculated at 0.15 
and 0.16 for target and mRNA titration experiments respectively. This value was 
doubled and subsequently added to the mean of the log RLUs for the control readings. 
This gave values of 3.92 and 3.95 for the target and mRNA titrations, respectively. 
Extrapolation to the x-axis estimates a limit of sensitivity of 0.251fmoles when 
detecting both complementary target oligonucleotide, and luciferase mRNA.
3.3.7. HPA for Luciferase mRNA.
Following optimisation of the various parameters described above, it was 
now possible to quantify the concentration of unknown luciferase mRNA samples by 
comparing chemiluminescence of the unknown samples against the 
chemiluminescence of a standard curve generated using serial dilutions of target oligo 
-  that is, a Hybridisation Protection Assay for luciferase mRNA had now been 
optimised. Assay components were combined in duplicate, as shown in Table 3.14. 
The final volume of helper added equates to half a volume of 5' helper and half a 
volume of 3' helper. Tubes were agitated gently by hand, covered with standard 
laboratory label tape, and incubated at 60°C for 30min (hybridisation). Selection 
reagent (300pl) was added and the tubes incubated for a further 15min at 60°C 
(selective hydrolysis). Chemiluminescence was detected as described in Section
3.2.5. The RLUs generated by each tube were recorded directly, and a standard curve 
was generated, in order to allow the calculation of luciferase mRNA concentration in 
fmol/ml.
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BLANK CONTROL STANDARD TEST
Hybridisation
Buffer
50 50 50 50
h 2o 50 30 20 20
Helper
(5pmol/pl)
10 10 10
Target - - 10 -
mRNA sample - - - 10
Diluted Probe 
(5fmol/ pi)
10 10 10
Final Volume 100 100 100 100
Table 3.14. Luciferase mRNA assay components. All figures given represent 
volumes, in microlitres.
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3.3.8. Detection of Luciferase mRNA Using a Two-Step Hybridisation and
Direct Capture of AE-Labelled Target Nucleic Acids.
a) Introduction.
Although the AE-probe can be detected with a relatively high degree of 
sensitivity as part of the HP A, there is interplay involved between the amount of AE- 
probe present and the background readings, which must be kept relatively low to fully 
exploit AE sensitivity. The effects of background on sensitivity are especially a 
problem in the development of a homogeneous assay format such as the HP A, because 
of the difficulty in discriminating between hybrid and unhybridised AE-probe 
molecules in solution. Although the differential hydrolysis step (Section 3.2.2.2) 
effectively reduces levels of chemiluminescence associated with unhybridised AE- 
probe to relatively low levels, a background level of chemiluminescent AE-probe 
remains. This inherent background, the Residual Fraction, has been described 
previously and is calculated as detailed in Section 3.3.2.
Whilst the chemiluminescence levels associated with the Residual 
Fraction do not present a problem when the HPA is used for the detection of a 
relatively abundant target nucleic acid, it can be desirable to further lower levels of 
background chemiluminescence (effectively increasing the signalinoise ratio) if the 
target nucleic acid is present at a relatively low concentration. The lowering of 
background levels of chemiluminescence can be achieved by separating hybridised 
and unhybridised AE-probe. This can be done by hybridising the AE-probe to the 
target nucleic acid (luciferase mRNA), followed by the subsequent pulling-down or 
“direct capture” of the labelled nucleic acid by a “bridging” oligonucleotide, which 
binds in turn, to a solid support (magnetic particles). AE-probe not hybridised to the 
target nucleic acid is readily washed away from the solid support and thus, the 
detection of any remaining chemiluminescence is a direct measure of the amount of 
target nucleic acid present. A schematic representation of the two-step, direct-capture 
technique is shown in Figure 3.16.
b) Probe Design.
Wherever possible, reaction conditions and oligonucleotide sequences 
that had been previously optimised for the HPA were utilised. The sequences of the 
AE-probe and the 5' and 3'- helper oligos have been detailed previously (Table 3.5),
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and since the binding of helper oligos had already been shown to facilitate the 
hybridisation of AE-probe to luciferase mRNA (Section 3.3.5), it was decided to 
utilise the sequence of the 5'-helper in the design of the bridging probe. A string of 14 
A- residues were added to the 3'- end of the 5'- helper to make the “PolyA bridge” 
(Table 3.15). Consequently, following the hybridisation of the AE-probe, the 3'- 
helper and the PolyA bridge to the luciferase mRNA, it was possible to immobilise or 
“capture” the AE-labelled mRNA on magnetic oligo dT^ beads. Appendix 3C shows 
where the 5' -  helper (and therefore, the PolyA bridge) binds within the luciferase 
coding sequence.
Oligo Sequence (5’-»3’)
PolyA
bridge
AAT TCA TTA TCA GTG CAA TTG TTT TGT CAC AAA AAA
AAA AAA AAA
Table 3.15. The sequence of the PolyA bridge, which was utilised in direct-capture 
assays, along with the luciferase AE-probe (see text for details).
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NNNN
\
GT G AC AA AAC AATT GC ACT GAT AAT G AATT CCTCT GG ATCT ACT AN N N..............L u c ife rase  mRNA
+
AA AAAAAAAAAAAAC ACT GTTTT GTT AACGT G ACT ATT ACTT A A PolyA -bridge
GG AG ACCT AG AT GATCC AATGG ATT CCC AE-PROBE
H y b rid isa tio n  1 
(60°C , 30m in)
NNNN
\
GTGACAAAACAATTGCACTGATAATGAATTCCTCTGGATCTACTANNN..............L u c ife rase  mRNA
A A A A A A A A A A A A A A C A C TG H ffG ffA A C G TG A C tA TfA C TTA 'A G G A G A C C TA G A TG A TN N N .............AE-PROBE
+
^ ^ ^ T T T T T T T T T T T T T T  PolyT m ag n e tic  b e a d s
H y b rid isa tio n  2 
(R T , 30m in)
NNNN
A  \
T T T T  T T T T  J  j  TTTTTGTGACAAAACAATTGpACJGATAATGAATTCCTCTGGATCTACTANNN.............. L u c ife rase  mRNA
a a a a a a a a a a a a a a c a c t g t t H g H a a c g t g a c t a t t a c t t a a g g a g a c c t a g a t g a t n n n  AE-PROBE
F igure  3.16 The two-step hybridisation protocol used in the direct-capture m ethod for quantification o f  luciferase mRNA 
using the AE-probe. The full sequence o f  the PolyA-bridge is shown, whilst only part o f  the AE-probe 
sequence is displayed, for orientation purposes. The relevant, complementary regions o f  the l,653bp 
luciferase mRNA are also shown. The rem ainder o f  the sequence is designated “-NNNN-”.
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c) Assay Format.
Luciferase AE-probe (50fmol) was combined with the luciferase 3'- 
helper probe (lOfmol) and the PolyA bridge (lnmol) in a 75mm luminometer tube. 
Dilutions of luciferase mRNA (heated at 60°C for 5min, followed by vortexing for 20- 
30sec, and donated by Dr Ceri Morris, MLT Ltd, as before) were added and a 
sufficient volume of 2x hybridisation buffer was added to bring the final reaction 
volume to 25 pi at a lx hybridistion buffer concentration. Following an incubation at 
60°C for 30min, magnetic oligo dTi4 beads were added (sufficient volume to bind 
lnmol of PolyA bridge and therefore bind approximately 20ng mRNA) and tubes 
incubated for a further 30min at RT.
Tubes were then placed on a magnetic stand and the supernatant 
removed. Wash buffer was added (1ml) and the beads were vortex ed vigorously for 
30sec. Tubes were again placed on the magnetic stand and the supernatant removed, 
until beads had been washed a total of four times. Following removal of the fourth 
wash, beads were resuspended in lx hybridisation buffer (50pl) and the associated 
chemiluminescence was measured, as per Section 3.2.5.
As shown in Figure 3.16, the two hybridisation conditions controlled the 
order of hybridisation; the first hybridisation allowed the AE-probe and PolyA bridge 
to hybridise to the luciferase mRNA, and followed the hybridisation conditions as 
used for the Luciferase HPA (60°C for 30mins). The second hybridisation step 
allowed the hybridisation of the poly-A tail of the PolyA bridge (now bound to the 
luciferase mRNA, along with the AE-probe) to the poly-T tail of the oligo dT]4 beads, 
and was carried out at RT for 30mins.
The first hybridisation step utilised a temperature below the Tm of the 
AE-probe and PolyA bridge binding to the target nucleic acid but above the Tm of the 
poly-A tail binding to the poly-T tail (assuming that an A-T bond raises the Tm by 
2°C, 14 x 2 = ~ 28°C). This condition favoured binding of the AE-probe and the 
PolyA bridge to luciferase mRNA, but not of the poly-A tail of the PolyA bridge 
binding to the poly-T tail of the oligo dTj4 beads. The temperature of the second 
hybridisation was below the Tm of the the poly-A tail binding to the poly-T tail, and 
thus was compatible with the immobilisation of AE-labelled luciferase mRNA to the 
magnetic oligo dTj4 beads. (“Tm” refers to the melting temperature at which 50% of 
hybridisation complexes formed between two nucleic acid sequences are denatured.
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At a temperature below the Tm, hybridisation is favoured, whereas at a temperature 
above the Tm, hybrid formation is not favoured).
d) Sensitivity.
In order to determine the limit of sensitivity of the direct-capture assay, a 
series of dilutions of luciferase mRNA (produced using the RiboMax™ In Vitro 
Transcription Kit (Promega), and donated by Dr Ceri Morris, MLT Ltd) were made 
and reactions were carried out as above. The limit of sensitivity was calculated as 
before for the luciferase HPA (Section 3.3.6.c); the standard deviation of the log 
RLUs for the five negative control values (containing lx hybridisation buffer and 
oligo dTi4 beads only -  no AE probe) was doubled and added to the mean of the log 
RLUs for these five values (Figure 3.17). This gave a value of 2.65. Intrapolation to 
the x-axis estimates a limit of sensitivity of 26amoles for the detection of luciferase 
mRNA. This compares with a value of 251amoles for the HPA (Section 3.3.6.c).
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Figure 3.17. The sensitivity profile for the luciferase AE-probe utilised in a direct- 
capture assay at a final probe concentration of 50fmol/reaction. AE- 
probe, 3'- helper and the PolyA bridge were hybridised with serial 
dilutions of luciferase mRNA for 30min at 60°C, prior to the addition of 
magnetic oligo dTi4 beads and a further 30min incubation at RT. Beads 
were washed four times, resuspended in lx hybridisation buffer (50^1), 
and the associated chemiluminescence detected.
Best line fit of data was obtained by regression analysis. The R2 
value for the fit was R2 = 0.980. Log of the average RLUs for 
negative control samples (lx hybridisation buffer and oligo dTn beads 
only) was 2.49 and the standard deviation for these 5 values was 0.08.
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3.4. Discussion.
The most common approach used to determine the sensitivity of an 
analytical technique is to assay the zero standard repeatedly and define the limit of 
sensitivity as being the concentration corresponding to two or three standard 
deviations above the mean. This equates to the probability that a single replicate of 
sample does not form part of the distribution of zero analyte values. In this way, the 
limit of sensitivity of the luciferase HPA was calculated by adding two standard 
deviations to the mean value for five replicates of the negative control sample (the 
negative controls contained AE probe but no target sequence) to give estimations for 
the limit of sensitivity of 0.25fmoles per reaction when quantifying both 
complementary oligonucleotide and luciferase mRNA. These estimations compare 
favourably with the value of 0.60fmoles, calculated by Arnold et al., (1989).
It was also possible to further increase the limit of sensitivity of AE 
detection, with an adaptation of the HPA. In this Direct Capture assay, hybridised 
AE-probe was physically separated from unhybridised AE-probe, effectively lowering 
the background levels of chemiluminescence. The AE-probe (from the luciferase 
HPA) and a bridging oligo (consisting of the sequence of the 5'- helper from the HPA, 
followed by a further 14 A- residues) were hybridised to the luciferase mRNA. The 
mRNA could then be pulled down onto oligo dT 14 magnetic beads, prior to detection 
of associated chemiluminescence. A simple luciferase mRNA titration demonstrated 
that the direct-capture assay was more sensitive than the HPA; 26amoles compared to 
251amoles.
As well as increased sensitivity, a second advantage of the direct capture 
assay is that luciferase mRNA (hybridised to AE probe and bridging oligo) can be 
separated from any other nucleic acids present (by pulling down of mRNA to oligo 
dTi4 magnetic beads). This could be an advantage when quantifying luciferase 
transcript levels from an in vitro transcription reaction (Chapter 6 ) which would 
include template (plasmid) DNA; non-specific binding of AE probe to the template 
DNA could lead to an increase in background levels of chemiluminescence and 
subsequent loss of sensitivity.
In order to develop assays which examine the effects of putative 
disruptors on transcription, it is essential that gene transcript levels can be quantified. 
Although it has been shown that the HPA can be successfully used for the
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quantification of luciferase mRNA, there are also a number of other techniques which 
can be employed in the detection of gene transcripts.
The RNAse Protection Assay (RPA) typically requires approximately 
lOpg of total RNA (Sambrook et al., 1989). Assuming that the mRNA fraction of a 
typical cell makes up about 2% of total RNA, that the average length of a mRNA 
molecule is 1.5kb and that the average relative molecular mass of a nucleotide is 350, 
this equates to approximately O.38pmoles of mRNA in a single sample. An mRNA is 
usually considered to be abundant if it constitutes >1% of the mRNA fraction 
(Sambrook et al., 1989). Therefore, if the RPA were to be used for the detection of an 
abundant mRNA from lOpg of total RNA, it can be estimated that it would be 
possible to detect at least 3.8finoles of mRNA, using the RPA. It is possible that the 
limit of sensitivity of the RPA lies below this level and is comparable with the limit of 
sensitivity of the HPA (0.25finol). However, the RPA relies on the use of radioactive 
isotopes and is more likely to take days, rather than hours to perform.
In comparison, a band can be detected from a Northern blot carried out 
under ideal conditions from as little as lOOng of total RNA, according to the estimates 
of Sambrook et al., (1989). Following the same logic as above for an abundant 
mRNA, this equates to an approximate limit of sensitivity of 0.038fmoles. This is 
more sensitive than the HPA and is approximately comparable to the limit of 
sensitivity for the direct capture assay (0.026fmol). However, although a Northern 
blot is potentially as sensitive as the direct capture method for the analysis of gene 
transcripts, it provides only qualitative data, whereas the direct capture is quantitative. 
In addition to this, Northern blots again rely on the use of radioactive isotopes, as well 
as taking days, rather than hours to perform.
An alternative method for the quantification of transcript levels is 
TaqMan® probe real-time quantitative PCR (QPCR; described in Chapter 5). The 
limit of sensitivity for a luciferase-specific primer and probe set was estimated at ~ 
lfg/pl of plasmid DNA (Section 5.4), equating to approximately 2amoles. This is 
significantly more sensitive than the HPA and the direct capture method. However, 
the QPCR technique is dependent on an amplification step and therefore exhibits 
relatively high CVs (10-20%), as well as being considerably more labour-intensive 
and expensive than the HPA.
It is hoped, therefore, that the successful optimisation of the HPA will 
provide a level of sensitivity within the measurement range required to quantify
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luciferase mRNA transcribed from a luciferase reporter construct, both from cellular 
and from in vitro transcription systems. Furthermore, this approach may provide 
additional advantages, including ease of use and the generation of fully quantitative 
results, with CVs of less than 7.5% (Thomas-Jones et al., 2003), thereby allowing 
more exacting measurements to be performed.
Since the in vitro transcription of the luciferase gene from a thyroid- 
responsive reporter construct is mediated via the binding of the thyroid receptor to a 
thyroid-reponse element in the promoter region of the gene, this necessitates the 
availability of purified, recombinant thyroid receptor.
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CHAPTER FOUR
THE CLONING, EXPRESSION AND CHARACTERISATION OF 
THE MURINE THYROID HORMONE RECEPTORS.
4.1 Introduction.
DNA-binding and transcriptional-activation assays will be developed in 
order to assess the impact of potential chemical modulators on the molecular 
machinery of the thyroid hormone system. Since a necessary component for each of 
these assays is pure thyroid receptor(s), a powerful expression system was required for 
the production of sufficient quantities of homogeneous recombinant protein.
The pET family of expression vectors (Novagen) offers a powerful, 
versatile and rapid system, which allows the expression of heterologous genes in 
E.coli. This family of vectors was developed for the cloning and expression of DNA 
sequences under the control of the T7 promoter, hence their name: plasmid for 
expression by T7 RNA polymerase. This system harnesses the transcription potential 
of the bacteriophage T7 promoter, as the host carries a fragment of DNA encoding the 
T7 RNA polymerase gene downstream from the the lacl gene and the lacUV5 
promoter. Thus, the addition of IPTG (a stable lactose analogue) induces expression 
of T7 polymerase, which in turn expresses the cloned DNA sequence from the pET 
vector.
It was decided to amplify, clone and express the murine forms of the 
thyroid receptors, as they share significant homology with the human forms of the 
protein. On an amino acid level, the TRal isoforms share 79% identity, whilst the 
TRpi isoforms are 94% identical. Functional analysis of recombinant protein can be 
assessed using the electrophoretic mobility shift assay (EMSA).
The EMSA is a powerful technique which allows both qualitative and 
quantitative analysis of protein-DNA interactions. It is based on the observation that 
the electrophoretic mobility of a nucleic acid through a polyacrylamide gel can be
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altered by the binding of protein. A radiolabelled oligonucleotide (probe) containing 
the sequence of interest is incubated with the recombinant protein and DNA-protein 
complexes and free probe are then separated by elecrophoresis on a non-denaturing 
polyacrylamide gel and visualised by autoradiography.
The malic enzyme (ME) gene is expressed ubiquitously, but is only up- 
regulated by T3 in the rat kidney, heart, and most prominently -  the liver (Jeannin et 
al., 1998). The presence of a positive TRE in the promoter region of the ME gene has 
been confirmed (Desvergne et al., 1991; Petty et al., 1990) and subsequent studies 
(Miyamoto et al., 1993) have employed the electrophoretic mobility shift assay 
(EMSA) to demonstrate that both TRa and TRp are able to bind to an oligo containing 
the ME-TRE.
4.1.1. The pET Expression System.
Target genes are cloned into the multiple cloning site of a pET plasmid, 
under the control of the bacteriophage T7 promoter. Expression is induced by 
providing a source of T7 RNA polymerase in the host cell. T7 polymerase is so 
selective and active that, when fully induced, almost all the cells’s resources are 
converted to target gene expression; the desired product can comprise more than 50% 
of the total cell protein just a few hours after induction (Studier and Moffatt, 1986).
Target genes are intially cloned using hosts that do not contain the T7 
RNA polymerase gene, thus eliminating plasmid instability due to the production of 
proteins potentially toxic to the host cell. Once established in a non-expression host, 
target protein expression is initiated by transferring the plasmid into an expression 
host containing a chromosomal copy of the T7 RNA polymerase gene under lac\JV5 
control. These hosts are lysogens of bacteriophage DE3 (itself a X derivative), and 
carry a DNA fragment containing the lacl gene, the lac\JV5 promoter, and the gene 
for T7 RNA polymerase (Studier and Moffatt, 1986). This fragment is inserted into 
the int gene, preventing DE3 from integrating into or excising from the chromosome 
without a helper phage. Once a DE3 lysogen is formed, the only promoter known to 
direct transcription of the T7 RNA polymerase gene is the /acUV5 promoter.
The lacUV5 promoter is a mutant of the Piac promoter, which is part of 
the lac operon, found in E.coli\ E.coli are able to utilise lactose as a source of carbon. 
The enzymes required for the use of lactose as a carbon source, are only synthesized
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when lactose is available as the sole carbon source. As part of the lactose {lac) 
operon, the three structural genes lacZ, lacY and lacA (encoding p-galactosidase, 
galactoside permease and thiogalactoside transacetylase, respectively) are transcribed 
from a single transcription unit, lacZYA, under the control of a single promoter Piac 
(Turner et al., 1997). The lacZYA transcription unit contains an operator site Oiac 
which is positioned at the 5’-end of the Piac promoter region. This site is bound with 
very high affinity by a protein called the lac repressor, which is a potent inhibitor of 
transcription when bound to the operator. The lac repressor is encoded by a separate 
regulatory gene lacl, which is also part of the lac operon; lacl is situated immediately 
upstream from P\ac.
In the absence of lactose, the lac repressor occupies the operator-binding 
site, whilst the RNA polymerase simultaneously occupies the lac promoter binding 
site. All but very low levels of transcription are blocked. When lactose is added, the 
low basal level of galactoside permease expressed allow it’s uptake, and p- 
galactosidase catalyses the conversion of some of this lactose to allolactose. 
Allolactose acts as an inducer and binds to the lac repressor, it causes a change in 
protein conformation which leads to dissociation of the repressor from the operator 
binding site (Turner et al., 1997). RNA polymerase is now able to rapidly transcribe 
the lacZYA genes. Thus, the addition of lactose, or a synthetic inducer such as 
isopropyl-p-D-thiogalactopyranoside (IPTG), very rapidly stimulates transcription of 
the lac operon structural genes, or whatever gene(s) may be under the control of the 
inducible promoter -  in the case of a DE3 lysogen host-strain, the T7 polymerase gene 
under the control of the lac\JV5 promoter (Figure 4.1).
The P^c promoter is not a particularly strong promoter. For high level 
transcription, it depends on the activity of a specific activator protein called cAMP 
receptor protein (CRP). Binding of CRP to the Piac promoter immediately upstream of 
the RNA polymerase binding site induces a 90° bend in DNA, increasing the affinity 
of RNA polymerase binding to the promoter and thus increasing transcription by up to 
50-fold.
The lac\JV5 promoter is a P[ac promoter mutant, which is strongly and 
constitutively active independent of CRP. Thus, the addition of IPTG to a growing 
culture of the lysogen induces T7 RNA polymerase expression, which in turn 
transcribes the target DNA from the pET plasmid.
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Even in the absence of IPTG, there is some expression of T7 RNA 
polymerase from the lac\JV5 promoter in the 2JDE3 lysogens. If target proteins are 
sufficiently toxic to affect cell growth and viability this basal level can be sufficient to 
prevent the establishment of plasmids in the XDE3 lysogens. One way of providing 
stability to target genes is to express them in host strains containing a compatible 
plasmid that encodes T7 lysozyme, a natural inhibitor of T7 RNA polymerase which 
works by binding to and inhibiting the polymerase enzyme. Upon induction of 
expression, however (achieved by the addition of IPTG), the T7 polymerase gene is 
up regulated and the low levels of lysozyme present are no longer able to inhibit the 
resultant high levels of T7 polymerase, and so the target gene is transcribed.
A further advantage of employing a strain which expresses T7 lysozyme, 
is that T7 lysozyme is a bifunctional protein; it cuts a specific bond in the 
peptidoglycan layer of the E.coli cell wall. Treatments that disrupt the inner 
membrane (e.g. ffeeze-thaw or mild detergents) thus induce rapid lysis of cells.
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Figure 4.1. Inducible transcription of the T7 polymerase gene in >.DE3-lysogenic
E.coli. In the absence of lactose, the lac repressor occupies the operator- 
binding site (Oiac), and blocks all but very low levels of transcription. 
When the inducer is added (IPTG), it binds to the lac repressor and 
causes a change in protein conformation which leads to dissociation of 
the repressor from the operator binding site. The promoter-bound RNA 
polymerase is no longer blocked, and transcription is induced.
119
Chapter Four Recombinant TR
The E.coli host strain, Rosetta™ BL21 (DE3) pLysS is a XDE3 lysogen, 
carrying the T7 polymerase gene under the control of the lac\JV5 promoter. It also 
carries a pLysS plasmid, which encodes T7 lysozyme. The Rosetta host strain offers 
an added advantage, in that it is designed to enhance the expression of eukaryotic 
proteins that contain codons rarely used in E. coli. This strain supplies tRNAs for 
AGG, AGA, AUA, CUA, CCC, GGA codons on a compatible chloramphenicol- 
resistant plasmid. Thus the Rosetta strain provides for “universal” translation, which is 
otherwise limited by the codon usage of E. coli. In Rosetta (DE3) pLysS the rare 
tRNA genes are present on the same plasmid that carries the T7 lysozyme gene.
Therefore, in order to allow the overexpression and purification of 
recombinant, murine thyroid receptors (which utilise codons rarely found in E.coli -  
see Table 4.2) it was decided to use the pET expression system in conjunction with the 
E.coli host strain Rosetta (DE3) pLysS. The pET vector chosen was pET-15b. The 
use of this expression vector would allow the addition of a N-terminal His-Tag to the 
recombinantly expressed protein, thus facilitating large-scale protein purification. 
Similar systems have been previously employed in the successful production of 
recombinant thyroid receptors (Zhang et al., 1996; Tong et al., 1995; and Forman et 
al., 1992).
Frequency of occurrence in gene sequence
CODON mTRa mTRp
AGG 4 4
AGA 1 4
AUA 1 4
CUA 3 5
CCC 7 1
GGA 2 4
Table 4.2. The codons encoded extra-chromosomally in the E.coli host strain
Rosetta™ BL21 (DE3) pLysS and their frequency of occurrence in the 
gene sequences of the murine thyroid receptors a and p.
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4.2. Experimental Approach and Results.
4.2.1. Amplification and Cloning of the DNAs Encoding the Murine
Thyroid Receptors, Alpha and Beta.
Total RNA was prepared from a whole mouse heart as described in 
Section 2.2.1.10. Although there is a tissue-specific distribution of TR isoforms 
(Section 1.2.1 from the Intro), nearly equal levels of TRa and TRp are seen in both the 
kidney and the heart (Hsu and Brent, 1998). The mRNA (~200ng) was reverse 
transcribed (Section 2.2.1.11) and an aliquot (lpl) of the resulting cDNA was used as 
a template for PCR. A PCR product encompassing the full-length cDNA sequence 
was amplified for both TRa and TRp.
Specific forward and reverse primers were designed for each gene. The 
forward primer was designed against the 5' region encoding the start codon, whilst the 
reverse primer was designed against the 3' region and encoded the stop codon. 
Forward and reverse primers were designed in such a way so as to engineer BglII sites 
on to each end of the amplified PCR product, so as to facilitate cloning of the 
fragment into pET-15b. For primer sequences see Appendix IB.
Amplification of the PCR products was achieved using the Expand™ 
High Fidelity PCR System. This consists of an enzyme mixture containing Taq DNA 
polymerase and a proofreading polymerase -  both thermostable enzymes. Reactions 
were carried out following the conditions described in Section 2.2.1.2 and the 
thermocycling parameters were as follows:
Chain denaturation 95°C 3min
95°C lmin
Primer annealing 60°C lmin
Chain extension 72°C 1.5min
Final extension 72°C lOmin
30 cycles
Soak 4°C
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A fragment which corresponded approximately to the predicted size was 
amplified for TRa (1233bp) and TR(3 (1383bp), see Figure 4.3. PCR products were 
purified by agarose gel electrophoresis, and ligated into the pGEM®-T vector, 
(Section 2.2.1.4.b and Section 2.2.1.8, for vector map see Appendix 2A). The 
resultant plasmids were subsequently transformed, separately, into competent DH5a 
cells, as described in Section 2.2.1.9.
A) Lane: X <|) TRa
1 353 \
1,078-----
872 ^
B) Lane: X <|> TRp
1,353
\
1 CY1Qi,U /o ----
/
872 /
Figure 4.3. Analysis of the TRa and TRp cDNA amplification reactions, performed 
by PCR. Mouse-heart cDNA was the template used. PCR products were 
analysed on a 1% agarose gel containing 0.5pg/ml ethidium bromide. 
Panel A): Amplification of TRa 
Panel B): Amplification of TRp
In both panels, the markers are as follows: X = X/HindLll and <|> = 
§\14/Haelll (See Table 2.4 for full list of DNA marker fragment sizes).
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4.2.2. Subcloning of the DNAs Encoding the Murine Thyroid Receptors
Into the Expression Vector pET-15b.
The pET vector chosen was pET-15b (for vector map, see Appendix 2B). 
This vector was chosen in order to allow the introduction of a N-terminal His-tag to 
the recombinantly expressed protein (Section 4.1.1). The His-tag sequence encodes a 
six-histidine peptide, whose presence can be exploited for both detection and 
purification of the recombinant protein. The cDNAs encoding TRa and TRp were 
cloned into the vector downstream from, and in-frame with, the His-tag. The BamHI 
site of pET-15b was chosen, in order to minimise the number of extra amino acid 
residues that would be added to the recombinant protein (Appendix 3B shows the 
sequence of the TR cDNAs cloned into the BamHI site of pET-15b, with amino acid 
translation). The amplified DNAs were excised from pGEM®-T with the restriction 
enzyme BgBl, and the released fragments gel purified (Section 2.2.1.4.b). pET15-b 
was digested with BamHI, the 5' phosphate groups removed and the linearised vector 
gel purified. (Sections 2.2.1.6, 2.2.1.7 and 2.2.1.4.b respectively). Purified, digested 
cDNAs were ligated directly into the linearised vector overnight at 16°C (Section 
2.2.1.8) and the individual ligation mixtures used to transform competent DH5a cells 
(Section 2.2.1.9).
It was necessary to screen for positive transformants, in which the DNA 
fragment had been inserted in the correct orientation, i.e. with the TR start codon 
downstream from and in frame with the N-terminal His-tag. Transformants were 
screened, using PCR, as described in Section 2.2.1.12. The primers used were gene- 
specific forward and T7 reverse (for primer sequences, see Appendices IB and 1A, 
respectively). Positive clones for TRa and TRp (which will subsequently be called 
pETTRa and pETTRP) were identified, and an overnight culture inoculated from the 
respective colony. Plasmid DNA was extracted (Section 2.2.1.3.a) and subsequently 
used to transform competent E.coli expression host cells Rosetta™ BL21 (DE3) 
pLysS. The induction of expression from pETTRa and pETTRp resulted in the 
production of a recombinant, N-terminal His-tagged fusion protein which will 
henceforth be referred to as TRa and TRp respectively, unless otherwise specified.
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4.2.3. Analytical Scale Expression of pETTRp and Analysis of Cell 
Extracts.
An overnight culture of Rosetta™ BL21 (DE3) pLysS cells transformed 
with pETTRp was used to inoculate 10ml of LB medium, containing the antibiotics 
ampicillin (100pg/ml) and chloramphenicol (34pg/ml), as described in Section
2.2.4.1. The culture was induced by the addition of IPTG to a final concentration of 
ImM, and samples (1ml) were taken through a timecourse of 0 -  240 minutes post­
induction. Soluble and insoluble protein fractions were prepared (Section 2.2.4.2) and 
analysed by SDS PAGE (Section 2.2.4.3) and western blotting, followed by detection 
with the Ni-NTA AP conjugate (Sections 2.2.4.4 and 2.2.4.5).
Expression of the cDNA encoding TRp resulted in the appearance of a 
single band of approximately 55kDa, which is consistent with the anticipated size for 
the recombinant His-tagged fusion protein. The Coomassie Blue stained gel and the 
western blot both indicate the accumulation of a band of the predicted size, but 
restricted to the insoluble fraction (Figure 4.4). The band was visible on the SDS gel 
from 30min post induction. The intensity of this band increasing progressively up to 
240min post induction and it was possible to confirm the presence of a His-tag using 
the western blot and Ni-NTA AP conjugate system (Sections 2.2.4.4. and 2.2.4.5.).
4.2.4. Optimisation of Induction Conditions for Expression of
Recombinant TRp.
Due to the lack of solubility initially observed for recombinant TRp 
(Section 4.2.3.), it was decided to manipulate the induction conditions in order to 
investigate whether it was possible to obtain protein in a soluble form.
Analytical scale induction cultures were grown at 37°C to an OD60 0 of 
between 0.4 and 0.6, as described in Section 2.2.4.1. Cultures were induced by the 
addition of IPTG to final concentrations of 0.25mM, 0.5mM and ImM. Cultures 
induced with each concentration of IPTG were then incubated at 20°C, 30°C and 
37°C. Samples were taken at times 0, 0.5, 1, 2, 3 and 4h. Soluble and insoluble 
samples were prepared (Section 2.2.4.2), analysed by SDS PAGE (Section 2.2.4.3) 
and western blots performed with the Ni-NTA AP conjugate (Sections 2.2.4.4 and 
2.2.4.5). The Coomassie Blue stained gel and the western blot showed that a band of 
predicted size could only be detected in the soluble fraction, which had been induced
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with 0.5mM IPTG, and grown, subsequently at 20°C (temporal profile is shown in 
Figure 4.5). However, the amount of soluble protein was a relatively small proportion 
of the total quantity of total recombinant TRp as exemplified when comparing the 
amount of soluble and insoluble recombinant TRP expressed at 4 hours (Figure 4.5 
Lanes 240 and I).
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Figure 4.4. Analytical-scale expression of recombinant His-tagged TRp. Analytical 
scale cultures were induced with ImM IPTG and subsequently grown at 
37°C. SDS-PAGE and western blot analysis of the insoluble fraction 
(lOpl sample volume) along a temporal profile is shown in:
Panel A: Coomassie Brilliant Blue stained gel and,
Panel B: Western Blot probed with Ni-NTA AP conjugate.
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Figure 4.5. Production of soluble recombinant His-tagged TRp. Analytical scale 
cultures were induced with 0.5mM IPTG and subsequently grown at 
20°C. A Coomassie Brilliant Blue stained SDS-PAGE gel (Panel A) and 
a western blot probed with Ni-NTA AP conjugate (Panel B) was 
performed along a temporal profile of protein induction. Soluble extracts 
(lOp.1 sample volume) from samples harvested at 0, 30, 60, 120, 180, and 
240 minutes are shown in the respective lanes whilst Lane I shows lOpl 
of the insoluble fraction harvested after 240 minutes.
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4.2.5. Preparative Scale Expression of TR|3, and Purification of
Recombinant Protein using Ni-NTA Agarose.
Large-scale expression of recombinant protein was performed in 11 of 
LB medium. An overnight culture (10ml) of Rosetta™ BL21 (DE3) pLysS cells 
transformed with pETTRp, was used to inoculate 500ml of fresh LB medium, 
containing the appropriate antibiotics.
The culture was grown at 37°C until the OD6 00 was between 0.4 and 0.6. 
Expression of recombinant protein was induced by the addition of IPTG to a final 
concentration of 0.5mM. The culture was subsequently grown at 20°C, with shaking, 
for 4h. Cells were harvested by centrifugation (10,000 x g, lOmin at 4°C), 
resuspended in lysis buffer (50mM NatLPCU, 300mM NaCl, lOmM imidazole, pH 
8.0), lysed by French pressing (four passes) and mixed with the Ni-NTA slurry, as 
described in Section 2.2.4.6.
The lysate/Ni-NTA slurry contaminate was poured onto a column and 
the flow-through collected. Non-bound proteins were removed by elution with wash 
buffer (8ml; 50mM NaH2P0 4 , 300mM NaCl, 20mM imidazole, pH 8.0), and the 
protein eluate monitored by recording the OD280 of each wash. Recombinant TRp was 
eluted by increasing the imidazole concentration to 250mM. Elution buffer was added 
to the column in five 1ml fractions. These samples were subsequently analysed by 
SDS PAGE (Section 2.2.4.3, Figure 4.6) and western blots with the Ni-NTA 
conjugate were again used to confirm the presence of a His-tagged protein (Sections
2.2.4.4. and 2.2.4.5, data not shown.).
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Figure 4.6. Large-scale purification of recombinant TR/3, using Ni-NTA resin. 1ml 
of an overnight culture (10ml) of Rosetta™ BL21 (DE3) pLysS cells 
transformed with pETTR(3, was used to inoculate 500ml of fresh LB 
medium. The culture was grown at 37°C until the OD6 0 0 was between 
0.4 and 0.6 and recombinant protein expression was induced by the 
addition of 0.5mM IPTG followed by growth at 20°C. Cells were 
harvested after 4hours, lysed (French Press) and mixed with the Ni-NTA 
slurry. The lysate/Ni-NTA slurry contaminate was poured onto a column 
and non-bound proteins removed by elution with wash buffer (containing 
20mM Imidazole). Recombinant TR/3 was eluted from the column by 
increasing the imidazole concentration to 250mM. A Coomassie 
Brilliant Blue stained SDS-PAGE gel shows five 1ml elutions (5pl 
sample volume).
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4.2.6. Optimisation of Induction Conditions for Expression of
Recombinant TRa.
The TRp cDNA was cloned and recombinant protein was successfully 
expressed before completion of the TRa cDNA subcloning. Therefore, upon 
completion of the cloning and subcloning of TRa, it was decided to study the 
temporal expression profile of TRa under the same conditions that had yielded 
recombinant TRp in the soluble fraction. Consequently, cultures were induced using 
an IPTG concentration of 0.5mM, and then subsequently grown at 20°C.
Profiling of the expression of soluble TRa resulted in the appearance of a 
single band of approximately 46kDa lhour post-induction, which is consistent with 
the anticipated size for the recombinant His-tagged fusion protein. The Coomassie 
Blue stained gel and the Ni-NTA western blot both showed the accumulation of a 
band of the expected size (Figure 4.7). Thus, it was possible to successfully express 
and purify TRa, on a preparative scale, following identical conditions used in the 
expression and purification of recombinant TRp, as described in Section 4.2.5, (Figure 
4.8).
4.2.7. Long-term Storage of Purified, Recombinant TRa and TRp.
In order to allow long-term storage of purified recombinant proteins at - 
20°C, it was necessary to dialyse the protein into the appropriate storage buffer (50% 
glycerol in PBS, 5mM DTT). In each instance, fractions 2, 3 and 4 (from Figures 4.6 
and 4.8, for TRp and TRa respectively) were pooled and dialysed into storage buffer, 
as described in Section 2.2.4.8. The storage of recombinant protein in any buffer 
other than the above storage buffer was found to cause precipitation of protein. 
Protein concentration was measured using the Bradford Asssay, as described in 
Section 2.2.4.7.a.
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Figure 4.7. Production of soluble recombinant His-tagged TRa Analytical scale 
cultures were induced with 0.5mM IPTG and subsequently grown at 
20°C. A Coomassie Brilliant Blue stained SDS-PAGE gel (Panel A) and 
a western blot probed with Ni-NTA AP conjugate (Panel B) was 
performed along a temporal profile of protein induction. Soluble extracts 
(lOpl sample volume) from samples harvested at 0, 30, 60, 120, 180, and 
240 minutes are shown in the respective lanes whilst Lane I.
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Figure 4.8. Large-scale purification of recombinant TRa, using Ni-NTA resin. 1ml
of an overnight culture (10ml) of Rosetta™ BL21 (DE3) pLysS cells 
transformed with pETTRa, was used to inoculate 500ml of fresh LB 
medium. The culture was grown at 37°C until the OD6 0 0  was between 
0.4 and 0.6 and recombinant protein expression was induced by the 
addition of 0.5mM IPTG followed by growth at 20°C. Cells were 
harvested after 4hours, lysed (French Press) and mixed with the Ni-NTA 
slurry. The lysate/Ni-NTA slurry contaminate was poured onto a column 
and non-bound proteins removed by elution with wash buffer (containing 
20mM Imidazole). Recombinant TRa was eluted from the column by 
increasing the imidazole concentration to 250mM. A Coomassie 
Brilliant Blue stained SDS-PAGE gel shows five 1ml elutions (5pi 
sample volume).
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4.2.8. EMSA Analysis.
4.2.8.1. Introduction.
In order to assess whether or not the recombinant protein was functional 
(i.e. was correctly folded and able to bind DNA) the electrophoretic mobility shift 
assay (EMSA) was used. This method relies on the principle that the mobility of a 
fragment of DNA through a gel matrix will be retarded when a protein has bound. A 
radiolabelled oligonucleotide (probe) containing the sequence of interest is incubated 
with the recombinant protein. The DNA-protein complex(es) and free probe are then 
separated by elecrophoresis on a non-denaturing polyacrylamide gel and visualised by 
autoradiography.
A double-stranded DNA duplex containing the ME-TRE (malic enzyme 
thyroid response element, see next Section, below) was made by annealing a 
complementary oligonucleotide pair as described in Section 2.2.4.9.a (for oligo 
sequences, see Appendix IE). The annealed duplex was radiolabelled with [a- P]- 
dCTP as described in Section 2.2.4.9.b. The annealed, radiolabelled duplex will 
henceforth be referred to as the “probe”.
4.2.8.2. Probe Design.
The ME gene is involved in lipid metabolism, in particular, lipid 
synthesis. Its expression is ubiquitous, but is only up-regulated by T3 in the rat 
kidney, heart, and most prominently -  the liver, which is a major target organ for the 
action of T3 (Jeannin et al., 1998; Petty et al., 1990). Liver malic enzyme (ME) is a 
tetrameric protein that catalyzes the reversible oxidative decarboxylation of L-malate 
to give carbon dioxide and pyruvate with the concomitant reduction of NAD(P)+ to 
NAD(P)H:
NAD(P)+ + L-malate 4 * CO2 + pyruvate + NAD(P)H + H+
The NAD(P)H produced is utilised in the biosynthesis of long-chain fatty 
acids or steroids, hence the classification of ME as a lipogenic enzyme (Chang and 
Tong, 2003). As has been previously mentioned (Section 1.5.1) TRs regulate target 
gene expression through binding to specific DNA sequences called TREs (thyroid
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response elements), in the regulatory regions of target genes. TRs can enhance or 
inhibit gene expression depending on the nature of the TRE. Heterodimer formation 
with RXR enhances DNA-binding affinity, and provides target gene specificity, as 
determined by the spacing between the two half sites. Accordingly, TR/RXR binds 
DR4, that is, a direct repeat - two half sites in one orientation, separated by 4bp. The 
half-site consensus sequence recognised by TRs often contains the sequence 
AGGTCA, and the direct repeat is the most potent, although other arrangements are 
possible (detailed in Section 1.5.1).
The ME-TRE (malic enzyme thyroid-responsive element), is a direct 
repeat motif with a 4-bp gap between the two hexamers, a DR4:
5 '----aggacgttgGGGTT AggggAGGAC Agtg------ 3'
Initial studies confirmed that the ME-TRE is a positive TRE, i.e. the 
transcription of genes under its control is activated by ligand-bound TRs, whilst 
transcription is repressed by unliganded TRs (Desvergne et al., 1991; Petty et al.,
1990). Subsequent studies (Miyamoto et al., 1993) employed the electrophoretic 
mobility shift assay (EMSA) to demonstrate that both TRa and TRp are able to bind 
the ME-TRE as monomers and homodimers. It was for these reasons that it was 
decided to use the ME-TRE to assess whether or not the purified TRs were able to 
bind DNA.
4.2.8.3. Analysis of Protein-DNA Interactions.
Each EMSA experiment was run on a minimum of two but more 
typically on three or more separate occasions in order to ensure reproducibility. In 
each instance, data shown is representative of a single experiment. Unless otherwise 
specified, “TR” refers to the purified, recombinant, N-terminal His-tagged murine 
forms of the fusion protein.
EMSA experiments were carrried out following the conditions outlined 
in Section 2.2.3.9.c. Figure 4.9 shows the binding of purified recombinant TRa and 
TRp (40pmol of each) to radiolabelled probe (3pmol). Shown also, as a positive 
control, is the binding of chicken TRa to probe (purified, recombinant C-terminal 
GST-tagged chicken TRa fusion protein, cTRa, 40pmol; Insight Biotech Ltd).
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Lane: TRa TR£ cTRa
CD 4
— Homodimer
— M onomer
Low Molecular weight 
DNA-protein Complex
Figure 4.9. The binding of recombinant TRs to the ME-TRE probe, analysed by the 
electrophoretic mobility shift assay. Recombinant TR (~40pmol) was 
combined with radiolabelled probe (3pmol) and subjected to 
electrophoresis through a non-denaturing acrylamide gel matrix. 
Following electrophoresis, the gel was dried and bands were visualised 
by autoradiography. Recombinant TRa, TR/3 and cTRa was loaded in 
Lane 1, 2 and 3 respectively.
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Figure 4.9 shows that purified, recombinant TRa and TRP were able to 
bind the ME-TRE probe. This result is confirmed by a previous study (Miyamoto et 
al., 1993) which also employed the EMSA to demonstrate that TRa and TRp are able 
to bind the ME-TRE as monomers and homodimers. The approximate sizes of the 
observed bands are consistent with the predicted sizes of the His-tagged recombinant 
murine proteins; 46kDa for TRa (Section 4.2.6), 55kDa for TRP (Section 4.2.3), 
whilst the predicted size for the GST-tagged cTRa was ~76kDa. An additional low 
molecular weight band is observed in the EMSA of TRa, this could possibly be 
caused by an N-terminal TRa truncation, containing His-tag and the DNA-binding 
domain of the protein binding to the ME-TRE probe; a band of lower molecular 
weight can be seen in the large scale preparation of TRa which may indicate the 
presence of truncated protein (Figure 4.8, Lane 3).
In order to prove that the presence of bands at the estimated sizes for 
homodimers and monomers was due to specific protein-DNA interactions it was 
necessary to carry out competitive EMSA experiments.
Further binding characterisation studies were carried out only on TRp 
and not TRa. Purified recombinant TRa precipitated rapidly out of solution; the 
protein samples loaded in Figure 4.9 had been quantified 12h previously to allow even 
loading of TRa and TRp, and yet the discrepancy in the intensity of the bands is 
immediately apparent. This observation from the EMSA in Figure 4.9 was further 
confirmed by eye -  a visible precipitate of TRa had formed in the storage tube.
4.2.8.4. Examination of the Specificity of DNA-Protein Complex Formation;
Competition EMSA Analysis.
In order to confirm whether the DNA-protein complexes shown in Figure 
4.9 represented specific interactions of recombinant TRP with the radiolabelled probe, 
competition EMSA was carried out on TRp (40pmol) as described in Section 2.2.4.10.
As shown in Figure 4.10, the intensities of the bands in complexes Cl 
and C2 decreased as the fold excess of the unlabelled ME-TRE oligo was increased. 
However, when the maximum (500-fold) excess of unrelated, non-specific, unlabelled 
duplex containing the NFkB binding site was used, no such competition was observed. 
This indicated that both complexes represented specific interactions of TRP with the 
radiolabelled ME-TRE probe.
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Lane: 1 2 3 4 5
Non-labelled ME-TRE 0 100 250 500 500
(fold excess) (N/S)
Figure 4.10. Competition studies of binding of TR/3 to the ME-TRE probe, analysed 
by the electrophoretic mobility shift assay (EMSA). Recombinant TR$ 
(40pmol), combined with radiolabelled probe (3pmol) and the 
indicated fold (Molar) excess of either non-labelled ME-TRE (lanes 1-4) 
or non-specific (N/S) probe (lane 5) were subjected to electrophoresis 
through a non-denaturing acrylamide gel matrix. Following 
electrophoresis, the gel was dried and bands were visualised by 
autoradiography. Cl and C2 refer to the DNA-protein complexes 
observed.
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4.2.8.5. Antibody Supershift Assays.
In order to confirm the identity of the DNA-protein complexes (Cl and 
C2) seen in Figure 4.10, antibody supershift experiments were performed using an 
antibody which recognises both the TRa and TRp isoforms (a gift from Prof. Jiemin 
Wong, Baylor College of Medicine, Houston, Texas, USA). Reactions were set up as 
described in Section 2.2.3.9.C, using TRp (40pmol) and an excess of anti-TR antibody.
Figure 4.11 shows the results of the supershift assay. The appearance of 
complex C3 in lanes 2 and 4 indicates the presence of an antibody-TR-DNA 
supershift complex for TRp and cTRa, respectively. A clear reduction in the intensity 
of cTRa Cl is associated with the appearance of C3, however this is not observed in 
the TRp supershift. This phenomenon may be explained through differential loading 
of material between the lanes containing TRp and TRp with antibody, an indication of 
which can be observed through the general increased intensity of the supershift 
separation (higher background). Therefore the intensity of Cl in the TRp supershift 
does not appear to reduce even though there is a significant C3 band. This data, taken 
together with the results from the competition EMSA (Figure 4.10), confirms that the 
appearance of the bands, B1;B2 and C1;C2, seen in Figures 4.9 and 4.10 respectively, 
is due to the formation of specific protein-DNA complexes. In the same way, 
complexes Cl and C2, seen in Figure 4.11, are due to the binding of TR to DNA, and 
are caused by monomer and homodimer binding, respectively.
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Lane: 1 2  3 4
TR/3 + +
cTRa + +
Antibody -  + -  +
Figure 4.11. EMSA analysis of antibody supershift assays, showing binding of an 
anti-TR antibody to TR/3 and cTRa Recombinant TR (40pmol) and 
radiolabelled probe (3pmol) were combined with an excess of the anti- 
TR antibody (which recognises TRa and TR/3) and subjected to 
electrophoresis through a non-denaturing acrylamide gel matrix. 
Following electrophoresis, the gel was dried and bands were visualised 
by autoradiography. Supershifts with TR/3 and cTRa were performed 
with independent batches of probe and a composite autoradiogram 
generated.
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4.2.9. EMSA Analysis as a way of Monitoring the Disruption of DNA-
Protein Binding.
4.2.9.1. Introduction.
The main aim of this project, as outlined in Section 1.9, is “the 
development of simple in vitro tests, which will provide evidence of thyroid 
disruption by chemicals”. The development of these assays necessitates being able to 
probe a number of binding interactions, including the binding of TRs to DNA. The 
EMSA has been used in conjunction with densitometric scanning of results to 
characterise the binding of TR to various TREs (Jeannin et al., 1998; Darling et al., 
1993; and Wahlstrom et al., 1992).
One approach which makes it possible to monitor whether a potential 
disruptor impacts on the binding of TR to DNA is to measure the affinity of the TR 
for the DNA. The K& (dissociation constant) of a protein is a measure of its affinity 
for its ligand. TR has two ligands; thyroid hormone and DNA. It should be possible 
to quantify the affinity of TR for a specific DNA sequence, i.e. the K& of TR for DNA. 
This affinity is influenced by the binding of a hormone or disruptor to the ligand 
binding domain. The monitoring of the effects of chemicals on the Kd of TR for DNA 
should provide the basis of a TR-DNA binding assay, by allowing the identification of 
chemicals which have the potential to affect transcription from thyroid-regulated 
genes by having an effect on the binding of TR to DNA.
4.2.9.2. Approach.
For a DNA-binding protein in the context of an EMSA, the K& of the 
protein is approximately equal to the protein concentration at which half the available 
DNA (probe) has become bound (Carey, J., 1991). The first step in attempting to 
develop a system to monitor the modulation of DNA-binding therefore, was to 
estimate the K& of TR for the ME-TRE probe. This was done using the EMSA; TR 
was titrated against a constant amount of probe, the amount of free probe was 
quantified by densitometric scanning of gels and the Kd was estimated from a plot of 
TR concentration vs. percentage of free probe.
In order to determine whether or not a potential DNA-binding modulator 
had an effect on TR binding to DNA the potential modulator was titrated against a 
constant amount of TR and probe and free probe was quantified as before
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(densitometric scanning of gels). The TR concentration used was the K<i as 
determined for TR in the absence of T3. An assay in this format allowed the effects of 
a large range of concentrations of potential binding modulators to be assessed. 
Therefore, it was possible to assess T3 and its analogues for potential effects on the 
binding of TR to DNA.
It was necessary to dissolve THs and their analogues in the required 
solvent, as per the manufacturer’s instructions (Sigma). In order to ensure that any 
observed effects were not caused by the presence of these solvents a negative control 
reaction was performed alongside each TH / TH-analogue titration. Negative 
reactions consisted of an equivalent final concentration of the solvent, in the absence 
of any TH / TH-analogue. All negative control reactions showed that the solvent 
present had no effect on the binding of TR to DNA. Each experiment was run on a 
minimum of two but more typically on three or more separate occasions in order to 
ensure reproducibility. In each case, data shown is from a single experiment but is 
representative of multiple experiments.
4.2.9.3. Estimating the KA of Recombinant TRp.
a) Ligand-free TRp.
A wide range of TRp concentrations (0-400pmol/reaction) were titrated 
against a constant probe concentration (0.3pmol/reaction). The midpoint 
concentration was estimated by eye from the radiogram in order to give an indication 
of the approximate magnitude of the dissociation constant, K& (data not shown). This 
allowed a second protein titration, of a narrower concentration range, to be carried out. 
TRp (0-120pmol/reaction) was combined with ME-TRE probe (0.3pmol/reaction), as 
described in Section 2.2.3.9.c and complexes were separated by gel electrophoresis 
(Section 2.2.3.9.d). The results are shown in Figure 4.12. Following electrophoresis 
and gel-drying, the radioactivity associated with bands was quantified as described in 
Section 2.2.3.9.e. The quantitative data was plotted as percentage of free probe vs 
TRp concentration, Figure 4.13. An estimation of the TRp concentration which binds 
approximately half the probe from Figure 4.13 gives a K& of approximately I.OjiM 
(final volume of an EMSA reaction is 40|il, Section 2.2.4.9.c). This estimate of Kd is 
only valid if the DNA concentration is negligible compared to the protein 
concentration at the midpoint (at least 10-, and preferably 100-fold lower; Carey,
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1991). A constant amount of probe (0.3pmol) was added to each titration reaction 
(final volume 40/d) -  this equates to a probe concentration of 0.0075/xM.
Lane: 1 2 3 4 5 6 7 8 9
TR0(pmol): 0 15 30 60 80 100 120 140 160
Free probe —►
Figure 4.12. EMSA analysis showing a titration of TR(3 binding to the ME-TRE 
probe. Recombinant TR/3 (0-160pmol) was titrated with radiolabelled 
probe (0.3pmol) and subjected to electrophoresis through a non­
denaturing acrylamide gel matrix. Following electrophoresis, the gel was 
dried and bands were visualised by autoradiography.
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TRp Concentration (jjM)
Figure 4.13. Densitometric analysis of an EMSA in which recombinant TRp (0- 
160pmol/reaction) was titrated against a constant amount of radiolabelled 
ME-TRE probe (0.3pmol/reaction). Quantitative densitometric data is 
plotted as percentage of free probe vs TRp concentration. (Figure 4.12 
shows the radiogram from which densitometric analysis was 
performed).
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b) Ligand-bound TRp.
In order to assess whether the above method for estimating the K<$ of TR 
is valid, it was decided to carry out a second protein titration, this time in the presence 
of T3 (lOOnM). Since T3 has been shown to lower the affinity of TR for DNA 
(Piedrafita et al., 1995; Sugawara et al., 1994 and Yen et al., 1992) it should be 
possible to measure an increase in the K& of TR for the ME-TRE probe. A TRp 
titration was carried out following the conditions detailed above, except with the 
addition of T3 to a final concentration of lOOnM. Complexes were separated by 
electrophoresis and gels dried. Results were analysed as before, and the radiogram 
and quantitative data are shown in Figures 4.14 and 4.15, respectively. An estimation 
of the TRp concentration which binds approximately half the probe from Figure 4.15 
gives a K& of approximately 1.8pM.
This increase in K& is reflective of a decrease in the affinity of TRp dimers for the 
ME-TRE DNA and is consistent with previous studies. Miyamoto et al., (1993) 
compared a non-T3-binding mutant with a wild-type receptor (TRP) and demonstrated 
that the addition of T3 induced dimer-specific dissociation from the ME-TRE whilst 
monomer binding remained virtually unaffected. The observed ligand-dependant 
disruption of dimer-DNA complex occurs due to a conformational change in TR 
which is caused by the binding of ligand to TR (Miyamoto et al., 1993).
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Lane: 1 2  3 4  5 6 7  8 9  10
TR0(pmol): 0 15 30 60 80 100 120 140 160 180
Free probe
Figure 4.14. EMSA analysis showing a titration of ligand-bound TR/3 binding to the 
ME-TRE probe. Recombinant TR/3 (0-180pmol) was titrated with 
radiolabelled probe (0.3pmol) in the presence of T3 (lOOnM) and 
subjected to electrophoresis through a non-denaturing acrylamide gel 
matrix. Following electrophoresis, the gel was dried and bands were 
visualised by autoradiography.
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Figure 4.15. Densitometric analysis of an EMSA in which ligand-bound 
recombinant TRp (lOOnM T3, 0-180pmol TRp/reaction) was titrated 
against a constant amount of radiolabelled ME-TRE probe 
(0.3pmol/reaction). Quantitative densitometric data is plotted as 
percentage of free probe vs TRp concentration. (Figure 4.14 shows the 
radiogram from which densitometric analysis was performed).
146
Chapter Four Recombinant TR.
4.2.9.4. The Effect of Thyroid Hormones and their Analogues on the Binding 
of Recombinant TRp to DNA.
The relative affinity of TR for THs and their analogues have been 
described previously (Cheek et al., 1999 and Ribeiro et al., 1992) and are as follows: 
T3 > T4 > Tetrac (tetraiodothyroaceticacid) > rT3”. Outer-ring deiodination of T4 
gives the biologically active T3, whilst inner-ring deiodination converts T4 to the 
biologically inactive metabolite rT3 -  which accounts for about 40% of T4 turnover 
and is the key step in the inactivaton of TH. The structures of the THs and the TH 
analogues which were analysed are shown in Figure 4.16.
Following previous studies, which showed that the higher the affinity of 
TR for the ligand, the greater the disruption of TR binding to DNA (Miyamoto et al., 
1993 and Yen et al., 1992) it was decided to compare these results with the results 
gained using the technique described above.
Recombinant TRp to a final concentration of 1 .OpM (the K& of ligand- 
free TRp as determined in Section 4.2.9.3.a) was combined in an EMSA reaction with 
a constant amount of radiolabelled ME-TRE probe (0.3pmol/reaction) and varying 
concentrations of either THs or their analogues, as described in Section 2.2.3.9.c. 
Complexes were separated by gel electrophoresis, the gels dried and the radioactivity 
associated with bands was quantified as described in Sections 2.2.3.9.d. and 2.2.3.9.e, 
respectively. The quantitative data is plotted relative to the amount of free probe 
observed in the absence of the relevant compound (arbitarily designated as 1).
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Figure 4.16. Thyroid hormones and their analogues.
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Figure 4.17. Densitometric analyses of EMSAs in which the effect of THs and their 
analogues on binding of TR/3 to the ME-TRE probe was analysed. A 
constant concentration of recombinant TR/3 (lptM) and radiolabelled 
ME-TRE probe (0.3pmol/reaction) was incubated with different 
concentrations of T3 ( A ) ,  T4 (♦), rT3 ( A )  and Tetrac (■). Quantitative 
densitometric data is plotted relative to the amount of free probe 
observed in the absence of the relevant compound. Each data set shown 
is representative of a single experiment. Abbreviations: T3, 
triiodothyronine; T4, tetraiodothyronine; rT3, reverse triiodothyronine 
and Tetrac, Tetraiodothyroaceticacid (see Figure 4.16 for chemical 
structures; see Appendix 4 for individual densitometric plots.
149
Chapter Four Recombinant TR.
4.3 Discussion.
The amplification of the cDNAs for TRal and TRpi from mouse heart 
cDNA, using gene-specific primers, resulted in the appearance of a single major 
product in both cases (Figure 4.3), even though there is more than one isoform of TRa 
and TRp (discussed previously, Section 1.2.1). This was as expected for TRp, as 
TRp2 expression is limited mainly to the pituitary, the hypothalamic TRH neurons, 
the developing inner ear and retina (Flamant and Samarut, 2003). Although the 
expression of TRal and TRa2 is ubiquitous, the 3'- primer spanning the stop codon 
was designed to selectively bind TRal and would have resulted in base-pair mis­
matching if this primer had bound to any TRa2 cDNA present. Prior to any 
expression studies, a full-length nucleotide sequence was obtained for both isoforms, 
confirming identity and the absence of any mutations in the cDNA (data not shown).
The thyroid hormone receptors TRa and TRp (representing the TRal 
and TRpi isoforms, respectively) were successfully purified following over­
production in E.coli. Initial expression studies were carried out using an IPTG 
concentration of ImM and an induction growth temperature of 37°C. This resulted in 
the production of insoluble recombinant TR (TRp: Figure 4.4, TRa: data not shown). 
Subsequent optimisation of the expression conditions allowed the expression of 
soluble protein; culture conditions can have a dramatic effect on solubility and 
localization of expressed protein - conditions that decrease the rate of protein 
synthesis, such as low induction temperatures, tend to increase the percentage of target 
protein found in soluble form by decreasing the rate of protein self-assocation and the 
formation of inclusion bodies (insoluble protein). This would explain the observation 
of increased expression levels of soluble TRa and TRp when induced at 0.5mM IPTG 
with subsequent growth at 20°C (Figures 4.5 and 4.7 respectively).
The expression of recombinant TRs as His-tagged fusion proteins 
allowed confirmation of protein identity following small-scale optimisation 
experiments. An Ni-NTA AP conjugate, which binds to His-tagged proteins, was 
used to probe Western blots of recombinant protein samples (Figures 4.5.b and 4.7.b 
for TRp and TRa respectively). A second advantage of expressing TRs as His-fusions 
was exploited to allow a one-step purification following a large-scale induction, using 
Ni-NTA agarose as described in Section 4.2.5. Production of recombinant TR in a
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soluble form did not necessarily indicate that the protein was folded properly. It was 
essential to establish that the recombinant TRs exhibited DNA binding activity.
EMSA analysis was used to demonstrate that both recombinant TRa and 
TRp were able to bind the ME-TRE probe as monomers and dimers (Figure 4.9). 
These results were in agreement with previous studies (Miyamoto et al., 1993), which 
also showed that recombinant TRa and TRp were able to bind to an ME-TRE 
containing oligo. The specificity of protein-DNA interactions was verified by 
carrying out a competition EMSA (Figure 4.10) and the identity of protein-DNA 
complexes was confirmed using an antibody supershift EMSA, which employed a TR- 
specific antibody (Figure 4.11).
Previous studies have used EMSA to characterise the DNA binding 
properties of TR monomers, TR-TR homodimers and TR-RXR heterodimer in the 
absence and presence o f T3. The overall number of TR homodimers binding to 
inverted palindromic TREs was reduced by T3 but the affinity of the bound TR 
homodimers for the TREs was unaltered (Ribeiro et al., 1992). This occurs due to a 
conformational change caused by ligand binding, as confirmed by a later study 
(Miyamoto et al., 1993). This study also demonstrated that the binding of TR 
homodimers to the ME-TRE is decreased in the presence of T3, whilst the binding of 
a TR mutant (with no ligand-binding ability) to the ME-TRE was not altered in the 
presence of T3. Yen et al., (1992) showed that the addition of TH analogues led to a 
decrease in binding of TR homodimers to an inverted palindromic TRE, but that the 
binding of TR monomers was unaffected. Miyamoto et al., (1993) showed that 
addition of T3 (and its analogues), whilst decreasing homodimer binding, did not lead 
to a decrease in the binding of TR monomers to the ME-TRE. Both studies also 
showed that the higher the affinity of TR for a particular ligand, the greater the 
disruption of TR binding to DNA (Miyamoto et al., 1993 and Yen et al., 1992).
Hence, the results shown in Figure 4.17 are consistent with those 
published previously. This indicates that the EMSA can be used to monitor suspected 
chemicals for potential effects on the binding of recombinant TR to a TRE-containing 
oligo and so is a convenient starting point for the development of non-radioactive TR- 
DNA binding assays. There are a number of technical limitations associated with the 
EMSA technique which also make it desirable to develop non-radioactive assays. 
There is inherent variability stemming from differences in efficiency of probe- 
labelling, differential loading of samples onto the gel and radioactive decay of the
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probe. These issues may be addressed cosmetically by optimising the exposure time 
of the gel to film but to establish true reproducibility the specific activity of each 
probe must be constant and the quantity loaded on the gel identical. EMSA assays 
were exploited in the characterisation of the recombinant TR in a qualitative mode to 
establish whether the recombinant molecule bound the target the DNA sequence. 
Deployment of EMSA assays to determine binding coefficients (in the presence or 
absence of a potential disruptor) required only quantitative comparison within a gel, 
where the specific activity of the probe was identical.
Therefore, an assay system was successfully developed, which allowed 
the monitoring of TR binding to DNA in the presence of a potential disruptor. The 
potential now exists to further optimise this system to allow the development of a non­
radioactive, high-throughput assay. Recombinant His-tagged TR could be 
immobilised to a solid phase (Ni-NTA beads) and bound to oligonucleotide probes 
labelled with the previously described chemiluminescent molecule, the acridinium 
ester. Any free AE-labelled probe could then be washed away and thus, detection of 
the remaining chemiluminescence associated with the beads would allow the 
quantification of DNA bound to the immobilised TR. If such an assay were optimised 
it would then be possible to monitor the effects of potential disruptors on the binding 
of recombinant TR to its cognate DNA.
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CHAPTER FIVE 
CELL CULTURE SYSTEMS.
5.1. Introduction
The effects of THs are mediated predominantly at the level of gene 
expression via thyroid hormone receptors (TRs: Section 1.5.1), which are ligand 
activated transcription factors that regulate target gene expression directly through 
binding to specific DNA sequences, known as TREs, in the promoter regions of target 
genes (Zhang and Lazar, 2000; Wu and Koenig, 2000).
The deployment of a cell culture approach to monitor the effects of 
putative disruptors on T3-moderated gene transcription will act in accordance with the 
EDTA’s recommendations to develop non-animal screening assays, whilst still 
maintaining a degree of biological relevance. Whilst revealing the effects of putative 
disruptors on the formation of a transcriptionally active complex a cell culture 
approach will also allow the addressing of two important factors which act to 
modulate gene expression; cell entry and the metabolism of potential disruptors.
The thyroid-responsive luciferase reporter construct pcTRELuc consists 
of the thyroid response element from the Malic Enzyme gene (ME-TRE) upstream of 
the coding sequence for the firefly luciferase gene (see Appendix 2D for vector map). 
In order to analyse the impact of potential disruptors on the transcriptional response 
mediated by TRs via the ME-TRE in a cellular environment, the reporter construct 
can be transfected into eukaryotic cells and the activity of the reporter gene can be 
measured by quantifying the levels of translated protein produced. In addition to 
measuring the levels of protein expressed from the reporter gene, it is also possible to 
measure levels of luciferase mRNA transcribed, and this can be done using the HPA 
(Section 3.3.7). The quantification of luciferase mRNA synthesis by HPA, would 
allow a comparison to be made between the temporal profiles for luciferase mRNA 
and protein expression. It is essential, therefore, that the quantities of mRNA 
harvested from transfected cells fall well within the detection range of the HPA, in 
order that the HPA can be used as a detection method.
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5.2. Approach.
Although the final aim was to be able to assess thyroid-responsiveness 
by measuring luciferase levels expressed from a thyroid-responsive reporter construct 
(pcTRELuc), initial transfection studies were carried out in order to determine the 
number of cells required to allow detection of luciferase mRNA by HPA under 
optimal conditions, i.e. in the presence of high levels of luciferase mRNA expression 
in a robust, well-characterised cell line. Transient transfections were carried out using 
the calcium phosphate precipitation method or TransFast™ Reagent (a liposome based 
transfection reagent; Sections 2.2.2.3.a and b, respectively) using U373s (a human 
glioblastoma astrocytoma, adherent cell-line). The pRG224 vector was used, which 
contains the luciferase gene under the control of the hCMV immediate-early (I.E.) 
promoter, which is strong and constitutively active.
A large-scale preparation of pRG224 was carried out (Section 2.2.1.3.b.) 
and the purity and concentration of DNA assessed (Section 2.2.1.5). pRG224 DNA 
was then transiently transfected into cells using either the calcium phosphate 
precipitation method or TransFast™ transfection reagent. Following a 24h incubation 
at 37°C in an atmosphere of 5% CO2 in air, cells were harvested, lysates were 
prepared and mRNA was purified (Sections 2.2.2.5.a and b, respectively). Lysates 
were prepared from transfected cells (Section 2.2.2.5.a) and then analysed, in 
duplicate, for luciferase activity and total cellular protein concentration, as described 
in Sections 2.2.2.6. and 22.2.1, respectively. mRNA was extracted according to 
Section 2.2.2.5.b and HP As performed in duplicate for luciferase (Sections 3.3.7) and 
P-actin mRNA. In order to allow the comparison of data sets from different 
experiments, all experimental data was normalised. In the case of cell lysates, this 
standardisation involved the calculation of a ratio of luciferase activity to total protein 
content of the lysate, that is, the specific luciferase activity. In the instance of HPA, 
the concentration of luciferase mRNA was normalised against the concentration of P- 
actin mRNA; a housekeeping gene whose expression is relatively constant within the 
experimental conditions used. Each experiment was carried out on two separate 
occasions, data is shown as mean ± standard deviation.
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Following the optimisation of transient transfection, it was decided to 
produce a stably-transfected cell line, expressing the pcTRELuc construct in CV1 
cells. CVls have been widely used in the characterisation of TREs and express both 
TRa and the 9-cis retinoic acid receptor RXR. In order to generate a number of clonal 
populations of stably-transfected cells, pcTRELuc DNA was transfected into cells 
using TransFast™ Reagent (Section 2.2.2.3.b). Clonal populations of CV1 cells were 
isolated and cultured as described in Section 2.2.2.4 and lysates were assayed for 
luciferase protein activity, as before.
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5.3. Results.
5.3.1. Transient Transfection using the Calcium-Phosphate Precipitation
Method.
Initial optimisation experiments involved the transfection of the pRG224 
luciferase reporter construct into the adherent cell-line, U373s. Cells were seeded at 
1.5 -  2.0 x 106cells/ml and were allowed to achieve approximately 80% confluence 
prior to transfection. Varying amounts of DNA were transfected into cells as 
described in Section 2.2.2.3.a. Following a 24h incubation, cell lysates were 
prepared, and mRNA extracted from samples. Although it was possible to measure 
luciferase protein activity in the cell lysate of cells harvested from the well of a 6-well 
plate, it was not possible to detect either the luciferase or P-actin mRNA using the 
HPA technology (data not shown); the HPA for luciferase mRNA was carried out as 
described previously (Section 3.3.7) and the P-actin mRNA assay was performed as 
described in the manufacturer’s Fathead Minnow P-Actin mRNA Assay Kit insert 
(MLT Research, Cardiff, UK). This kit allows detection of P-actin mRNA from a 
number of species, as the probe is designed to a highly conserved region of the P-actin 
gene.
It was decided, therefore, to “scale up” and subsequent transfection 
experiments were carried out as above, and involved the transfection of the pRG224 
luciferase construct into U373s, seeded in T75s (75cm2 tissue culture flasks). 
Although it was now possible to quantify the concentration of p-actin mRNA using 
the HPA, it was still not possible to detect a signal using the luciferase HPA (data not 
shown). It was therefore decided to conduct further transfection optimisations using a 
liposome-based transfection method, TransFast™, in the hope that this method would 
give a higher degree of transfection efficiency.
5.3.2. Optimisation of Transient transfection, using TransFast™ Reagent
The transient transfection of U373s with pRG224 was optimised for i) 
the amound of plasmid DNA, ii) the transfection reagent (TransFast™) to plasmid 
DNA ratio, and iii) the exposure period of cells to the DNA-transfection reagent 
complex.
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a) Amount of DNA.
Cells were seeded in a T75 flask and allowed to achieve approximately 
80% confluence prior to transfection (approximately 24h). Increasing amounts of 
DNA (8 to 64pg), complexed with a constant amount of transfection reagent (1:1) 
were carefully layered over cells before a lh incubation at 37°C in an atmosphere of 
5% CO2 in air. The complex was then removed from cells and replaced with an 
appropriate volume of pre-warmed growth medium, prior to a further 24h incubation. 
Cells were then harvested and the lysates assayed for luciferase protein activity. The 
results are shown in Figure 5.1.A. HPA analysis on mRNA extracted from the same 
samples indicated that the minimum amount of pRG224 DNA that had to be 
transfected into cells before luciferase mRNA levels could be measured was 16pg 
(Figure 5.1.B). For economic reasons, further optimisation experiments were 
therefore conducted using this amount of DNA, hence minimising the amount of 
TransFast™ required.
b) TransFast™:DNA Ratio, and Incubation Period.
Cells were transfected, as above, with a constant amount of pRG224 
DNA (16pg) and different ratios of Transfection reagentiDNA (0.5:1 to 8:1). Each 
transfection was carried out separately and cells were exposed to the transfection 
reagent:DNA complex for a range of times. Complexes were then removed from the 
cells and replaced with an appropriate volume of growth medium, prior to a further 
24h incubation. Cells were harvested and the lysates assayed for luciferase protein 
activity. The results from these optimisation experiments (carried out in duplicate) 
are shown in Figure 5.2.
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Figure 5.1. The effect of increasing amounts of DNA transfected on levels of 
luciferase mRNA and protein expression in adherent U373 cells. Cells 
were transfected with the indicated amount of pRG224 DNA, complexed 
with TransFast™ in a 1:1 ratio. Error bars indicate standard deviations 
from two separate experiments performed in duplicate.
Panel A: Specific luciferase protein activity. (Concentration of total 
protein of samples remained constant).
Panel B: Expression of luciferase mRNA, measured using the HP A. 
(levels of actin mRNA of samples remained constant).
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Figure 5.2. The effect of the ratio of TransFast™:DNA on luciferase protein 
production in U373 cells. Cells were exposed to pRG224 DNA 
(16pg), complexed with the indicated ratios of TransFast™ for 1,2 and 4 
hours. Cell lysates were prepared and luciferase activity measured and 
normalised to concentration of protein present in the cell lysates.
Panel A: A bar chart representation of the specific Luciferase activity, 
shown using linear scale. Panel B: A scatter plot representation of the 
quantity of specific Luciferase activity, shown using a logarithmic scale.
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Extending the time of cellular exposure to the transfection reagent:DNA 
complex increased levels of luciferase activity. It is likely that a greater exposure 
time allows greater uptake of DNA into cells, either by endocytosis or possibly the 
fusion of the liposome with the plasma membrane. Luciferase levels do not peak for 
the exposure times of lh and 2h, however for the exposure time of 4 hours, luciferase 
levels reach a peak at a transfection reagent:DNA ratio of 4:1, after which, a decrease 
in luciferase levels is observed, as the ratio of transfection reagent:DNA is further 
increased. This is likely to be due to the fact that the transfection reagent is toxic to 
the cells; significant cell death was observed immediately prior to the removal of the 
transfection reagent:DNA complex. Cell death was such, that upon harvesting, 
(following a 24h incubation), cells were yet to attain 100% confluence -  whereas in 
all other instances, cells were 100% confluent at the time of harvesting.
The data in Figure 5.1.B indicates that it was possible to use the HP A to 
quantify luciferase mRNA, following the transient transfection of cells with a 
luciferase reporter construct. Further optimisation of transfection (Figure 5.2) 
indicated that it was possible to further increase the levels of luciferase expression. 
However, it was necessary to use a liposome-based transfection reagent. The use of 
this reagent for the screening for large numbers of potential thyroid disruptors would 
be prohibitively expensive. Although the data from these experiments has been 
normalised using total protein content of the lysate, this does not actually relate in any 
way to the efficiency of transfection. This doesn’t initially present a problem -  as the 
main priority of these experiments was to establish the number of cells needed to 
allow luciferase quantification by HP A. However, if such a system were to be used to 
look at the effects of potential thyroid disruptors on transcription, data would have to 
be normalised, with regard to efficiency of transfection. In order to allow 
quantification of transfection efficiency, it is usual to co-transfect a reporter construct 
that acts as a positive control (commonly a vector expressing (3-galactosidase). Since 
it is only possible to transfect a limited concentration of DNA into a population of 
cells, having to co-transfect a control vector as well as an experimental reporter 
construct(s) into cells decreases the concentration of experimental construct it is 
possible to transfect. Coupled with the fact that there is a large degree of variability 
inherent to transient transfection systems, and that future studies would use a thyroid-
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responsive luciferase reporter construct (even the most potent of TREs would not 
match the strength of the hCMV immediate-early promoter; personal communciation, 
Dr Peter Kille), it was decided to produce a cell-line which was stably-transfected 
with a thyroid-responsive luciferase reporter construct.
161
Chapter Five Cell Culture
5.3.3. Production of a Stably-Transfected Cell Line.
The goal of stable, long-term transfection is to isolate and propagate 
individual clones which have incorporated the transfected DNA into their genome. It 
is therefore necessary to distinguish nontransfected cells from those that have taken 
up the exogenous DNA. This screening can be achieved by drug selection, when an 
appropriate drug resistance marker is included in the transfected DNA; the thyroid- 
responsive luciferase reporter construct pcTRELuc contains the neomycin 
phosphotransferase gene (see Appendix 2D for a vector map). The adherent African 
Green Monkey kidney cell line, CV1, has been widely used to study the 
characteristics of various TREs. Previous studies (Ribeiro et al., 2001; Bhat et al., 
1997 and Zhang et al., 1996) have co-transfected TR-expressing constructs or 
recombinant TR protein, along with the thyroid-responsive constructs. However, a 
PCR reaction using gene-specific primers and cDNA from CV1 cells showed that 
these cells express TRa but not TRf3 (data not shown; mRNA was extracted from 
adherent, non-transfected cells and cDNA generated by reverse transcription, as 
described in Sections 2.2.2.5 and 2.2.1.11 respectively. Primers and thermocycling 
conditions were as described in Section 4.2.1). CV1 cells also express the 9-cis 
retinoic acid receptor (RXR; Safer et al., 1997), another member of the NR 
superfamily, which is the preferential heterodimer partner for TR when binding to a 
positive TRE (Zhang and Lazar, 2000). Thus, it was deemed that it would not be 
necessary to transfect a source of TR or RXR into cells, and so it was decided to 
stably transfect CV1 cells with the pcTRELuc reporter construct.
Cells were seeded at 1.5 -  2.0 x 106cells/ml in a 6-well plate and were 
allowed to achieve approximately 80% confluence prior to transfection. pcTRELuc 
DNA (10pg) complexed with TransFast™ was transfected into each well, as described 
in Section 2.2.2.3.b. Following a 24h incubation, non-selective growth medium was 
replaced with medium containing the neomycin analogue, G418. Cells were 
incubated at 37°C until individual cell clones were visible (approximately 5-6 days.) 
Individual clones (five in total) were isolated as described in Section 2.2.2.4. Cells 
were subsequently maintained in growth medium supplemented with hormone- 
stripped foetal bovine serum.
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a) Construction of the Thyroid-Responsive Luciferase Reporter
Construct, pcTRELuc.
The MAL-TKLuc vector has been described previously by Collingwood 
et al., (1994) and was kindly donated by Richard Caswell (Cardiff University). It 
contains a natural direct repeat TRE from the malic enzyme gene (Desvergne et al., 
1991) upstream of the viral TK promoter and the luciferase gene. Components of 
MAL-TKLuc were used in the construction of a vector which would allow for the 
development of a stably-transfected cell line; the luciferase gene under the control of 
the ME-TRE from MAL-TKLuc was combined with the coding sequence for the 
neomycin phosphotransferase gene -  allowing for selection of stably-transfected cells.
A schematic representation showing the important features of MAL- 
TKLuc is shown in Figure 5.3. A number of restriction digests (Section 2.2.1.6) were 
carried out to confirm the integrity of the vector. Restriction endonuclease digestion 
with various combinations of enzymes were analysed by agarose gel electrophoresis 
(Section 2.2.1.1, Figure 5.4).
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Figure 5.3. A schematic representation (not drawn to scale) showing the various components, along with approximate 
sizes, of the MAL-TKLUC reporter vector. Known restriction sites are also shown, with the approximate 
location of the anomalous BamUl site shown in bold, red text. The construction of this vector has been 
described previously (Collingwood et al., 1994). The blue lines represent pGEM7zf (+), which is the 
original vector, into which the various components were cloned. For a detailed description of how the 
vector was constructed, see text, Section 5.3.1.1.a.
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Figure 5.4. Analysis of restriction endonuclease digestion of MAL-TKLuc.
Following digestion of the reporter vector with the indicated enzymes, 
fragments were analysed on a 1% agarose gel containing 0.5jig/ml 
ethidium bromide.
Lane 1: Apal;
Lane 2: Hindlll;
Lane 3: BamHV,
Lane 4: Hindlll and BamHI.
DNA markers are as follows: X = XIHindlll and <|> = §\14IHae\\\.
(See Table 2.4 for full list of DNA marker fragment sizes).
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b) Construction and Verification of the Vector pcTRELuc.
i) Subcloning of the TRE-luciferase Fragment into pcDNA3.1.
pcDNA3.1 (Invitrogen) is a mammalian expression vector, which 
encodes the selectable marker neomycin (for plasmid map, see Appendix 2C). The 
hCMV immediate early promoter was removed from pcDNA3.1(-), by restriction 
endonuclease digestion with BglR and BamHl (Section 2.2.1.6 ). Sticky 5'- ends 
were dephosphorylated in order to prevent re-ligation of the vector (Section 2.2.1.7) 
and the digested dephosphorylated fragment, of approximately 4.4kb, was purified by 
extraction from an agarose gel as described in Section 2.2.1.4.b, (Figure 5.5).
Digestion of the reporter vector MAL-TKLuc with BamHl liberated a 
fragment consisting of the malic enzyme TRE, the thymidine kinase promoter and the 
luciferase coding sequence. The fragment was purified by extraction from an agarose 
gel, as above. This BamHl fragment was then ligated into the BamHUBglH digested 
pcDNA3.1 as described in Section 2.2.1.8. The ligation mix was used to transform 
competent DH5a cells (Section 2.2.1.9) prior to the small-scale isolation of plasmid 
DNA from a number of colonies (Section 2.2.1.3.a). Constructs were screened in 
order to determine the orientation of the TRE-containing insert, in relation to the 
pcDNA3.1 vector. pcTRELuc was constructed in this way in preference to an 
amplification-based method in order to eliminate the possibility of the introduction of 
mutations caused by the PCR process. Since the final construct contained the TK- 
TRE-Luciferase components and the neomycin resistance gene, it was therefore 
compatible with the propagation of a stably-transfected cell line, as well as with in 
vitro transcription systems.
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Lane:
Figure 5.5. Analysis of the gel-purified constituent parts of the pcTRELuc vector 
and of restriction endonuclease digestion, confirming the integrity of the 
final construct. Fragments were analysed on a 1% agarose gel 
containing 0.5jig/ml ethidium bromide.
Lane 1: Gel purified BgUVBamHl digested pcDNA3.1.;
Lane 2: Gel purified TRE-luciferase fragment, excised from MAL - TK 
Luc by BamHl digestion.;
Lane 3: pcTRELuc digested with Hindlll;
Lane 4: pcTRELuc digested with Apal.
DNA markers are as follows: X = X/Hindlll and <|> = <\>114/Haelll.
(See Table 2.4 for full list of DNA marker fragment sizes).
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ii) Screening of Recombinant Clones.
The TRE-luciferase insert was cloned into BglHJBamHl sites of 
pcDNA3.1. As is shown in Appendix 2C, the BamHl site was at nucleotide number 
977 in the original, uncut vector. A further 19bp downstream from this BamHl site is 
a Hindlll site, at nucleotide number 996. The proximity of the Hindlll site to the 
BamHl site allowed the screening of recombinant clones. Figure 5.6 is a schematic 
representation, showing alternative ways that the ita/wHI-digested TRE-luciferase 
fragment could have been orientated, upon ligation into the Bglll/ZtawHI-digested 
pcDNA3.1. Hindlll digestion of a clone with the fragment in one orientation resulted 
in the production of three bands, of approximate sizes 4500bp, 2609bp and 250bp. 
Hindlll digestion of a clone in the second orientation, however, resulted in the 
production of three alternative bands: 699lbp, 250bp and lOObp. It was, therefore, a 
simple matter to select a clone with the fragment inserted in the correct orientation 
(orientation 1 in Figure 5.6).
iii) Sequencing of the Promoter Region from pcTRELuc.
Once a positive pcTRELuc clone had been selected, the promoter region 
(5' to the luciferase start codon) of the construct was sequenced. The primer pGL2 
(see Appendix ID for primer sequence) was used, and the sequencing reaction 
performed as described in Section 2.2.1.13. To confirm the exact sequence four 
independent sequencing reactions were performed and electrophoretograms compared 
to allow removal of any sequencing artefacts. The resulting sequence was reversed 
and complemented (Appendix 3A), using DNAsis (Section 2.2.1.14.b.) and BlastN 
search was performed (Section 2.2.1.15) and the malic enzyme TRE was identified, as 
was the herpes simplex virus thymidine kinase (TK) promoter.
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Figure 5.6. A schematic representation showing the different ways in which the TRE-luciferase fragment could have become
orientated upon ligation into the BglW/BamHX digested pcDNA3.1. Blue lines and blue text (restriction sites) represent 
sequence from pcDNA3.1.
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5.3.3.1. Transcriptional Response of Clones to T3.
a) In the Absence of Exogenous TR.
Cells from each clonal population were seeded as before, and allowed to 
achieve approximately 50% confluence. Growth medium was removed, and replaced 
with medium to which T3 (lOOnM) had been added. Following a further 48h 
incubation, during which time approximately 100% confluence was attained, cells 
were harvested and the lysates assayed for luciferase protein activity. The results are 
shown in Figure 5.7.A.
The results in Figure 5.7.A demonstrate that each clone had a different 
degree of transcriptional responsiveness to T3, as well as differing levels of basal 
transcription (i.e. in the absence of T3). It is possible that the observed variations in 
the degree of responsiveness to T3 treatment could be due to the incorporation of the 
pcTRELuc construct into differently-controlled regions of the host cell’s chromatin. 
Some areas of chromatin are constitutively active and conducive to transcriptional 
activation, whilst others are consititutively repressed (see Section 1.5.2).
It was postulated that the observed differences in overall levels of 
transcription (i.e. the different levels of transcription observed in the presence and 
absence of T3 between clonal populations) could be explained by the incorporation of 
different numbers of copies of the pcTRELuc construct into the host cell’s chromatin. 
In order to test this hypothesis, genomic DNA from each clonal population was 
extracted and a southern blot was carried out, as described in Sections 2.2.1.16 and 
2.2.1.17, respectively. A probe was designed, which was complementary to the 
pcTRELuc sequence, from upstream (5'-) of the ME-TRE sequence to downstream 
(3'-) of the luciferase start codon. The results of the Southern blot are shown in 
Figure 5.3.B. The quantification of the levels of radioactivity associated with bands 
was carried out as described in Section 2.2.1.17.e and allowed an estimation of the 
relative number of copies of pcTRELuc incorporated per clone to be made. Since 
clone2 showed the lowest detectable levels of transcription, as well as the lowest 
detectable copy number (Figures 5.1.A  and B, respectively) the copy number of the 
other clones was calculated relative to this. The results are shown in Figure 5.7.A and 
confirm the positive correlation between the levels of transcription (both basal and 
induced) and the number of copies of the pcTRELuc construct incorporated into the 
host cell’s genome.
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Figure 5.7. Panel A: The transcriptional response of the stably-transfected clonal 
populations. Cells were transfected with pcTRELuc and grown under 
selective (G418+) conditions. Individual clones were isolated and 
cultured in growth medium supplemented with hormone-stripped serum. 
Cells were incubated for 48h in the presence or absence of T3 (lOOnM). 
Following harvesting, cell lysates were assayed for luciferase protein 
activity. Error bars represent standard deviations from two separate 
experiments, carried out in duplicate.
Also shown is the relative copy number of pcTRELuc, calculated by 
quantitative densitometric analysis of data from the southern blot in 
Panel B.
Panel B: A southern blot was carried out on gDNA extracted from 
adherent cells from each clonal population. A radiolabelled probe was 
designed to incorporate the ME-TRE and luciferase start codon.
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b) In the Presence of Co-transfected TR.
The observed up-regulation in luciferase transcription seen in the 
presence of T3 (lOOnM) for all clones was of a lesser magnitude than expected. 
Previous studies have shown as much as a 10 to 15-fold up-regulation of transcription 
in response to T3 in transiently transfected CV1 cells using the ME-TRE upstream of 
the chloramphenicol acetyl transferase (CAT) reporter sequence (Bhat et al., 1997 and 
Umesono et al., 1991). However, these studies and other previous studies (Ribeiro et 
al., 2001 and Zhang et al., 1996) all co-transfect either recombinant TR protein or a 
TR-expressing plasmid, along with the thyroid-responsive reporter construct into 
cells. This suggests that the endogenous levels of TR expressed in CV1 cells may be 
insufficient to allow maximum levels of transcriptional upregulation in the presence 
of T3, and that further protein may be required. Since a PCR (described in Section 
5.3.3) demonstrated that CV1 cells express TRa, it was decided to transfect cells with 
recombinant TRp. Given that the cells from stably-transfected clone 5 gave the 
largest response to T3 (Figure 5.7.A), subsequent studies were carried out using cells 
from this clonal population. Cells were seeded as before, and allowed to achieve 
approximately 80% confluence. Recombinant TRp, purified as described in Section
4.2.5, was transfected into cells (2pg/10mm dish) using ProteoJuice™ Protein 
Transfection Reagent, as recommended in the manufacturer’s instructions (Novagen). 
After four hours, the transfection reagent was removed and replaced with growth 
medium, supplemented with stripped serum. Cells were maintained at 37°C until 
100% confluence was achieved (approximately 48h) in the presence or absence of T3 
(lOOnM). Following harvesting, cell lysates were assayed for luciferase protein 
activity. The results are shown in Figure 5.8.
The results shown in Figure 5.8 indicate that the absence of endogenous 
TRp expression in CV1 cells may be limiting the T3-induced transcriptional response 
in the stably-transfected cells. In order to confirm that TRp had been successfully 
transfected and that the observed effects were caused by the presence of exogenous 
TRp, it would be necessary to wash the transfected cells and prepare a lysate which 
could be probed or the presence of the recombinant protein. This could be achieve by 
performing a western blot to confirm the presence of the His-tagged protein, using the 
Ni-NTA AP conjugate, as described previously (Section 2.2.4.5).
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Figure 5.8. The transcriptional response of clone 5 cells to T3. Cells were 
subjected to ProteoJuice™ Protein Transfection Reagent for four hours, 
in the presence or absence of recombinant TR(3 (2pg). The transfection 
reagent was replaced with growth medium supplemented with hormone- 
stripped serum in the presence or absence of T3 (lOOnM). Following 
attainment of 100% confluence, cells were harvested and lysates were 
assayed for luciferase protein activity. Error bars represent standard 
deviations from two separate experiments, carried out in duplicate.
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5.4. Discussion.
The optimisation of transient transfections, using the liposome-based 
transfection reagent, Transfast™ allowed the detection of luciferase mRNA, using the 
HP A. It was hoped that it would be possible to carry out a comparison between the 
temporal profiles for the expression of luciferase mRNA and the translation of 
luciferase protein. However, in order to purify sufficient quantities of luciferase 
mRNA it was necessary to use a large number of cells (a confluent T75) and hence, a 
large volume of TransFast™. This made large numbers of further experiments 
economically unviable and so it was decided to generate a stably-transfected cell line, 
in the hope that this would allow the detection of luciferase mRNA via HP A, from 
smaller numbers of cells and without the need for carrying out transient transfections.
The efficiency of transient transfections can be highly variable, 
depending on experimental conditions and the type of cells used. In contrast, all 
stably-transfected cells in a clonal population should contain the transfected DNA. 
However, it is likely that a greater number of copies of the reporter construct would 
be transfected per cell during transient transfections. This would be one possible 
explanation for the vastly reduced specific luciferase protein activity seen in the 
stably-transfected clones, compared to the transient transfections (100s Vs 100,000s). 
A second reason for the observed decrease in specific luciferase activity would be the 
relative potencies of the promoters used. All transient transfection optimisations used 
the pRG224 vector, where the luciferase gene is under the control of the hCMV 
immediate-early promoter. The stably transfected CV1 cell-line was made using the 
pcTRELuc construct, where the luciferase gene is under the control of the much less 
potent malic enzyme thyroid responsive element (ME-TRE). These reasons, in turn, 
explain why it was not possible to use the HPA to measure luciferase mRNA purified 
from stably-transfected cells, either in the absence or presence of T3.
In addition to being unable to measure luciferase mRNA purified from 
stably-transfected cells, the observed up-regulation in T3-induced luciferase 
transcription for all clones was of a lesser magnitude than expected (Section
5.3.3.1.b). A possible explanation for the lower than expected observed up-regulation 
of luciferase transcription is provided by Tillman et al., (1993), who used transient 
transfections to examine the effects of T3 and TRp on luciferase expression in CV1 
cells. Using the wild-type and a mutated form of TRp (mTRp, where cysteine-122 
was changed to serine-122 in the first zinc finger of the DNA binding domain) they
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demonstrated that the activity of the luciferase reporter was down-regulated in a T3 
and TRp dependent manner. They also showed that T3 and TRp dependent inhibition 
of luciferase expression occurred consistently to a greater or lesser extent with various 
mutations of the herpes simplex virus thymidine kinase (TK) promoter sequence, i.e. 
was independent of a TRE sequence. A 1.5 to 2-fold inhibition of expression was 
observed when a construct was used which contained the non-mutated TK promoter 
sequence (i.e. the same TK sequence as is in the pcTRELuc vector). This inhibition 
was not reversed when a single copy of the rat growth hormone positive TRE was 
placed 5' to the TK promoter (5'TRE-tkLUC). This TRE had previously been shown 
to stimulate CAT reporter expression approximately 2-fold (Brent et al., 1989). The 
effects of a strong positive TRE were then investigated using the TREpX2-tks-LUC 
construct; two copies of TREp were inserted 5' to the TK promoter (TREp is synthetic 
variant of the rat growth hormone TRE). T3 and TRP dependent inhibition of 
luciferase expression was now reversed and was stimulated approximately 5-fold.
In order to confirm that this was a phenomenon specific to the luciferase 
sequence, Tillman et al., (1993) conducted a series of experiments using the CAT 
reporter sequence. Expression from these constructs was not down-regulated in the 
presence of T3 and TRp. These studies also demonstrated that the activity of a strong, 
positive TRE was unaffected by the use of a luciferase reporter construct; TREpX2- 
tks-LUC was stimulated 5.6 ± 1.6-fold in CV1 cells in the presence of T3 and TRp. 
TREpX2-tks-CAT, a construct identical to TREpX2-tks-LUC except that CAT 
replaced the LUC reporter, was stimulated 6.3 ± 0.2-fold under identical conditions. 
These results were consistent with a previous study by Glass et al., (1989) who also 
used a TREpx2-tk-LUC construct in CV1 cells to show an upregulation of luciferase 
expression of approximately 5-fold, in the presence of TRp and T3. Although the 
exact mechanism of this unexpected response was unclear, Tillman postulated that 
regulation of luciferase activity could occur at the gene expression level, or at the 
level of luciferase mRNA or protein stability. The Tillman study was followed up by 
Maia et al., (1996) who postulated that there may be a negative TRE in the luciferase 
cDNA. Consistent with this they transiently transfected a TK-LUC vector into JEG-3 
cells to show that unliganded TR induced luciferase expression, whilst the addition of 
T3 reduced expression levels by up to as much as 80% (Maia et al., 1997). In order to 
postulate the possible implications of these studies for the work performed in this 
thesis, it is necessary to estimate the relative strengths of the promoters used. Bhat et
175
Chapter Five Cell Culture
al., (1997) reported the relative strengths of the promoters he employed to be as 
follows; ME-TRE ~ 10-fold upregulation compared to a 40-fold upregulation caused 
by TREp. The study by Umesono et al., (1991) demonstrated that ME-TRE caused a 
15-fold upregulation of expression, compared to a 20-fold upregulation caused by 
TREp. The combination of transcriptional suppression caused by the putative internal 
luciferase TRE and the unknown relative strength of the ME-TRE used in these 
studies limits the possible value of the data generated.
Although it was possible to detect the presence of TRa transcripts by 
PCR (Section 5.3.3) it is possible that protein levels were not sufficiently high to 
allow a maximal transcriptional response in the presence of T3. It may be possible 
that the small amounts of endogenous TRa present are sufficient to allow T3 induced 
upregulation under physiological conditions, however when overloaded with 
relatively large amounts of plasmid DNA containing the ME-TRE the amount of 
endogenous TR present becomes a limiting factor, hence the need to transfect 
exogenous TR. The results shown in Figure 5.8 illustrate that transfection of 
recombinant TRp into cells lead to a greater transcriptional response in the presence 
of T3. This is consistent with previously published results (Jeannin et al, 1998) 
where the increased expression levels of a CAT reporter where shown to be directly 
proportional to the amount of TR expression plasmid transfected into cells.
Although previous studies (Ribeiro et al., 2001, Bhat et a l , 1997, Zhang 
et al, 1996 and Umesono et a l, 1991) all co-transfect a source of recombinant TR 
into CV1 cells, they do not transfect a source of 9-cis retinoic acid receptor (RXR, the 
preferential heterodimer partner for TR when binding to a positive TRE) suggesting 
that endogenous levels of this protein are sufficient. The studies mentioned above co­
transfect TR expression vectors encoding the human forms of TR, suggesting that 
they are able to heterodimerise with the endogenous RXR from the CV1 cells (green 
monkey kidney cell line). A number of studies have also utilised TR expression 
vectors encoding the rat forms of TR, suggesting that the rat protein is able to 
heterodimerise with the endogenous RXR found in human cell lines. Izumo and 
Mahdavi, (1988) showed that rat TRa (rTRa) was a T3 dependent transcriptional 
factor, which bound to aMHC-TRE (myosin heavy chain) and activated expression of 
a CAT reporter by approximately 10-fold in HeLa cells. Studies carried out to 
confirm the identity and location of the ME-TRE by Desvergne et a l, (1991) used a 
series of CAT reporter constructs under the control of various ME-TRE deletions in
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NIH 3T3 cells. They co-transfected rTRa and T3 to demonstrate a 11-fold 
upregulation of CAT expression. Petty et al., (1990) carried out studies similar 
studies except they utilised COS-7 cells. Co-transfection of rTRa and T3, led to a 5- 
fold upregulation of CAT expression.
Since a stably-transfected cell line was generated to minimise both 
expense and the inter-assay variability observed with transient transfections, a 
possible future objective would be to generate a stably-transfected cell line which 
expressed the luciferase gene under the control of the ME-TRE promoter as well as 
the TRp protein-coding sequence, under the control of a separate promoter.
As has been previously stated, the effects of thyroid hormones (THs) are 
mediated at the level of gene expression via the thyroid hormone receptors (TRs), 
which bind to specific DNA sequences. TRs in turn, recruit coregulatory proteins 
which act as bridging molecules and contact the basal transcriptional machinery 
(Section 1.5.3). Although the effects of a putative disruptor on T3-mediated 
transcription can be monitored using a cell culture system, this system is reliant upon 
the entry of the disruptor into the cell. In addition, the disruptor may also be 
metabolised and altered upon cell entry. Therefore, the development of an in vitro 
(cell free) transcription system, to be used in conjunction with a cell culture system, 
will provide further insights into how a cellular environment effects the properties of 
a potential disruptor.
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CHAPTER SIX 
IN VITRO TRANSCRIPTION.
6.1. Introduction.
The Malic Enzyme TRE (ME-TRE) described in Chapter 4, is a natural 
direct-repeat, positive TRE; the most potent of the TREs. Although TRs are capable 
of binding to the ME-TRE as monomers or homodimers (see Section 4.2.8.3), they 
bind preferentially to positive TREs as heterodimers with the retinoid X receptor (9- 
cis retinoic acid receptor or RXR), (Mangelsdorf and Evans, 1995). Heterodimer 
formation between TR and RXR enhances DNA-binding affinity and provides target 
gene specificity (Mangelsdorf et al., 1995).
In order to analyse the impact of potential disruptors on the 
transcriptional response mediated by TRs via the ME-TRE, the DNA sequence can be 
fused to a reporter gene, combined with a nuclear extract containing the necessary 
transcriptional machinery, and the levels of mRNA produced can be quantified. A 
commonly used reporter is the luciferase gene from the common firefly (Photinus 
pyralis) and a nuclear extract from HeLa cells can be used; HeLa cells do not express 
TR but express RXR and the cofactors necessary for TR function (Kim et al., 1999). 
Quantification of luciferase mRNA expression from such a system would allow an 
assessment of the effect on transcription of a potential disruptor.
Traditional methods for mRNA detection from in vitro transcription 
systems, including the “run-off’ assay and primer extension, involve the use of 
radioactive nucleotides. However, it has been shown previously (Section 3.3.7) that it 
is possible to quantify luciferase mRNA using the HPA, and it is proposed to use this 
quantification method as an alternative to the radionuclide-dependent primer 
extension assay.
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6.2. Approach.
In order to develop a system which would allow the monitoring of the 
effects of putative disruptors on thyroid receptor-mediated transcription, an in vitro 
transcription system was developed which utilised a nuclear extract, a thyroid- 
reponsive reporter construct and recombinant TR. The ME-TRE (malic enzyme 
thyroid-reponsive element) was cloned upstream of the firefly luciferase gene 
sequence to give pcTRELuc (the reporter vector also contained the neomycin 
phosphotransferase gene which allowed the generation of stably-transfected cell lines; 
described in Chapter Five). Luciferase gene transcripts from in vitro reactions were 
initially quantified using the traditional radioactive isotope-dependent primer 
extension method. The possibility of quantifying luciferase mRNA with non­
radioactive methods was then investigated; using both TaqMan® Probe real-time 
quantitative PCR and the Hybridisation Protection Assay (HPA) technologies.
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6.3. Results.
6.3.1. In vitro Transcription Reactions.
The main aim of the work described in this chapter was to develop non­
radioactive assays for the detection of luciferase mRNA from in vitro transcription 
systems. However, before such assays could be developed, it was necessary to 
confirm the integrity of the in vitro transcription system, which used the pcTRELuc 
reporter construct and purified recombinant TR. This was done using the traditional 
primer extension method, for detection of luciferase mRNA.
In vitro transcription (IVT) reactions were carried out as described in 
Section 2.2.1.18.a. Each set of IVT experiments was run on a minimum of two 
separate occasions, but more typically on three or more separate occasions in order to 
ensure reproducibility. Quantitative data represents the mean value from two separate 
experiments, carried out in triplicate. Error bars indicate the standard deviations for 
these data.
6.3.1.1. Detection of Luciferase mRNA by Primer Extension.
pcTRELuc template DNA and HeLa nuclear extract were combined with 
recombinant TRp (either ligand-free or ligand-bound) as indicated (Figure 6.1). The 
pGL2 primer (see Appendix ID for primer sequence) and §\14IHaell\ Markers were
•  32end-labelled with y- P-ATP and primer extension analysis of transcripts was 
performed as described in Sections 2.2.1.18.C. and 2.2.1.18.b, respectively. The 
results shown correspond with the previously published data of Lee et al., (1994), who 
used an in vitro transcription system to show that ligand-free TR and RXR combined 
caused an increase in transcription from the ME-TRE, compared to levels observed in 
the presence of RXR alone (shown in Figure 6.1. A; compare lanes 4-6 with lanes 1-3). 
The same study by Lee et al., also showed a further increase in the transcriptional 
response upon the addition of lOOnM T3. In order to confirm these trends, 
quantitative data from two separate primer extension experiments was plotted (Figure
6.1.B. Although the transcriptional responses observed in Figure 6.1.B are of a lesser 
magnitude than those described by Lee et al., (approximately 2.5 and 3.5 compared to 
4 and 7), there are a number of differences between the two systems. Lee et al. used a 
nuclear extract solely as a source of basal transcriptional machinery, then added both
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recombinant TR and RXR. The system described here uses the HeLa nuclear extract 
both as a source of basal transcriptional machinery and of RXR. Lee et al. 
investigated a range of concentrations of recombinant TRa whereas this study used a 
single concentration of TRp.
The results in Figure 6.1 .A show two primer extension products. Using 
the sequence information from Appendix 3A it was estimated that the desired product 
should be approximately 105bp long. For this reason it was only the primer extension 
product marked in Figure 6.1.A that was quantified by densitometry. The presence of 
a second product of higher molecular weight could possibly be due to the presence of 
an alternative transcriptional start site.
In its present format it would be difficult to exploit this technology to 
quantify disruptor activity - it may be possible that further optimisation of this system 
could have resulted in the observation of a larger transcriptional response in the 
presence of T3. However, the aim of the subsequent work in this chapter was the 
development of non-radioactive assays for the detection of luciferase mRNA from in 
vitro transcription systems. It was decided to try and reproduce the results shown in 
Figure 6.1 using an alternative method, before carrying out any further optimisations 
of the system.
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6.1. Analysis of in vitro transcription reactions by Primer Extension.
Panel A. An autoradiogram showing analysis of transcripts by primer 
extension. Lanes 1-3: pcTRELuc (4nM) was combined with HeLa 
nuclear extract. Lanes 4-6: pcTRELuc (4nM) was combined with HeLa 
nuclear extract and TRjS (80nM). Lanes 7-9: negative control, 
pcTRELuc (4nM) only (no nuclear extract or TR/3). Lane 10:
<j)174///,aeIII size markers. (See Table 2.4 for full list of DNA marker 
fragment sizes).
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Figure 6.1. Analysis of in vitro transcription reactions.
Panel B: Quantitative densitometric analysis of the primer extension 
product indicated in Panel A was carried out. HeLa nuclear extract and 
pcTRELuc (4nM) were combined with: no TR/3 or T3 (“No TR/3”), TR/3 
only (80nM, “TR/3”) or TR/3 (80nM) and T3 (lOOnM, “TR/3 + T3”). The 
transcriptional response is plotted relative to basal levels observed (i.e. 
the level of transcription observed in the absence of TR/3; designated 1). 
No primer extension product was observed in the absence of HeLa 
nuclear extract or TR/3 (see Panel A, lanes 7-9). Quantitative data is 
representative of the mean of six independent primer extensions.
Error bars indicate the standard deviations for these data.
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6.3.1.2 Detection of Luciferase mRNA using TaqMan® 5*-Exonuclease
Probe Quantitative PCR.
TaqMan Probe® real-time quantitative PCR has been shown to be a 
sensitive method for measuring gene transript levels (Eun et al., 2000). The detection 
methodology of the TaqMan® Probe real-time quantitative PCR uses specific 
fluorescent probes to hybridise template DNA within the specified amplicon. The 
TaqMan® probes are labelled at the 5' termini with the reporter dye FAM (6- 
carboxyfluorescein) and at the 3' termini with TAMRA (6-carboxy-tetramethyl- 
rhodamine) which is a universal quencher molecule. The spatial proximity of the 
reporter dye to the universal quencher quenches fluorescent emission. A primer pair 
is designed in order to amplify an amplicon of approximately lOObp and the probe is 
designed in such a way so as to be complementary to the target sequence. Upon 
amplification, the hybridised probe is digested by the 5'— ►3'- exonuclease activity of 
Taq DNA polymerase in the primer extension phase of amplification, thereby 
releasing the reporter dye, resulting in an increase in the fluorescent signal (Nasabardi 
et al., 1999). A diagrammatic representation of this technology is shown in Figure
6.2. The sequences of the probe and primers designed for quantification of luciferase 
mRNA are given in Appendix IF.
a) TaqMan® Probe and Primer Design.
Primers and probes were designed using the Primer Express ™ software 
package (PE Applied Biosystems; Section ). TaqMan® probes were synthesized by 
QLAgen (Sussex, UK) with the reporter dye FAM and universal quencher TAMRA 
covalently attached to the 5' and 3' ends, respectively. The 3' ends were also 
phosphorylated in order to prevent probe extension. Primers were designed to amplify 
a region of approximately lOObp, whilst the probe was complementary to a region 
within this target area. The following guidelines were adhered to during the design 
process:
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1: Polymerisation 2: Strand Displacement
n  ®
Primer] Probe
3: Cleavage 4: Polymerisation Completed
w w
*
Figure 6.2. Illustration of TaqMan® probe technology quantitative PCR 
amplification reactions. The symbol “R” represents the reporter 
fluorescent molecule; “Q” represents the quencher molecule.
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i) Probe guidelines:
♦ The probe should be between 9 - 40bp in length.
♦ The probe should have a GC content of between 20 -  80%.
♦ The probe must not contain more G’s than C’s.
♦ There must be no more than four contiguous G’s.
♦ There must be no G on the 5' end of the probe.
♦ Tm should be 10°C higher than the Tm of the primers.
ii) Primer guidelines:
♦ The primers should be between 9 -  40bp in length.
♦ The probe should have a GC content of between 20 -  80%.
♦ A maximum of 2 G/C at the 3' end.
♦ Tm of the primers must be between 58 -  60°C.
♦ A maximum of 2°C difference allowed between the Tm of primer 
pairs.
iii) Amplicon guidelines:
♦ The amplicon should be between 50 -  150bp in length.
♦ The 3' end of the primer should be as close as possible to the 
probe, without overlapping.
b) Template Preparation,
i) Standard Dilution Series for Calibration.
Stock plasmid preparations containing an insert corresponding to the 
target sequence to be amplified for quantification purposes were purified, quantified 
and ethanol-precipitated to a known concentration as described in Sections 2.2.1.3.b.,
2.2.1.5. and 2.2.1.4.a.ii., respectively.
A standard dilution series of calibration standards were prepared by 
diluting purified plasmid to a range of concentrations in H2O, from 500pg/pl to lfg/pl, 
at 10-fold intervals.
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ii) Sample cDNA.
In vitro transcription reactions were carried out and mRNA purified as 
described in Section 2.2.1.18.a. Samples were treated with RQ1 RNAse-free DNAse 
(Promega) at 37°C for lh to remove pcTRELuc template DNA, prior to enzyme 
inactivation (70°C for lOmin). cDNA was generated from the purified mRNA by 
reverse transcription (Section 2.2.1.11.) and samples were diluted 1:10 in HPLC-grade 
water prior to quantitative analysis.
cj Optimisation of TaqMan® Quantitative PCR Amplifications.
Prior to optimisation, the amplification reactions consisted of the 
following : 2.5pl of template DNA, 5' and 3' primers , both at 0.9pM (synthesised by 
MWG Biotech, Germany), 200nM probe, 0.2mM dATP, dCTP and dGTP, 0.4mM 
dUTP, 1 Unit of in-house Taq DNA polymerase buffered in 20mM Tris-HCl (pH 8.3), 
50mM KC1, 4mM MgCh, lpM ROX (5-carbosy-X-Rhodamine, a machine calibration 
dye). The PCR reactions were performed in 25pl volumes in PCR 96-well plates, 
using optical lids, and subjected to the following thermal cycling parameters using the 
ABI Prism® 7700 Sequence Detection System:
Chain denaturation 95°C lOsec
Primer annealing 50°C 5 sec 25 cycles
Chain extension 60°C 4min
Soak 4°C
As with any amplification technique, optimisation was required. 
Optimisation of two variables was necessary for the use of TaqMan® probe real-time 
PCR quantification in the ABI Prism® 7700 sequence detection system:
i) Oligonucleotide Primer concentrations, and
ii) Probe concentration.
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i) Primer Concentration.
Forward and reverse primers were tested at three different 
concentrations, resulting in nine different primer-concentration combinations (Table 
6.3). A final probe concentration of 200nM and lng of pcTRELuc DNA were used, 
and thermocycling reactions carried out under the conditions described in Section
6.3.2.2.C. The primer combination which gave the lowest Ct value and therefore the 
best amplification rate was taken as having the optimal reaction conditions. As can be 
seen from Figure 6.4, a concentration of 900nM for both forward and reverse 
oligonucleotide primers gave the largest fluorescent response. Therefore, all further 
optimisation and quantification reactions were carried out using this combination of 
concentrations.
Final 
Primer 
Cone. (nM)
Primer
Type
Final 
Primer 
Cone. (nM)
Primer
Type
Final 
Primer 
Cone. (nM)
Primer
Type
1. 50 
50
Forward
Reverse
2. 50 
300
Forward
Reverse
3. 50 
900
Forward
Reverse
4. 300 
50
Forward
Reverse
5. 300 
300
Forward
Reverse
6. 300 
900
Forward
Reverse
7. 900 
50
Forward
Reverse
8. 900 
300
Forward
Reverse
9. 900 
900
Forward
Reverse
Table 6.3. 1"he nine combinations of final primer concentrations analysed in the
optimisation of TaqMan® probe quantitative PCR reactions.
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6
5 H
4
3
2 H 
1
F=50nM, R=50nM 
F=50nM, R=300nM 
F=50nM, R=900nM 
F=300nM, R=50nM 
F=300nM, R=300nM 
F=300nM, R=900nM 
F=900nM, R=50nM 
F=900nM, R=300nM 
F=900nM, R=900nM
10 15 20 25
Cycle Number
Figure 6.4. TaqMan® Probe real-time QPCR oligonucleotide primer concentration 
optimisation.
Oligonucleotide primer concentrations were tested in duplicate, using 
combinations of 3 primer concentrations; 50nM, 300nM and 900nM, as 
indicated. “F” refers to the concentrations of Forward primer and “R” to 
the concentration of Reverse primer. Cycling reactions were carried out 
as described, using the nine different oligonucleotide combinations in the 
presence of fluorescent probe (200nM) and pcTRELuc plasmid DNA 
(Ing).
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ii) Probe Concentration.
Eight different probe concentrations were tested (Table 6.5) and 
reactions were performed as described in Section 6.3.2.2.C, using the forward and 
reverse primers at 900nM (as determined in Section 6.3.2.2.c.i, above). As can be 
seen from Figure 6.8, the optimal probe concentration (i.e. the concentration which 
gave the lowest Ct value and therefore the best amplification rate) was 200nM. (An 
additional set of negative reactions were also prepared with H2 O replacing the 
pcTRELuc template DNA, in order to ensure that any fluorescence observed could be 
attributed to the amplification of template DNA).
Final Probe Concentration (nM)
i 25
i i 50
i i i 75
iv 100
V 125
v i 150
v ii 175
v i i i 2 0 0
Table 6.5. The eight final-reaction probe concentrations analysed in the 
optimisation of TaqMan® probe quantitative PCR reactions.
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25nM
50nM
75nM
lOOnM
125nM
150nM
175nM
200nM
0 5 10 15 20 25 30 35 40
Cycle Number
-0.5 J
Figure 6.6. TaqMan® Probe real-time QPCR Probe concentration optimisation.
Fluorescent probe concentrations were tested in duplicate using the 
concentrations 200, 175, 150, 125, 100, 75, 50 and 25nM. Cycling 
reactions were carried out as described, using 900nM each primer and 
pcTRELuc plasmid DNA (lng).
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d )
i) Quantification of Standards using TaqMan Probe® Real-Time
QPCR.
Stock plasmid preparations of pcTRELuc were prepared as described in 
Section 6.3.2.2.b.i. and diluted in TE buffer to known concentrations, spanning a 
range from lng/pl to lOfg/pl at 10-fold intervals. TaqMan® real-time QPCR 
amplification reactions were carried out in triplicate (using the optimal conditions, 
determined as described in Section 6.3.2.2.c) for each standard concentration. The 
quantitative amplification of the standard dilution series is shown in Figure 6.7.A. A 
regression line was generated using the standard curve, by plotting the cycle number 
required to attain threshold fluorescence pertaining to the mid-logarithmic part of the 
amplification, against the logio[concentration of target gene] and is shown in Figure 
6.7.B. Quantification of standards confirmed that the TaqMan real-time QPCR 
method had been correctly optimised and could now be used for the quantification of 
luciferase mRNA from in vitro transcription systems.
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Figure 6.7. Quantitative amplification of a standard dilution series (raw data from 
pcTRELuc standards), analysed in triplicate. The concentration range 1- 
6 represents lng, lOOpg, lOpg, lpg, lOOfg and lOfg respectively.
Panel A: Amplification curves for each standard. An example of 
threshold value of fluorescence is marked with a dashed line. A no 
template control (NTC) reaction was also performed.
Panel B: Linear regression analysis of the standard dilution series.
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ii) Quantification of Samples using TaqMan Probe® Real-Time QPCR.
In vitro transcription reactions were carried out in triplicate, as described 
previously in this chapter (Section 6.3.1.). Following DNAse digestion to remove 
template DNA, cDNA was generated from mRNA samples and 2.5pi added to the 
final amplification reaction, as described in Sections 2.2.1.19.b.ii. and 2.2.1.19.d 
respectively. Samples were analysed in triplicate alongside the standard dilution 
series. The concentration of target molecules in each cDNA sample was quantified by 
regression analysis, extrapolating each sample in the standard range. The results 
shown in Figure 6.8 are representative of a single experiment.
No TR/? TRyS T R £ + T3 N egative
Figure 6.8. Analysis of in vitro transcription reactions. pcTRELuc (4nM) was 
combined with HeLa nuclear extract, with the indicated combinations of 
TR/3 (80nM) and T3 (lOOnM). Negative samples contained only 
pcTRELuc (4nM), and no nuclear extract or TR/3. mRNA samples were 
DNAse-treated and reverse transcribed. Luciferase expression levels 
were quantified using TaqMan® probe real-time QPCR. Mean values 
from triplicate samples are shown, and error bars indicate the standard 
deviations of these triplicates.
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A detectable amplicon was associated with the negative samples, 
containing plasmid, but no nuclear extract or TRp (Figure 6.8). This amplification 
cannot be due to the presence of reverse-transcribed cDNA, as there is no 
transcriptional machinery present in the negative samples to allow for mRNA 
production. It is unlikely that this is due to contamination of the QPCR reaction since 
there is no amplification associated with the no template controls (Figure 6.7). It was 
therefore concluded that the amplification seen in the negative samples in Figure 6.8 
were due to the presence of undigested pcTRELuc. Under optimal conditions, the 
DNAse used to treat samples prior to reverse transcription should digest double­
stranded plasmid into fragments as small as 4bp in length (technical information 
provided by Promega). However, pcTRELuc was initially present at a very high 
concentration, when the sensitivity of the TaqMan® probe real-time QPCR method is 
considered; the final initial concentration of pcTRELuc was 20ng/pl (500ng/25pl 
reaction), whilst it was actually possible to detect as little as lfg/pl (Figure 6.7). 
Therefore, if the efficiency of the DNAse treatment varied between samples, it is 
possible that the presence of undigested pcTRELuc DNA would affect the quantitative 
data generated by TaqMan® probe real-time QPCR amplification.
In addition to the amplification seen in the negative samples (Figure 6.8), 
there is also a high degree of variability observed between samples, as indicated by 
the relatively large standard deviations. In order to determine whether the 
reproducibility of data was being affected by a factor other than DNAse treatment 
efficiency, a normalisation experiment was carried out. In order to counteract possible 
variation introduced by inconsistent reverse transcription efficiencies between 
samples, values obtained from TaqMan® probe real-time QPCR amplification 
reactions are usually normalised. This is done by quantifying the expression levels of 
a control gene in the sample (e.g. actin), however, since the luciferase mRNA being 
quantified is from an in vitro transcription reaction, there is no control gene transcript. 
This issue was overcome by spiking each purified luciferase mRNA sample with a 
fixed amount of worm mRNA (2ng per sample; kindly donated by Huw Ricketts, 
Cardiff University), prior to the generation of cDNA. Consequently, it was possible to 
carry out TaqMan® probe real-time QPCR amplification reactions using the luciferase 
probe and primer set, as well as a probe and primer set (optimised previously) 
designed for the quantification of actin mRNA expression levels. The normalised data 
is shown in Figure 6.9. From the relatively large standard deviations shown in Figure
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6.9, it can be seen that the normalisation of quantitative luciferase expression data 
against actin levels made virtually no difference to the reproducibility of experimental 
data, suggesting that the reverse transcription efficiencies are relatively constant and 
that the variation is introduced by the DNAse treatment step.
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Figure 6.9. Analysis of in vitro transcription reactions, spiked with worm Actin 
mRNA. pcTRELuc (4nM) was combined with HeLa nuclear extract, 
with the indicated combinations of TR/3 (80nM) and T3 (lOOnM). 
Negative samples contained only pcTRELuc (4nM), and no nuclear 
extract or TR/3. All samples were spiked with worm mRNA (2ng), prior 
to DNAse-treatment and reverse transcription. Luciferase and actin 
expression levels were quantified using TaqMan® probe real-time 
QPCR. The mean (+/- S.D.) expression levels of the luciferase gene 
normalised against actin levels, are shown.
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iii) Quantification of Samples using Direct Capture of AE-Labelled
Target Nucleic Acids.
An alternative, non-radioactive assay which would enable the specific 
quantification of luciferase mRNA and would not be affected by the presence of 
template DNA is the HPA (described in Chapter 3), since the luciferase AE-probe 
would be unable to hybridise to the double-stranded pcTRELuc plasmid DNA. 
Unfortunately, the quantities of luciferase mRNA produced during the in vitro 
transcription reaction proved to be below the limit of sensitivity of the HPA (data not 
shown).
The direct-capture technique (Section 3.3.8), was approximately 10-fold 
more sensitive than the HPA, when used for the detection of luciferase mRNA 
transcribed in vitro from the RiboMax™ In Vitro Transcription Kit (Promega). 
However, the detection of mRNA under these experimental conditions did not 
accurately reflect the experimental conditions which would be encountered upon 
quantifying an mRNA sample from the in vitro transcription system described 
previously in this chapter. The presence of template pcTRELuc DNA caused an 
increase in background levels of chemiluminescence. Although DNAse treatment of 
samples countered this increase, background levels of chemiluminescence were still 
higher than observed in the absence of template DNA. The use of DNAse caused 
further complications, as with any enzyme, it is most efficient under certain buffer 
conditions. These buffer conditions differed from the IVT optimal buffer conditions, 
which, in turn, differed from the optimal buffer conditions which allowed 
hybridisation of the AE-probe to luciferase mRNA. Although it would have been 
possible to purify nucleic acids between steps (using a phenol-chloroform extraction 
followed by ethanol precipitation), the relatively low abundance of luciferase mRNA 
present, meant that further purification steps would reduce yield and increase 
variability, therefore this approach was not taken.
198
Chapter Six In vitro Transcription
6.4. Discussion.
The in vitro transcription system used a HeLa nuclear extract as a source 
of basal transcription factors. Reactions consisted of the pcTRELuc reporter 
construct, recombinant TRp (ligand free and ligand-bound) and the nuclear extract. 
The radionuclide-dependent primer-extension method coupled with densitometric 
scanning of bands, was used as a means of estimating expression levels of luciferase 
mRNA. Once it had been established that the in vitro transcription system was 
successfully producing mRNA, it was decided to try and quantify mRNA using non­
radioactive methods prior to further optimisation of the in vitro transcription system.
Following the optimisation of a probe and primer set specific for the 
luciferase gene-sequence, Taqman® probe real-time quantitative PCR was used as a 
detection method for mRNA. Although it was possible to measure mRNA, the 
reproducibility of experiments was poor, as indicated by the large standard deviations 
seen for triplicates in Figure 6.8. At first, it was postulated that this may have been 
due to the varying efficiency of the reverse-transcriptase reaction. However, the 
spiking of luciferase mRNA samples with worm mRNA allowed the quantification of 
actin mRNA, also using Taqman® probe QPCR. Results demonstrated that the 
efficiency of the RT reaction was having little or no effect on the reproducibility of 
results. The second variable to be investigated was the possible presence of 
pcTRELuc template DNA in amplification reactions. Although DNAse treatment was 
carried out pcTRELuc was initially present at a very high concentration; 20ng/pl 
(500ng/25pl reaction). The sensitivity of TaqMan® probe real-time QPCR 
amplification meant that it was actually possible to detect as little as lfg/pl 
pcTRELuc, as shown by the standard curve in Figure 6.7. Therefore, it was concluded 
that the efficiency of DNAse treatment was inconsistent, and that the presence of 
undigested pcTRELuc DNA was affecting the quantitative data generated by 
TaqMan® probe real-time QPCR amplification. Template DNA removal was 
attempted using RNeasy columns (which bind DNA but not RNA), but was 
unsuccessful.
Hybridisation Protection Assay (HPA), an alternative non-radio active 
technique, was used in an attempt to quantify luciferase mRNA. However, HPA was 
not sensitive enough to measure the relatively small amounts of mRNA produced 
from the in vitro transcription reaction. Luciferase mRNA quantification was also 
attempted using a second AE-based assay, the direct-capture technique, where the
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sensitivity of AE detection is increased by separating hybridised AE-probe from 
unhybridised AE-probe, effectively lowering levels of background 
chemiluminescence. Although the direct-capture method has been shown to be 
approximately 10-fold more sensitive than the HPA, it still was not possible to 
quantify luciferase mRNA using this technique, possibly due to technical difficulties; 
buffer compatibility between different parts of the assay and the increase in 
background levels of chemiluminescence associated with the presence of the 
pcTRELuc template DNA.
The direct-capture technique still has potential as a non-radioactive 
technique which could be used to quantify luciferase mRNA from IVT systems. 
Further optimisation of buffer conditions could allow the development of a 
homogeneous assay, whilst it is possible that a selective hydrolysis step (described 
previously; Section 3.2.22.) could further lower background levels, prior to detection 
of the chemiluminescent signal.
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Chapter Seven 
General Discussion.
7.1. Introduction.
Scientific interest in possible thyroid modulation by chemicals present in 
the environment has intensified recently due to the central importance of this 
endocrine system to growth, development, reproductive viability and health 
(McLachlan, 2001).
Initial concern focussed on environmental chemicals that could impact 
on thyroid-mediated developmental, as well as reproductive, processes within wildlife 
species. However, in addition to the reports of abnormalities within wildlife 
populations (Brucker-Davies, 1998; Crain et al., 1998), there are also a number of 
publications in which human reproductive health appears to be compromised, and a 
possible link to environmental chemical contamination suggested (Johansen et al., 
1997; Steenland et al., 1997; see Section 1.6 for more detail).
The aim of this research was the development of in vitro assays, which 
would support a sequential testing strategy for potential thyroid disrupting chemicals. 
In this context, sequential testing refers to a gradual, step-wise strategy for the 
assessment of chemicals, beginning with the evaluation of the ability of a chemical to 
disrupt the interaction between the thyroid receptor and its cognate piece of DNA. 
Chemicals found to have an effect on TR-DNA binding could then be screened for 
transcriptional effects, using the cell-free transcriptional assay. Finally, prior to any 
animal testing, a cell culture system could be employed to provide additional 
information regarding the entry of chemicals into cells, as well as the effect of 
metabolism on the transcriptional modulation by chemicals.
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7.2. Potential Tier 1 Screening (T1S) In vitro Assays.
Although a number of limitations are associated with the simple in vitro 
assays developed as part of this research (for example, they do not take into 
consideration the interaction of thyroid hormones with serum thyroid-binding 
proteins) they represent a convenient starting point for the identification of potential 
thyroid-disrupting chemicals - in view of the large numbers of chemicals that could be 
subject to testing for potential thyroid effects (a possible 80,000+, see Section 1.6), the 
development of rapid high-throughput assay systems would be a major advantage.
The proposed in vitro assays would fit within EDSTAC’s tiered 
screening system (Section 1.7.1), and allow the identification of chemicals with 
potential thyroid-disrupting properties. This would allow a reduction in the number of 
compounds to be tested using in vivo studies, and/or would compliment the results of 
T1S in vivo studies such as the Amphibian Metamorphosis Assay and the Male and 
Female Rat Pubertal Assays.
7.2.1. Cell Culture Systems.
The cell culture system described in Chapter 5 consists of a luciferase 
reporter construct, where the luciferase gene is under the control of the Malic Enzyme 
TRE. The binding of TR to this TRE regulates luciferase gene expression in a ligand- 
dependent manner and thus it should be possible to measure the effect of a potential 
thyroid disruptor on the transcriptional response from this construct. The use of a 
cellular system in conjunction with the cell-free in vitro transcriptional system to 
study the impact of a potential disruptor on transcription, would allow an insight to be 
gained into the entry of potential disruptors into cells, as well as the effect of 
metabolism on a chemical’s disruptor properties.
Initial experiments focussed on the transient transfection of the pRG224 
vector (where the luciferase gene is under the control of the hCMV immediate-early 
promoter) into U373 cells. The two endpoints measured for the quantification of 
luciferase expression levels were luciferase protein (measured using the Promega 
Luciferase Assay) and luciferase mRNA (measured using the HPA). The eventual 
objective was to use a thyroid-responsive promoter upstream of the luciferase gene, in 
order to quantify the transcriptional and translated protein response to thyroid- 
mediated stimulus in the presence of potential disruptors. However, even using the 
pRG224 vector (where luciferase expression is under the control of a relatively potent
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promoter), such large numbers of cells were required in order to purify sufficient 
quantities of mRNA for detection by HPA, that such experiments were deemed 
unviable.
There are a number of disadvantages associated with transient 
transfection systems, including an inherent variability of efficiency and the potential 
toxic effect of transfection reagents. In order to negate these variables and in an 
attempt to increase overall luciferase expression levels, a stably-transfected cell line 
was generated. pcTRELuc was transfected into CV1 cells (which express both TRa 
and the 9-cis retinoic acid receptor) which were subsequently grown under G418 
(Neomycin) selective pressure. Following the isolation and propagation of a number 
of clonal populations of stably-transfected cells, the response of cells to T3 was 
quantified. Although a T3-dependent up-regulation of luciferase transcription was 
detected, this was of a lesser magnitude than expected. Further experiments indicated 
that this could possibly be due, in part, to a lack of endogenous TR/3 in the cells. The 
discussion in Chapter Five details the work of Tillman et al.y (1993) and Maia et al., 
(1996) who postulated that there may be a negative TRE present in the luciferase 
coding sequence. They concluded that any results drawn from experiments involving 
the use of thyroid-responsive luciferase reporter constructs in CV1 cells should be 
interpreted with caution. Many previous studies cited in the literature (Ribeiro et al., 
2001; Bhat et al., 1997; Zhang et al., 1996; Umesono et al., 1991) utilise thyroid- 
responsive CAT reporter contructs in CV1 cells. A possible future directive might be 
the generation of a stably-transfected cell line using a different construct; the CAT 
gene under the control of a TRE one direction, and the coding sequence for TRa 
and/or TR/3 under the control of a different promoter. In this way, the uncertainties 
surrounding the use of thyroid-responsive luciferase constructs would be avoided, 
whilst the assay would still benefit from the advantages offered by a stably transfected 
cell line. During the course of this thesis, Bogazzi et al., (2005) utilised a ME-TRE 
CAT reporter construct and transient transfection studies to demonstrate the 
antagonistic effects of Aroclor 1254 (a commercial mix of PCBs) on the thyroid 
receptor. This latter study illustrates the potential benefits of a reporter based 
approach, as proposed in the aims of this thesis, unfortunately the specific genetic 
construct exploited did not facilitate comparable success within our studies.
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7.2.2. In Vitro Transcription Systems.
The in vitro transcription (IVT) system described in Chapter 6 utilises 
pcTRELuc; the same ME-TRE luciferase reporter construct as the cell culture system 
described above. However, the IVT reactions do not utilise the host cell’s 
transcriptional machinery, instead, they employ a HeLa nuclear extract. HeLa cells do 
not express TR, but express RXR and the cofactors necessary for TR function.
Used in conjunction with the cell culture system, the IVT system would 
allow for the screening of chemicals for any effects on TR-mediated transcription. 
The IVT system has the advantage that it does not require the chemical to enter the 
cell, and the metabolic processing of any chemical would be minimised. Also, if  a 
chemical were to somehow affect translation of the luciferase protein (which is the 
endpoint measured from the cell culture system) it would be possible to differentiate 
this effect from an effect on gene transcription, by using these two systems together.
Following the intial optimisation of the IVT system and the 
quantification of luciferase mRNA transcripts using the radionuclide-dependent 
primer extension technique, the possibility of quantifying luciferase mRNA using 
non-radioactive techniques was investigated. A luciferase-specific primer and probe 
set was optimised, in order to allow transcript quantification using TaqMan® probe 
real-time QPCR. However, since TaqMan® QPCR is a highly sensitive technique that 
quantifies the reverse-transcribed products of the luciferase mRNA transcripts, it was 
necessary to remove the pcTRELuc template DNA, prior to the reverse-transcription 
reaction. A number of techniques were used, singly, or in combination, in an attempt 
to remove all template DNA. However it was not possible to consistently achieve 
reproducibly low background readings, and so TaqMan® probe QPCR was deemed 
unsuitable as a detection technique to quantify luciferase transcript levels from IVT 
systems.
Although the HPA had been successfully used previously in the 
quantification of luciferase mRNA, the small amounts of mRNA produced via the 
IVT system proved to lie below the limit of sensitivity of the HPA. Components of 
the HPA were used, however, in the development of an alternative AE-based assay. 
The direct-capture technique is described in Section 5.3.2.3 and was successfully used 
to detect as little as 26amoles of luciferase mRNA (compared to 251amoles of 
mRNA, detected using the HPA). Due to the limitations of sensitivity of the HPA, the 
absolute aim of the thesis was not achieved for the in vitro transcription systems.
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However, although the direct-capture technique described still requires further 
refinement and optimisation, it has the potential to be developed into a novel, 
straightforward, high-throughput assay, which could be used to screen chemicals for 
effects on TR-mediated transcription. If an alternative Cell Culture system were 
developed which utilised a CAT reporter construct (Section 7.2.1, above), then it 
would be necessary to design and optimise an AE probe, helper and polyA-bridge to a 
region of the CAT reporter sequence.
7.2.3. TR-DNA Binding Assays.
The regulation of transcription on thyroid-responsive genes is mediated 
by the thyroid receptor, and a pre-requisite of this control is the binding of TR to 
DNA. TR-DNA binding was monitored using the electrophoretic mobility shift assay 
(EMSA). Since this technique relies upon the binding of protein to a radiolabelled 
probe (double-stranded oligonucleotide), it was possible to quantify the amount of free 
probe in a given reaction by densitometric scanning of dried gels. The K& of a protein 
refers to the protein concentration at which approximately half the ligand 
(radiolabelled probe, in this instance) has become bound, and so is a measure of a 
protein’s affinity for its ligand. Thus, the K& of TR for DNA was estimated, and the 
effect of T3 and its analogues (whose relative affinities for TR were known) on the 
TR-DNA binding was monitored. Consistent with previously published data, the 
results from the EMSA studies revealed that the higher the affinity of TR for a 
particular ligand, the greater the disruption of TR-DNA binding.
Therefore, an assay system was successfully developed, which allowed 
the monitoring of TR binding to DNA and the quantification of binding disruption in 
the presence of a potential EED. The potential exists to further optimise this system, 
to allow the development of a non-radioactive, high-throughput assay. Recombinant 
His-tagged TR could be immobilised to a solid phase (Ni-NTA beads) and 
oligonucleotide probes labelled with the previously described acridinium ester could 
subsequently bind. Any free AE-labelled probe could be washed away and thus, the 
detection of any remaining chemiluminescence associated with the beads would allow 
the quantification of DNA binding to the immobilised TR.
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7.2.4. Alternative Assays.
During the course of this thesis, a number of studies have described the 
development of assays which could potentially fit into EDSTAC’s Tier 1 Screening 
and Testing batteries. Bogazzi et al., (2005) used a thyroid-responsive CAT reporter 
construct to examine the effects of Aroclor 1254 (A1254, a commercial mix of PCBs) 
on gene expression. A1254 inhibited TR action on the ME-TRE CAT reporter 
construct, however A1254 did not alter the ability of TR to bind to the ME-TRE in a 
gel shift assay. This study illustrates the importance of the use of complimentary 
systems to screen chemicals for potential thyroid effects. Gutleb et al., (2005) have 
developed the “T-test” which is an in vitro bioassay based on thyroid hormone 
dependent cell proliferation of a rat pituitary tumour cell line (GH3) in serum-free 
medium. This same system was utilised by Kitamura et al., (2005) to demonstrate the 
thyroid agonistic effects of a number of hydroxylated PCBs. Opitz et al., (2005) 
developed the Xenopus Metamorphosis Assay (XEMA) to detect thyroid-disrupting 
activities of potential EEDs. They monitored developmental rates as a means of 
assessing the thyroidal status of the differentially treated tadpoles. The metamorphic 
development of tadpoles to juvenile froglets is dependent on TH and in accordance 
with this, they showed that T4 accelerated tadpole development whereas mammalian 
anti-thyroidal compounds such as propylthiouracil (PTU) and ethylenethiourea (ETU) 
caused developmental retardation of X  laevis tadpoles.
It is possible that a QSAR (Quantitative Structure Activity Relationships) 
approach could be developed for predicting the binding affinities of chemicals to the 
TR. Hong et al., (2002) developed a decision tree-based model to evaluate 58,000 
chemicals for binding to the estrogen receptor by using physiochemical data and 
SARs from a training set of molecules with a known binding affinity for the rat 
estrogen receptor. The model involves using a set of exclusion filters to narrow the 
window of structural criteria for testing. This computational approach had a low 
false-negative rate and predicted that 80% of the 58,000 chemicals would show 
negligible binding to the estrogen receptor.
206
Chapter Seven Discussion
7.3. Concluding Remarks.
The thyroid system is so complex that understanding its normal function 
is difficult enough, but deciphering environmental disruptions to it is staggeringly 
difficult. Many of the chemicals of concern were produced to improve human welfare 
and provide economic benefit (e.g. to increase crop production). The science of 
endocrine disruption, however, is now revealing many unexpected adverse 
consequences, resulting from the ability of very low levels of these compounds to 
interfere with gene expression. Most of the chemicals now implicated have been 
subjected to little if any rigorous testing (Myers et al., 2003). Krimsky (2000) states 
what he terms the “environmental endocrine hypothesis” which asserts that “a diverse 
group of industrial and agricultural chemicals in contact with humans and wildlife 
have the capacity to mimic or obstruct hormone function -  not simply disrupting the 
endocrine system like foreign matter in a watchworks, but fooling it into accepting 
new instructions that distort the normal development of the organism...”. From the 
standpoint of human pathology, the environmental endocrine hypothesis could turn 
out to be the most significant environmental health hypothesis since the discovery of 
chemical mutagenesis” (McLachlan, J.A., 2001).
The development of the OECD’s “toolbox” of assays for potential 
thyroid disruptors (described in Section 1.8) will allow assessments to be made 
regarding the potential human health impact from the release of novel chemicals into 
the environment, as well as the risk associated with chemicals that are already in use. 
The “toolbox” is organised into a number of compartments or levels each 
corresponding to a different level of biological complexity. Even though the toolbox 
may be full of testing tools, this does not imply that they will all be needed for 
assessment purposes. Scientists are attempting to minimise animal use by using as 
few animals as possible in the most precise and sensitive assays, and by incorporating 
sensitive in vitro assays wherever possible (Gray Jr et al., 2002). The use of the TR- 
DNA binding assay developed here, as well as other high throughput pre-screening 
assays, (e.g. quantitative structure activity modelling, QSAR), allows for the 
prioritisation of chemicals for further screening (see Figure 7.1). The cell culture and 
in vitro transcription systems could subsequently be employed, meaning that 
chemicals testing positive in vitro could then be evaluated further using more 
extensive, higher tier animal tests.
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Thus, the concepts for three potential in vitro assays have been 
developed over the course of this thesis. Potential limitations were identified within 
each approach which significantly limit the utility of the assays developed, however, 
potential technical modifications (detailed in the relevant Chapters) have been 
proposed which would provide the basis for future developments. The requirement 
for the development of assays which could potentially fit into EDSTAC’s Tier 1 
Screening and Testing batteries has been recognised by the Scientific community, as 
illustrated by the previously mentioned studies of Bogazzi et al., (2005) Gutleb et al., 
(2005) Kitamura et al., (2005), detailed in Section 7.2.4. Therefore we are now seeing 
the development of assays which are relatively straightforward and inexpensive, and 
would allow for the screening and prioritisation of large numbers of chemicals for 
potential thyroid-disrupting properties, prior to further in vivo studies.
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Figure 7.1. There are currently over 80,000 industrial chemicals in use today (Keith, L.H. 1997). The use o f the in vitro assays 
developed as part o f  this thesis (double-boxed in blue and black) within a tiered screening strategy (EDSTAC Tier 1 
Screening Assays; Route 1) allows the identification o f  chemicals with potential thyroid-dsirupting properties. This reduces 
the number o f animal tests carried out, by limiting thenumber o f  chemicals subjected to higher Tier testing. The fete o f  
chemicals released into the environment (with associated consequences) is illustrated in Route 2.
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APPENDIX 1 
OLIGONUCLEOTIDE SEQUENCES.
A) Universal Primers and Their Sequences.
Primer Sequence (5’—>3’)
M13 For CAG GAA ACA GCT ATG AC
M13 Rev GTA AAA CGA CGG CCA GT
T7 For AAA TAC GAC TCA CTA TAG
T7 Rev GCT AGT TAT TGC TCA GCG G
Random Hexamers (N)6
Oligo (dT) TTT TTT TTT TTT TTT
B) Thyroid Receptor Primers, used for PCR Amplification.
(BgUl restriction sites in bold).
Primer Sequence (5?-»3’)
TRa For GAG ATC TGA TGG AAC AGA AGC CAA GCA AG
TRa Rev
GAA GAT CTT TAG CGG CCG CTG ACT TCC TGA TCC TCA
AAGAC
TRp For GAGATC TGA TGA CTC CTA ACA GTA TGA CAG
TRp Rev
GAA GAT CTT TAG CGG CCG CTG TCC TCA AAT ACT TCT
AAG AAC
C) Oligonucleotides used in the Luciferase HPA.
Primer Sequence (5f-*3’)
AE-probe CCC TTA GGT AAC CTA GTA GAT CCA GAG G
5' - helper AAT TCA TTA TCA GTG CAA TTG TTT TGT CAC
3' - helper ACG CAG GCA GTT CTA TGC GGA AGG GCC ACA
Target oligo CCT CTG GAT CTA CTG GGT TAC CTA AGG G
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D) The pGL2 used to Sequence Upstream of the Luciferase Start
Codon.
Primer Sequence (5’—>3’)
pGL2 CTT TAT GTT TTT GGC GTC TTC CA
E) The Malic Enzyme TRE-Containing Primer Pair used for Probe
Generation in the EMSA Analysis of Recombinant Proteins.
Sequences in bold indicate non-complimentary regions which form 5’- 
overhangs upon annealing, allowing subsequent “filling in” by Klenow polymerase, 
and generation of a radiolabelled duplex.
Primer Sequence (5’->3’)
2G-ME-
TRE-FOR GGC ATC CAG GAC GTT GGG GTT AGG GGA GGA CA
2G-ME-
TRE-BAK GGT CCA CTG TCC TCC CCT AAC CCC AAC GTC CT
F) Probe and Prim er Sequences, used in the Taqman Real-Time
Quantitative PCR Analysis of Luciferase mRNA.
Sequence (5’—>3')
5' Primer TGC TTT TAC AGA TGC ACA TAT CGA
3' Primer TGC CAA CCG AAC GGA CAT
Probe TGA ACA TCA CGT ACG CGG AAT ACT TCG A
229
Appendix 2
APPENDIX 2
VECTOR MAPS.
A) pGEM-T (Promega).
Xmn I 1994
Sea l 1875
fl ori 1 start
Apa I 
Aat II 
Sph I 
BstZ I
Nco I 
Sac-II
20
Amp'
pGEMM
Vector
(3000bp) Spe I 
Not I 
B$!Z\ 
Pst I 
$ 3 / I 
N de  1 
Sac I 
BstX I 
Nsi I
75
82
103
112
126
or i
t  SP6
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B) pET-15b Vector map, showing multiple cloning sites, and position of 
His-Tag (Novagen).
Aat 11(5635) 
Ssp 1(5517)
Sea 1(5193) 
PVU 1(5083)
Pat 1(4958)
Bsa 1(4774) 
Ahd 1(4713)
AJwN 1(4236)
BspLUl 1 1(3820)
Sap 1(3704) 
Bstl 107 1(3591) 
ACC 1(3590) 
BsaA 1(3572) 
Tth111 1(3565)
Bpu1102 1(267)
BamH 1(319) 
X ho 1(324) 
N de 1(331)
Nco 1(389)
Xba 1(428)
Bfll 11(494)
SgrA 1(535) 
sph  1(691) 
EcoN 1(751)
EcoR 1(5706) 
Cla 1(24) 
Hind 111(29
V
s
pET-15b
(5708bp)
Mlu 1(1216) 
Bd 1(1230)
BstE 11(1397) 
'A pa 1(1427)
BSSH 11(1627)
Hpa 1(1722)
PshA 1(2061)
Bpu101(2926) 'B sm  1(2704) 
MSC 1(2791)
Eag 1(2284) 
Nru 1(2319) 
BspM 1(2399)
T 7 p r o m o te r  p r im e r  # 6934^
Bgi || T 7 p r o m o t f ________iacoporotor________  xtw l rb»
AGATCTCGATCCCGCGAAATTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGA 
Mcol HjyTag A fctoi Xho\ B a /n H I
TATACCATGGGCAGCAGCCATCATCATCATCATCACAGCAGCGGCCTGGTGCCGCGCGGCAGCCATATGCTCGAGGATCCGGCTGCTAACAAAGCCCGA 
M « t G I y S « r S « r H I s H l s H l s H i s H i  s H l s S e r S e r G I y L e u V a J ^ r o A r g G I ^ S e r H I s M e t L e u G I u A s p P r o A I a A I o A s n L y s A I a A r g
6pu11021 thrombin T7 terminator____________
AAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTG 
L y s G I u A I o G I u L t u A I o A I a A I o T h r A I a G I u G I n E n d*4----------------
T7 terminator primer 469337-3
pET-15b cloning/expression region
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C) pcDNA3.1(-) Expression Vector Map, with Multiple Cloning Site 
Shown (Invitrogen).
977 bp 996 bp
© 22 co © © B  *0 . c  "2 — 22
■© C  S  Q .-Q  < C O ( 0 O O & ) Q 0 )  D . $  Qs 5
I
> — —00 =
BgllI 
(13 bp)
pcDNA3.1 (-)
5427 bp
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D) The pcTRELuc Reporter Construct, with Important Features
Shown.
o
^  < > a.xn
CJ
aoo
Z
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A PPEN D IX  3
DNA SEQUENCES.
A) DNA Sequence for the Promoter Region of the pcTRELuc
Reporter Construct.
• The sequence highlighted in grey is the splice-sequence generated upon the 
ligation of the BamHl sticky end of the 250bp TRE-containing fragment from 
MAL-TKLUC to the BglII sticky end of pcDNA3.1.
• The Malic enzyme TRE is shown underlined, in red.
• TheTK promoter, as identified by BlastN search, is in blue.
• The two sequences highlighted in yellow are the HindUl sites into which the 
ME-TRE was cloned.
• The beginning of the luciferase coding region is shown in italics.
• The sequence to which the pGL2 primer binds is highlighted in H
• The TATA box is in bold, black type, and the estimated start site of
transcription is indicated by a blue, inverted triangle.
tgacgtcgacggatcgggagatccccgggtaccccgggttcgaaatcgataagcttgcatgcctgcaggtcgactctaga
ggatca g g a cg ttggggttaggggaggacagtggacgatccggccccgcccagcgtcttgtcattggcgaattcgaac
acgcagatgcagtcggggcggcgcggtccgaggtccacttcgcatattaaggtgacgcgtgtggcctcgaacacvcga
gcgaccctgcagcgacccgcttaacagcgtcaacagcgtgccgcagatctaagcttggcattccggtactgttggtaaa^l
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B) Nucleotide Sequence and Amino Acid Translation for the N-
terminal End of TRa and TR/3, Expressed from pET-15b.
The genes for the murine forms of TRa and TR/3 were amplified by PCR 
and ligated into pGEM-T. cDNAs were excised by BglII digestion, gel-purified and 
ligated into the expression vector, pET-15b, which had been digested with BamRl.
Nucleotide sequence from the pET-15b expression vector, beginning 
with the start codon from the vector, is in blue. The His-tag is highlighted in yellow. 
Sequence in red represents the ligated gene sequence for TRa or TR/3, with the start 
codon in italics, underlined and bold.
atg ggc age age cat cat cat cat cat cac age age ggc ctg gtg
Met Gly Ser Ser His His His His His His Ser Ser Gly Leu Val
ccg cgc ggc age cat atg etc gag gat ctg atg
Pro Arg Gly Ser His Met Leu Glu Asp Leu Met
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C) Nucleotide Sequence for the Photinus Pyralis Luciferase Gene,
Showing Probe and Helper Binding sites, as used in the Luciferase 
HPA.
The coding sequence for the firefly luciferase gene is shown in black. 
The highlighted sequences indicate the specific regions to which the components of 
the HPA assay bound. In red is the binding site for the Acridinium Ester Probe, in 
blue the 5’ -  helper (also the sequence used for the polyA bridge) and in purple the 3' 
-  helper.
atggaagacgccaaaaacataaagaaaggcccggcgccattctatcctctagaggatggaaccgctggagagcaactgc
ataaggctatgaagagatacgccctggttcctggaacaattgcttttacagatgcacatatcgaggtgaacatcacgtacgcg
gaatacttcgaaatgtccgttcggttggcagaagctatgaaacgatatgggctgaatacaaatcacagaatcgtcgtatgcag
tgaaaactctcttcaattctttatgccggtgttgggcgcgttatttatcggagttgcagttgcgcccgcgaacgacatttataatg
aacgtgaattgctcaacagtatgaacatttcgcagcctaccgtagtgtttgtttccaaaaaggggttgcaaaaaattttgaacgt
gcaaaaaaaattaccaataatccagaaaattattatcatggattctaaaacggattaccagggatttcagtcgatgtacacgttc
gtcacatctcatctacctcccggttttaatgaatacgattttgtaccagagtcctttgatcgtgacaaaacaattgcactgata
atgaattcctctggatctactgggttacctaagggtgtggcccttccgcatagaactgcctgcgtcagattctcgcatgc
cagagatcctatttttggcaatcaaatcattccggatactgcgattttaagtgttgttccattccatcacggttttggaatgtttact
acactcggatatttgatatgtggatttcgagtcgtcttaatgtatagatttgaagaagagctgtttttacgatcccttcaggattac
aaaattcaaagtgcgttgctagtaccaaccctattttcattcttcgccaaaagcactctgattgacaaatacgatttatctaattta
cacgaaattgcttctgggggcgcacctctttcgaaagaagtcggggaagcggttgcaaaacgcttccatcttccagggatac
gacaaggatatgggctcactgagactacatcagctattctgattacacccgagggggatgataaaccgggcggggtcggt
aaagttgttccattttttgaagcgaaggttgtggatctggataccgggaaaacgctgggcgttaatcagagaggcgaattatg
tgtcagaggacctatgattatgtccggttatgtaaacaatccggaagcgaccaacgccttgattgacaaggatggatggcta
cattctggagacatagcttactgggacgaagacgaacacttcttcatagttgaccgcttgaagtctttaattaaatacaaaggat
atcaggtggcccccgctgaattggaatcgatattgttacaacaccccaacatcttcgacgcgggcgtggcaggtcttcccga
cgatgacgccggtgaacttcccgccgccgttgttgttttggagcacggaaagacgatgacggaaaaagagatcgtggatta
cgtcgccagtcaagtaacaaccgcgaaaaagttgcgcggaggagttgtgtttgtggacgaagtaccgaaaggtcttaccg
gaaaactcgacgcaagaaaaatcagagagatcctcataaaggccaagaagggcggaaagtccaaattgtaa
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APPENDIX 4 
TH / T3-Analogue/ Binding Disruption Plots.
Recombinant TR/3 to a final concentration of 1.0/xM (the K& of ligand- 
free TR/3 as determined in Section 7.3.1.a) was combined in an EMSA reaction with a 
constant amount of radiolabelled ME-TRE probe (0.3pmol/reaction) and varying 
concentrations of either THs or their analogues, as described in Section 2.2.4.9.C. 
Complexes were separated by gel electrophoresis (Section 2.2.4.9.d), the gels dried 
and the radioactivity associated with bands was quantified as described in Section 
2.2.4.9.e. The quantitative data is plotted relative to the amount of free probe 
observed in the absence of the relevant compound (arbitarily designated as 1).
A) Triiodothyronine (T3).
1.250
1.200
1.150
1.100 -I
1.050
1.000 + -  
0 20 40 60 80
Disruptor Concentration (//M)
100
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B) Tetraiodothyronine (T4).
1.400
1.350 
1.300
1.250 -
1.200 -
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1.100
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100
C) Tetraiodothyroaceticacid (TETRAC).
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D) Reverse Triiodothyronine (rT3).
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